Methods and devices for cell selection and stimulation
The on-column stimulation of T cells using anti-CD3 and anti-CD28 antibodies addresses the inefficiencies of separate selection and stimulation steps in existing methods, achieving faster and less stressful production of stimulated T cells for cell therapy.
Patent Information
- Application Number
- JP2021523658
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-06-13
- Filing Date
- 2019-10-30
- Publication Date
- 2024-11-13
- Estimated Expiration
- 2039-10-30
AI Technical Summary
Existing cell therapy methods require separate selection and stimulation steps for producing suitable cell populations, which are time-consuming and can cause cellular stress due to additional processing steps, impacting downstream cell processing.
A method for on-column stimulation of T cells using an oligomeric stimulatory reagent containing anti-CD3 and anti-CD28 antibodies, allowing for simultaneous selection and stimulation without additional reagents or washing steps, and collecting stimulated T cells within 24 hours by gravity flow.
This method reduces processing time and minimizes cellular stress, producing high-quality stimulated T cells suitable for genetic engineering and cell therapy applications.
Smart Images

Figure 0007582940000055 
Figure 0007582940000056 
Figure 0007582940000057
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 753,911, entitled "METHODS FOR SELECTION AND STIMULATION OF CELLS AND KITS AND APPARATUS FOR SAME," filed October 31, 2018; U.S. Provisional Application No. 62 / 842,511, entitled "METHODS FOR SELECTION AND STIMULATION OF CELLS AND KITS AND APPARATUS FOR SAME," filed May 2, 2019; and U.S. Provisional Application No. 62 / 861,314, entitled "METHODS FOR SELECTION AND STIMULATION OF CELLS AND KITS AND APPARATUS FOR SAME," filed June 13, 2019, the contents of which are incorporated herein by reference in their entireties for all purposes.
[0002] INCORPORATION BY REFERENCE TO SEQUENCE LISTING This application is filed with an electronic Sequence Listing. The Sequence Listing is provided as a file named 7350423019240SeqList.txt, created on October 29, 2019, and is 94,112 bytes in size. The information in the electronic format of the Sequence Listing is incorporated herein by reference in its entirety.
[0003] Field The present disclosure provides a method for selecting and stimulating a plurality of cells in a cell sample using column chromatography, and collecting and / or eluting the cells without using additional steps or reagents to promote cell detachment from the column. In some aspects, the methods provided herein reduce the time required to produce a population of selected and stimulated cells useful for genetic engineering and, therefore, cell therapy, compared to existing methods. Also provided are articles of manufacture and devices. [Background technology]
[0004] background Various cell therapy approaches are available for treating diseases and conditions. These approaches include those using immune cells, such as T cells (e.g., CD4+ T cells and CD8+ T cells), which may be genetically engineered with recombinant receptors, such as chimeric antigen receptors. Methods for producing suitable cell populations for use in such cell therapies, e.g., selected (enriched) and stimulated cell populations, often require separate selection and stimulation steps, which can lengthen the manufacturing process. Furthermore, selection techniques may involve contaminating selected cells with selection agents, such as selection-related particles, e.g., Fab fragments, as well as competitive and / or free binding agents used to promote cell detachment from the stationary phase, necessitating additional washing steps and / or media changes to purify the output composition. Additional processing steps can result in cell stress, which, in addition to requiring significant time to complete, potentially impacts downstream cell processing or even cell biology. Therefore, improved methods that minimize cell handling and processing time are needed to produce cell populations suitable for use in, e.g., cell therapies. Methods, articles of manufacture and apparatus are provided that meet such needs. Summary of the Invention
[0005] overview A method for on-column stimulation of T cells is provided, comprising: adding an oligomeric stimulating reagent capable of delivering a stimulatory signal in T cells to a stationary phase containing a plurality of immobilized T cells, thereby initiating incubation of the stimulating reagent with one or more T cells, wherein the stationary phase comprises a selection agent that specifically binds to a selection marker on the surface of one or more T cells or a subset thereof, the oligomeric stimulating reagent comprising one or more stimulating agents comprising (i) a first stimulating agent that is an anti-CD3 antibody and (ii) a second stimulating agent that is an anti-CD28 antibody; and collecting one or more of the plurality of T cells from the stationary phase by gravity flow within 24 hours of the initiation of incubation, thereby producing a composition containing stimulated T cells. In the provided method, the selection agent that specifically binds to the selection marker on the surface of one or more T cells or a subset thereof immobilizes the plurality of T cells on the stationary phase.
[0006] A method for on-column stimulation of T cells is provided, comprising the steps of: incubating an oligomeric stimulating reagent capable of delivering a stimulatory signal in T cells with a plurality of immobilized T cells immobilized on a stationary phase, thereby initiating incubation of the stimulating reagent with one or more T cells, wherein the stationary phase comprises a selection agent that specifically binds to a selection marker on the surface of one or more T cells or a subset thereof, and the oligomeric stimulating reagent comprises one or more stimulating agents, including (i) a first stimulating agent that is an anti-CD3 antibody and (ii) a second stimulating agent that is an anti-CD28 antibody; and collecting one or more of the plurality of T cells from the stationary phase by gravity flow within 24 hours of the initiation of incubation, thereby producing a composition containing stimulated T cells. In the provided method, the selection agent that specifically binds to a selection marker on the surface of one or more T cells or a subset thereof immobilizes the plurality of T cells on the stationary phase.
[0007] A method for on-column stimulation of T cells is provided, comprising the steps of: mixing an oligomeric stimulating reagent capable of delivering a stimulatory signal in T cells with a plurality of immobilized T cells immobilized on a stationary phase, thereby initiating incubation of the stimulating reagent with one or more T cells, wherein the stationary phase comprises a selection agent that specifically binds to a selection marker on the surface of one or more T cells or a subset thereof, the oligomeric stimulating reagent comprising one or more stimulating agents comprising (i) a first stimulating agent that is an anti-CD3 antibody and (ii) a second stimulating agent that is an anti-CD28 antibody; and collecting one or more of the plurality of T cells from the stationary phase by gravity flow within 24 hours of the initiation of incubation, thereby producing a composition containing stimulated T cells. In the provided method, the selection agent that specifically binds to the selection marker on the surface of one or more T cells or a subset thereof immobilizes the plurality of T cells on the stationary phase.
[0008] A method for on-column stimulation of T cells is provided, comprising: incubating a plurality of T cells immobilized on a stationary phase with one or more stimulatory agents to deliver a stimulatory signal in one or more T cells of the plurality of T cells, wherein the stationary phase comprises a selection agent that specifically binds to a selection marker on the surface of the one or more T cells, wherein specific binding of the selection agent to the selection marker expressed by the one or more T cells results in immobilization of the one or more T cells to the stationary phase; and collecting the one or more T cells from the stationary phase by gravity flow within 24 hours from the start of incubation without adding a competitor or free binder to elute the plurality of T cells from the stationary phase, thereby producing a composition containing stimulated T cells.
[0009] Methods for on-column stimulation of T cells are provided, comprising: incubating a plurality of T cells immobilized on a stationary phase with one or more stimulatory substances to deliver a stimulatory signal in one or more T cells of the plurality of T cells, wherein the stationary phase comprises a selection substance that specifically binds to a selection marker on the surface of the one or more T cells, and wherein specific binding of the selection substance to the selection marker expressed by the one or more T cells immobilizes the one or more T cells on the stationary phase; and collecting the one or more T cells from the stationary phase by gravity flow within 24 hours of the start of incubation, thereby producing a composition containing stimulated T cells. In some embodiments, the stationary phase contains at least one of one or more stimulatory substances capable of delivering a stimulatory signal in the one or more T cells. In some embodiments, the at least one stimulatory substance is a first stimulatory substance, and the stationary phase further comprises one or more second stimulatory substances capable of enhancing, attenuating, or modifying the stimulatory signal of the first stimulatory substance. In some embodiments, the stimulatory substance is a first stimulatory substance, and prior to the incubating step, a stimulatory reagent containing one or more second stimulatory substances capable of enhancing, attenuating or modifying the stimulatory signal of the first stimulatory substance is added to the stationary phase.In some embodiments, the stimulating substance is a first stimulating substance, and prior to the incubating step, a stimulating reagent containing one or more of a second stimulating substance capable of enhancing, attenuating, or modifying the stimulating signal of the first stimulating substance is added to the stationary phase. In some embodiments, the one or more stimulating substances are a first stimulating substance and a second stimulating substance, and prior to the incubating step, a stimulating reagent containing a second stimulating substance capable of enhancing, attenuating, or modifying the stimulating signal of the first stimulating substance is added to the stationary phase. In some embodiments, prior to the incubating step, a stimulating reagent containing at least one of the one or more stimulating substances is added to the stationary phase.
[0009] In some embodiments, at least one stimulatory substance is a first stimulatory substance, and the one or more stimulatory substances further contain one or more second stimulatory substances capable of enhancing, attenuating, or modifying the stimulatory signal of the first stimulatory substance. In some embodiments, at least one of the one or more stimulatory substances, optionally the first stimulatory substance, is capable of delivering a stimulatory signal, the stimulatory signal being mediated by the TCR / CD3 complex in T cells, a CD3-containing complex in T cells, and / or an ITAM-containing molecule in T cells. In some embodiments, at least one of the one or more first stimulatory substances is capable of delivering a stimulatory signal, the stimulatory signal being mediated by the TCR / CD3 complex in T cells, a CD3-containing complex in T cells, and / or an ITAM-containing molecule in T cells. In some embodiments, the second stimulatory substance is capable of specifically binding to a costimulatory molecule on said one or more T cells. In some embodiments, the first stimulatory agent delivers a stimulatory signal via the TCR / CD3 complex in the T cell, a CD3-containing complex in the T cell, and / or an ITAM-containing molecule in the T cell, and the second stimulatory agent binds to a costimulatory molecule on the T cell.
[0010] A method for on-column stimulation of T cells is provided, comprising the steps of: adding a sample containing a plurality of T cells to a stationary phase, wherein the stationary phase contains a selection agent that binds to a selection marker on the surface of one or more of the plurality of T cells, thereby immobilizing said one or more of the plurality of T cells on the stationary phase; adding to the stationary phase a stimulating reagent containing one or more stimulating agents capable of delivering a stimulatory signal in one or more of the plurality of T cells, thereby initiating incubation of the stimulating reagent with one or more T cells; and within 24 hours of initiating the incubation, collecting one or more of the plurality of T cells from the stationary phase by gravity flow without adding a competitor or free binding agent to elute the plurality of T cells from the stationary phase, thereby producing a composition containing stimulated T cells.
[0011] A method for on-column stimulation of T cells is provided, comprising the steps of: adding a sample containing a plurality of T cells to a stationary phase, wherein the stationary phase contains a selection agent that binds to a selection marker on the surface of one or more of the plurality of T cells, thereby immobilizing said one or more of the plurality of T cells on the stationary phase; adding a stimulatory reagent to the stationary phase, the stimulatory reagent containing one or more stimulatory agents capable of delivering a stimulatory signal in one or more of the plurality of T cells, thereby initiating incubation of the stimulatory reagent with the one or more T cells; and collecting one or more of the plurality of T cells from the stationary phase by gravity flow within 24 hours of the start of incubation, thereby producing a composition containing stimulated T cells.
[0012] Provided is a method for on-column stimulation of T cells, comprising the steps of: incubating a sample containing a plurality of T cells on a stationary phase, the stationary phase containing a selection agent that binds to a selection marker on the surface of one or more of the plurality of T cells, thereby immobilizing said one or more of the plurality of T cells on the stationary phase, with a stimulatory reagent containing one or more stimulatory agents capable of delivering a stimulatory signal in one or more of the plurality of T cells, thereby initiating incubation of the stimulatory reagent with the one or more T cells; and within 24 hours of the initiation of incubation, collecting one or more of the plurality of T cells from the stationary phase by gravity flow without adding a competitor or free binder to elute said plurality of T cells from the stationary phase, thereby producing a composition containing stimulated T cells.
[0013] A method for on-column stimulation of T cells is provided, comprising the steps of: (1) mixing (a) a sample containing a plurality of T cells with (b) a stationary phase containing a selection agent capable of specifically binding to a selection marker expressed on the surface of one or more of the plurality of T cells, wherein specific binding of the selection agent to the selection marker results in immobilization of the plurality of T cells to the stationary phase; (2) adding a stimulating reagent containing one or more stimulating agents capable of delivering a stimulatory signal in the T cells to the stationary phase, thereby initiating incubation of the stimulating reagent with the one or more T cells; and (3) within 24 hours of the start of incubation, collecting one or more of the plurality of T cells from the stationary phase by gravity flow without adding a competitor or free binder to elute the plurality of T cells from the stationary phase, thereby producing a composition containing stimulated T cells.
[0014] A method for on-column stimulation of T cells is provided, comprising the steps of: (1) mixing (a) a sample containing a plurality of T cells with (b) a stationary phase containing a selection agent capable of specifically binding to a selection marker expressed on the surface of one or more of the plurality of T cells, wherein specific binding of the selection agent to the selection marker immobilizes the one or more of the plurality of T cells to the stationary phase; (2) adding a stimulating reagent containing one or more stimulating agents capable of delivering a stimulatory signal in the T cell to the stationary phase, thereby initiating incubation of the stimulating reagent with the one or more T cells; and (3) collecting one or more of the plurality of T cells from the stationary phase by gravity flow within 24 hours of the start of incubation, thereby producing a composition containing stimulated T cells.
[0015] Provided is a method for on-column stimulation of T cells, comprising: adding an oligomeric stimulating reagent to a stationary phase containing a plurality of immobilized T cells, thereby initiating incubation of the stimulating reagent with one or more T cells of the plurality of immobilized T cells, wherein the stationary phase comprises a selection agent that specifically binds to a selection marker on the surface of one or more T cells, wherein specific binding of the selection agent to the selection marker expressed by the one or more T cells results in immobilization of the one or more T cells to the stationary phase, wherein the oligomeric stimulating reagent contains (i) a plurality of streptavidin molecules or streptavidin mutein molecules and (ii) one or more stimulating agents capable of delivering a stimulatory signal in one or more T cells, and wherein the size of the oligomeric stimulating reagent is: i) greater than 50 nm in radius; ii) at least 5×10 6and (iii) at least 100 streptavidin tetramers or streptavidin mutein tetramers per oligomeric stimulating reagent. In some embodiments, the method further comprises collecting one or more of said plurality of T cells from the stationary phase by gravity flow within 24 hours of initiating incubation, thereby producing a composition containing stimulated T cells. In some embodiments, the method further comprises collecting one or more of said plurality of T cells from the stationary phase by gravity flow within 24 hours of initiating incubation, without adding a competitor or free binder to elute said plurality of T cells from the stationary phase, thereby producing a composition containing stimulated T cells.
[0016] In some embodiments, harvesting one or more of the plurality of T cells from the stationary phase occurs within about 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 hours from the start of incubation. In some embodiments, harvesting one or more of the plurality of T cells from the stationary phase occurs within about 2-24, 3-24, 4-24, 5-24, 6-24, 7-24, 8-24, 9-24, 10-24, 11-24, 12-24, 13-24, 14-24, 15-24, 16-24, 17-24, In some embodiments, harvesting one or more of the plurality of T cells from the stationary phase occurs within about 12, 10, 8, 6, 4, or 2 hours from the start of incubation. In some embodiments, harvesting one or more of the plurality of T cells from the stationary phase occurs within 6 hours from the start of incubation. In some embodiments, harvesting one or more of the plurality of T cells from the stationary phase occurs within 5 hours from the start of incubation. In some embodiments, harvesting one or more of the plurality of T cells from the stationary phase is performed within 4.5 hours or about 4.5 hours from the start of incubation. In some embodiments, harvesting one or more of the plurality of T cells from the stationary phase is performed within 4 hours from the start of incubation. In some embodiments, harvesting one or more of the plurality of T cells from the stationary phase is performed within 3 hours from the start of incubation.
[0017] In some embodiments, the initiation of incubation with the stimulating reagent occurs within 10 minutes or less, 20 minutes or less, 30 minutes or less, 45 minutes or less, 60 minutes or less, 90 minutes or less, or 120 minutes or less after adding or mixing the sample containing the plurality of T cells with the stationary phase. In some embodiments, the initiation of incubation with the stimulating reagent occurs within 20 to 100 minutes or within about 20 to 100 minutes after adding or mixing the sample containing the plurality of T cells with the stationary phase. In some embodiments, the initiation of incubation with the stimulating reagent occurs within 30 to 90 minutes or within about 30 to 90 minutes after adding or mixing the sample containing the plurality of T cells with the stationary phase. In some embodiments, the incubation with the stimulating reagent is initiated within 30 to 80 minutes or within about 30 to 80 minutes after adding or mixing the sample containing the plurality of T cells with the stationary phase. In some embodiments, the incubation with the stimulating reagent is initiated within 30 to 70 minutes or within about 30 to 70 minutes after adding or mixing the sample containing the plurality of T cells with the stationary phase. In some embodiments, the incubation with the stimulating reagent is initiated within 30 to 60 minutes or within about 30 to 60 minutes after adding or mixing the sample containing the plurality of T cells with the stationary phase. In some embodiments, the incubation with the stimulating reagent is initiated within 30 to 50 minutes or within about 30 to 50 minutes after adding or mixing the sample containing the plurality of T cells with the stationary phase. In some embodiments, the incubation with the stimulating reagent is initiated within 30 to 40 minutes or within about 30 to 40 minutes after adding or mixing the sample containing the plurality of T cells with the stationary phase. In some embodiments, the initiation of incubation with the stimulatory reagent is performed within 30 minutes or within about 30 minutes after adding or mixing the sample containing the plurality of T cells with the stationary phase.In some embodiments, the initiation of incubation with the stimulating reagent is carried out within 40 minutes or within about 40 minutes after adding or mixing the sample containing a plurality of T cells with the stationary phase. In some embodiments, the initiation of incubation with the stimulating reagent is carried out within 50 minutes or within about 50 minutes after adding or mixing the sample containing a plurality of T cells with the stationary phase. In some embodiments, the initiation of incubation with the stimulating reagent is carried out within 60 minutes or within about 60 minutes after adding or mixing the sample containing a plurality of T cells with the stationary phase. In some embodiments, the initiation of incubation with the stimulating reagent is carried out within 70 minutes or within about 70 minutes after adding or mixing the sample containing a plurality of T cells with the stationary phase. In some embodiments, the initiation of incubation with the stimulating reagent is carried out within 80 minutes or within about 80 minutes after adding or mixing the sample containing a plurality of T cells with the stationary phase. In some embodiments, the initiation of incubation with the stimulatory reagent is performed within 90 minutes or within about 90 minutes after adding or mixing the sample containing the plurality of T cells with the stationary phase.
[0018] In some embodiments, at least one of the one or more stimulatory substances is capable of delivering a stimulatory signal, the stimulatory signal being a stimulatory signal via the TCR / CD3 complex in T cells, a CD3-containing complex in T cells, and / or an ITAM-containing molecule in T cells. In some embodiments, the at least one stimulatory substance is a first stimulatory substance, and the stimulatory reagent further contains one or more second stimulatory substances capable of enhancing, attenuating, or modifying the stimulatory signal of the first stimulatory substance. In some embodiments, the second stimulatory substance is capable of specifically binding to a costimulatory molecule on the one or more T cells. In some embodiments, the costimulatory molecule is selected from among CD28, CD90 (Thy-1), CD95 (Apo- / Fas), CD137 (4-1BB), CD154 (CD40L), ICOS, LAT, CD27, OX40, or HVEM. In some embodiments, the second stimulatory substance is capable of specifically binding to CD28. In some embodiments, the first stimulatory agent specifically binds CD3 and the second stimulatory agent specifically binds CD28.
[0019] In some embodiments, the stimulator is or contains a substance selected from the group consisting of an antibody fragment, a monovalent antibody fragment, a proteinaceous binding molecule with immunoglobulin-like function, a molecule containing an Ig domain, a cytokine, a chemokine, an aptamer, an MHC molecule, an MHC-peptide complex; a receptor ligand; and a binding fragment thereof; and / or the stimulator contains an antibody fragment; the stimulator is or contains a Fab fragment; the stimulator is selected from the group of bivalent antibody fragments consisting of (Fab)2' fragments and bivalent single-chain Fv (scFv) fragments; the stimulator is a monovalent antibody fragment selected from the group consisting of Fab fragments, Fv fragments, and scFvs; and / or the stimulator is a proteinaceous binding molecule with antibody-like binding properties selected from the group consisting of an aptamer, a mutein based on a polypeptide of the lipocalin family, a glubody, an ankyrin scaffold-based protein, a crystalline scaffold-based protein, an adnectin, and an avimer.
[0020] In some embodiments, the first stimulatory substance and the second stimulatory substance are, or contain, independently, a substance selected from the group consisting of an antibody fragment, a monovalent antibody fragment, a proteinaceous binding molecule with immunoglobulin-like function, an Ig domain-containing molecule, a cytokine, a chemokine, an aptamer, an MHC molecule, an MHC-peptide complex; a receptor ligand; and a binding fragment thereof; and / or the first stimulatory substance and the second stimulatory substance independently contain an antibody fragment; the first stimulatory substance and the second stimulatory substance are, or contain, independently, a Fab fragment; or the first stimulatory substance and the second stimulatory substance are, or contain, independently , (Fab)2' fragments, and bivalent single-chain Fv (scFv) fragments; the first stimulatory agent and the second stimulatory agent are independently monovalent antibody fragments selected from the group consisting of Fab fragments, Fv fragments, and scFvs; and / or the first stimulatory agent and the second stimulatory agent are independently proteinaceous binding molecules with antibody-like binding properties selected from the group consisting of aptamers, muteins based on polypeptides of the lipocalin family, glubodies, ankyrin scaffold-based proteins, crystalline scaffold-based proteins, adnectins, and avimers.
[0021] In some embodiments, one or more stimulatory agents comprise a monovalent antibody fragment. In some embodiments, the first stimulatory agent and the second stimulatory agent independently comprise a monovalent antibody fragment. In some embodiments, the first stimulatory agent comprises a monovalent antibody fragment that binds to CD3, and the second stimulatory agent comprises a monovalent antibody fragment that binds to CD28. In some embodiments, the monovalent antibody fragment is selected from the group consisting of a Fab fragment, an Fv fragment, and a single-chain Fv fragment (scFv). In some embodiments, the first stimulatory agent is an anti-CD3 Fab and the second stimulatory agent is an anti-CD28 Fab.
[0022] A method for on-column stimulation of T cells is provided, comprising the steps of: adding an oligomeric stimulatory reagent capable of delivering a stimulatory signal in T cells to a stationary phase containing a plurality of immobilized T cells, thereby initiating incubation of the stimulatory reagent with one or more T cells, wherein the stationary phase contains a selection agent capable of specifically binding to a selection marker on the surface of one or more T cells or a subset thereof, and wherein specific binding of the selection agent to the selection marker expressed by said one or more T cells or a subset thereof results in immobilization of said at least a plurality of T cells to the stationary phase, and wherein the selection agent and a Fab fragment capable of specifically binding to a selectable marker selected from the group consisting of CD3, CD4, and CD8; the oligomeric stimulatory reagent contains (i) a plurality of streptavidin mutein molecules, (ii) a first stimulatory agent which is a Fab fragment capable of specifically binding to CD3 and capable of delivering a stimulatory signal in one or more T cells, and (iii) a second stimulatory agent which is a Fab fragment capable of specifically binding to CD28 and capable of enhancing, attenuating, or modifying the stimulatory signal, and the size of the oligomeric stimulatory reagent is: i) a radius of greater than 50 nm; ii) at least 5×10 6 and (iii) comprising at least 100 streptavidin tetramers or streptavidin mutein tetramers per oligomeric stimulating reagent, and within 24 hours of the start of incubation, collecting one or more of the plurality of T cells from the stationary phase by gravity flow without adding a competitor or free binder to elute the plurality of T cells from the stationary phase, thereby producing a composition containing stimulated T cells.
[0023] In some embodiments, the T cells are derived from a sample that is or comprises a whole blood sample, a buffy coat sample, a peripheral blood mononuclear cell (PBMC) sample, an unfractionated T cell sample, a lymphocyte sample, a leukocyte sample, an apheresis product, or a leukocyte apheresis product. In some embodiments, the sample is an apheresis product or a leukocyte apheresis product. In some embodiments, the apheresis product or leukocyte apheresis product has been previously cryofrozen.
[0024] In some embodiments, incubating with one or more stimulatory agents causes one or more of the plurality of immobilized T cells to release from the stationary phase. In some embodiments, incubating with the first stimulatory agent and the second stimulatory agent causes one or more of the plurality of immobilized T cells to release from the stationary phase.
[0025] In some embodiments, the stimulator is biotin, a biotin analog that reversibly binds to streptavidin or avidin, In some embodiments, the one or more stimuli further comprise a streptavidin-binding peptide selected from the group consisting of: a calmodulin-binding peptide that reversibly binds to calmodulin, a FLAG peptide that reversibly binds to an antibody that binds to the FLAG peptide, and an oligohistidine tag that reversibly binds to an antibody that binds to the oligohistidine tag. In some embodiments, the one or more stimulatory agents further comprise a streptavidin-binding peptide selected from the group consisting of: It further contains a streptavidin binding peptide having TIFF0007582940000003.tif4128.
[0026] In some embodiments, the first stimulatory agent and the second stimulatory agent are independently selected from biotin, streptavidin, or a biotin analog that reversibly binds to avidin, TIFF0007582940000004.tif48166, a calmodulin-binding peptide that reversibly binds to calmodulin, a FLAG peptide that reversibly binds to an antibody that binds to the FLAG peptide, and an oligohistidine tag that reversibly binds to an antibody that binds to the oligohistidine tag. In some embodiments, the first stimulatory agent and the second stimulatory agent each further comprise a streptavidin-binding peptide selected from the group consisting of: It further contains a streptavidin binding peptide having TIFF0007582940000006.tif4128.
[0027] In some embodiments, the selected agent is or comprises a substance selected from the group consisting of an antibody fragment, a monovalent antibody fragment, a proteinaceous binding molecule with immunoglobulin-like function, a molecule containing an Ig domain, a cytokine, a chemokine, an aptamer, an MHC molecule, an MHC-peptide complex; a receptor ligand; and binding fragments thereof; and / or the selected agent comprises an antibody fragment; the selected agent is or comprises a Fab fragment; the selected agent is selected from the group of bivalent antibody fragments consisting of (Fab)2' fragments and bivalent single-chain Fv (scFv) fragments; the selected agent is a monovalent antibody fragment selected from the group consisting of Fab fragments, Fv fragments and scFvs; and / or the selected agent is a proteinaceous binding molecule with antibody-like binding properties selected from the group consisting of an aptamer, a mutein based on a polypeptide of the lipocalin family, a glubody, an ankyrin scaffold-based protein, a crystalline scaffold-based protein, an adnectin, and an avimer.
[0028] In some embodiments, the selection agent is biotin, a biotin analog that reversibly binds to streptavidin or avidin, In some embodiments, the selection agent further comprises a streptavidin-binding peptide selected from the group consisting of: a calmodulin-binding peptide that reversibly binds to calmodulin; a FLAG peptide that reversibly binds to an antibody that binds to the FLAG peptide; and an oligohistidine tag that reversibly binds to an antibody that binds to the oligohistidine tag. In some embodiments, the selection agent further comprises a biotin analog that reversibly binds to biotin, streptavidin, or avidin; In some embodiments, the selection agent further comprises a streptavidin-binding peptide selected from the group consisting of the sequence It further contains a streptavidin binding peptide having TIFF0007582940000009.tif4128.
[0029] In some embodiments, the selection marker is a T cell coreceptor; the selection marker is or contains a member of the T cell antigen receptor complex; the selection marker is or contains a CD3 chain; the selection marker is or contains a CD3 zeta chain; the selection marker is or contains CD8; the selection marker is or contains CD4; the selection marker is or contains CD45RA; the selection marker is or contains CD27; the selection marker is or contains CD28; and / or the selection marker is or contains CCR7. In some embodiments, the selection marker is selected from the group consisting of CD3, CD4, and CD8. In some embodiments, the selection marker is CD3.
[0030] In some embodiments, specific binding between the selection agent and the selection marker does not induce a signal to the T cell, or does not induce a stimulatory, activating, or proliferative signal to the T cell. In some embodiments, the selection agent comprises a monovalent antibody fragment that binds to CD3, CD8, or CD4. In some embodiments, the selection agent is an anti-CD3 Fab, an anti-CD8 Fab, or an anti-CD4 Fab. In some embodiments, the selection agent is an anti-CD3 Fab. In some embodiments, the anti-CD3 Fab comprises an OKT3 antibody Fab fragment. In some embodiments, the anti-CD3 Fab comprises a variable heavy chain having the sequence set forth in SEQ ID NO:31 and a variable light chain having the sequence set forth in SEQ ID NO:32.
[0031] In some embodiments, the stimulating reagent is soluble. In some embodiments, the stimulating reagent is not, and is not bound to or associated with, a solid support, a stationary phase, a bead, a microparticle, a magnetic particle, and / or a matrix; and / or the reagent is flexible, does not contain a metallic or magnetic core, is composed entirely or primarily of organic polymers, is not spherical, substantially spherical, or uniform in shape, and / or is not rigid. In some embodiments, the stimulating reagent is or contains streptavidin, avidin, or a mutein of streptavidin that reversibly binds to biotin, a biotin analog, or a biologically active fragment thereof; an avidin or mutein of streptavidin that reversibly binds to a streptavidin-binding peptide; a reagent containing at least two chelating groups K, wherein the at least two chelating groups are capable of binding to a transition metal ion; a substance capable of binding to an oligohistidine affinity tag; a substance capable of binding to glutathione-S-transferase; calmodulin or an analog thereof; a substance capable of binding to calmodulin-binding peptide (CBP); a substance capable of binding to a FLAG peptide; a substance capable of binding to an HA tag; a substance capable of binding to maltose-binding protein (MBP); a substance capable of binding to an HSV epitope; a substance capable of binding to a myc epitope; or a substance capable of binding to a biotinylated carrier protein.
[0032] In some embodiments, the stimulating reagent is or contains a streptavidin or avidin mutein that reversibly binds to biotin or a biologically active fragment; the stimulating reagent is or contains a streptavidin or avidin mutein that reversibly binds to a biotin analog or a biologically active fragment; and / or the stimulating reagent is or contains a streptavidin or avidin mutein that reversibly binds to a streptavidin-binding peptide.
[0033] In some embodiments, the stimulation reagent is an oligomeric stimulation reagent containing a plurality of streptavidin molecules or streptavidin mutein molecules, and the size of the oligomeric stimulation particle reagent is: i) greater than 50 nm in radius; ii) at least 5×10 6 g / mol and / or (iii) at least 100 streptavidin tetramers or streptavidin mutein tetramers per oligomeric particle reagent. In some embodiments, the oligomeric stimulating reagent is soluble. In some embodiments, the oligomeric stimulating reagent is not, and is not bound to or associated with, a solid support, stationary phase, bead, microparticle, magnetic particle, and / or matrix; and / or the reagent is flexible, does not contain a metal or magnetic core, is composed entirely or primarily of organic multimers, and / or is not rigid.
[0034] In some embodiments, the streptavidin or streptavidin mutein molecule reversibly binds or has the ability to reversibly bind to biotin, a biotin analog, or a streptavidin-binding peptide. In some embodiments, the streptavidin mutein contains the amino acid sequence Val44-Thr45-Ala46-Arg47 or Ile44-Gly45-Ala46-Arg47 at sequence positions corresponding to positions 44-47 in streptavidin in the sequence of amino acids set forth in SEQ ID NO:1, or the streptavidin mutein contains the amino acid sequence Val44-Thr45-Ala46-Arg47 at sequence positions corresponding to positions 44-47 in streptavidin in the sequence of amino acids set forth in SEQ ID NO:1. In some embodiments, the streptavidin-binding peptide is TIFF0007582940000010.tif49165.
[0035] In some embodiments, the oligomeric particle reagent comprises a radius of greater than 60 nm, greater than 70 nm, greater than 80 nm, or greater than 90 nm. In some embodiments, the oligomeric particle reagent comprises a radius of 50 nm to 150 nm, 75 nm to 125 nm, 80 nm to 115 nm, or 90 nm to 110 nm, inclusive, or a radius of 90 nm ± 15 nm or 95 nm ± 20 to 25 nm. In some embodiments, the radius is the hydrodynamic radius.
[0036] In some embodiments, the oligomeric particle reagent comprises a molecular weight of at least 5×10 7 g / mol or at least 1×10 8 g / mol; and / or 5 × 10 7 g / mol ~ 5 × 10 8 g / mol, 1×10 8 g / mol ~ 5 × 10 8 g / mol, or 1×10 8 g / mol~2×10 8 g / mol. In some embodiments, the oligomeric particle reagent contains at least 500 streptavidin tetramers or streptavidin mutein tetramers, at least 1,000 streptavidin tetramers or streptavidin mutein tetramers, at least 1,500 streptavidin tetramers or streptavidin mutein tetramers, or at least 2,000 streptavidin tetramers or streptavidin mutein tetramers; and / or 1,000 to 20,000 streptavidin tetramers or streptavidin mutein tetramers, 1,000 to 10,000 streptavidin tetramers or streptavidin mutein tetramers, or 2,000 to 5,000 streptavidin tetramers or streptavidin mutein tetramers. In some embodiments, the oligomeric stimulating reagent is added to the stationary phase at a concentration of about 1 to about 2 μg / million cells.
[0037] In some embodiments, the selection agent is directly or indirectly bound to the stationary phase, hi some embodiments, the selection agent is indirectly bound to the stationary phase via a selection reagent to which the selection agent reversibly binds. In some embodiments, the selection reagent is or contains streptavidin, avidin, or a mutein of streptavidin that reversibly binds to biotin, a biotin analog, or a biologically active fragment thereof; an avidin or mutein of streptavidin that reversibly binds to a streptavidin-binding peptide; a reagent containing at least two chelating groups K, wherein the at least two chelating groups are capable of binding to a transition metal ion; a substance capable of binding to an oligohistidine affinity tag; a substance capable of binding to glutathione-S-transferase; calmodulin or an analog thereof; a substance capable of binding to calmodulin-binding peptide (CBP); a substance capable of binding to a FLAG peptide; a substance capable of binding to an HA tag; a substance capable of binding to maltose-binding protein (MBP); a substance capable of binding to an HSV epitope; a substance capable of binding to a myc epitope; or a substance capable of binding to a biotinylated carrier protein. In some embodiments, the selection reagent is or contains a streptavidin or avidin mutein that reversibly binds to biotin or a biologically active fragment; the stimulating reagent is or contains a streptavidin or avidin mutein that reversibly binds to a biotin analog or a biologically active fragment; and / or the stimulating reagent is or contains a streptavidin or avidin mutein that reversibly binds to a streptavidin-binding peptide. In some embodiments, the streptavidin or streptavidin mutein molecule reversibly binds to or has the ability to reversibly bind to biotin, a biotin analog, or a streptavidin-binding peptide.
[0038] In some embodiments, the streptavidin mutein contains the amino acid sequence Val44-Thr45-Ala46-Arg47 or Ile44-Gly45-Ala46-Arg47 at sequence positions corresponding to positions 44-47 in streptavidin in the sequence of amino acids set forth in SEQ ID NO: 1, or the streptavidin mutein contains the amino acid sequence Val44-Thr45-Ala46-Arg47 at sequence positions corresponding to positions 44-47 in streptavidin in the sequence of amino acids set forth in SEQ ID NO: 1. In some embodiments, the streptavidin-binding peptide is TIFF0007582940000011.tif48170. In some embodiments, the streptavidin-binding peptide is selected from the group consisting of the sequence I have TIFF0007582940000012.tif4128.
[0039] In some embodiments, the methods provided herein are carried out at or about 37°C. In some embodiments, collecting comprises washing the stationary phase with medium that does not contain a competitor or free binder for eluting the T cells from the stationary phase. In some embodiments, collecting by gravity flow comprises adding medium to the stationary phase that does not contain a competitor or free binder for eluting the T cells from the stationary phase. In some embodiments, the composition containing the stimulated T cells does not contain a competitor or free binder. In some embodiments, the competitor or free binder is or contains biotin or a biotin analog, optionally, the biotin analog is D-biotin. In some embodiments, the competitor or free binder is D-biotin. In some embodiments, the method comprises further incubating the composition containing the stimulated T cells after said collecting. In some embodiments, the further incubation is carried out at or about 37°C±2°C; and / or the further incubation is carried out in the presence of an additional agent capable of delivering a signal in the T cells. In some embodiments, the additional agent is contained in the medium used to wash the stationary phase. In some embodiments, the additional agent has the ability to enhance or induce proliferation of T cells, CD4+ T cells and / or CD8+ T cells. In some embodiments, the additional agent is a cytokine selected from IL-2, IL-15 and IL-7. In some embodiments, the additional incubation is carried out for a period of 72 hours, 48 hours or less, 24 hours or less, or 12 hours or less.
[0040] In some embodiments, the method further comprises introducing a recombinant nucleic acid molecule encoding a recombinant protein into the stimulated T cells of the composition, thereby producing a composition comprising the transduced T cells. In some embodiments, the recombinant protein is an antigen receptor. In some embodiments, the recombinant protein is a chimeric antigen receptor.
[0041] In some embodiments, the chimeric antigen receptor (CAR) contains an extracellular antigen recognition domain that specifically binds to a target antigen and an intracellular signaling domain comprising an ITAM. In some embodiments, the intracellular signaling domain comprises the intracellular domain of the CD3-zeta (CD3ζ) chain. In some embodiments, a transmembrane domain linking the extracellular domain and the intracellular signaling domain is further included. In some embodiments, the transmembrane domain comprises the transmembrane portion of CD28. In some embodiments, the intracellular signaling domain further comprises the intracellular signaling domain of a T cell costimulatory molecule. In some embodiments, the T cell costimulatory molecule is selected from the group consisting of CD28 and 41BB. In some embodiments, the nucleic acid further comprises a promoter operably linked to the nucleic acid encoding the recombinant antigen receptor.
[0042] In some embodiments, the introduction of the recombinant nucleic acid is achieved by transduction using a viral particle. In some embodiments, the viral particle is a retroviral vector particle. In some embodiments, the viral particle is a lentiviral vector particle.
[0043] In some embodiments, the method further comprises incubating the composition comprising the transduced cells under conditions for viral integration, optionally at or about 37°±2°C. In some embodiments, the incubating the composition comprising the transduced cells is carried out for up to 96 hours after introduction. In some embodiments, the incubating the composition comprising the transduced cells is carried out for up to 72 hours after introduction. In some embodiments, the incubating the composition comprising the transduced cells is carried out for up to 48 hours after introduction. In some embodiments, the incubating the composition comprising the transduced cells is carried out for up to 24 hours after introduction. In some embodiments, the incubating the composition comprising the transduced cells is carried out for at least 18 hours after introduction.
[0044] In some embodiments, the method further comprises culturing the composition containing the transduced cells under conditions for viral integration, thereby producing a composition containing cultured T cells. In some embodiments, the method further comprises culturing the composition containing the transduced cells under conditions for T cell expansion. In some embodiments, the culturing is carried out for a period of 14 days or less, 12 days or less, 10 days or less, 8 days or less, or 6 days or less. In some embodiments, for 5 days or less.
[0045] In some embodiments, the method further comprises harvesting the engineered T cells, thereby generating an output population of engineered T cells. In some embodiments, the method further comprises harvesting the engineered T cells at 48 to 120 hours, inclusive, after initiating exposure to a stimulatory reagent. In some embodiments, harvesting is performed within 120 hours after initiating exposure to a stimulatory agent. In some embodiments, harvesting is performed within 96 hours after initiating exposure to a stimulatory agent. In some embodiments, harvesting is performed within 72 hours after initiating exposure to a stimulatory agent. In some embodiments, harvesting is performed within 48 hours after initiating exposure to a stimulatory agent.
[0046] In some embodiments, the percentage of naive-like cells is greater than or greater than about 60% of the total T cells in the population, the total CD4+ T cells in the population, or the CD8+ T cells or recombinant protein-expressing cells thereof in the population at the time of harvest. In some embodiments, the naive-like T cells comprise CD27+CCR7+ cells.
[0047] In some embodiments, the introduction is carried out in a serum-free medium. In some embodiments, the incubating step is carried out in a serum-free medium. In some embodiments, the culturing step is carried out in a serum-free medium. In some embodiments, the serum-free medium contains 0.5 mM to 5 mM dipeptide form of L-glutamine, 0.5 mM to 5 mM L-glutamine, and optionally at least one protein in a basal medium, and the medium does not contain serum. In some embodiments, the serum-free medium contains a recombinant cytokine selected from among IL-2, IL-15, and IL-7, optionally recombinant human IL-2, recombinant human IL-15, and / or recombinant human IL-7. In some embodiments, the serum-free medium does not contain a recombinant cytokine selected from among IL-2, IL-15, and IL-7, optionally recombinant human IL-2, recombinant human IL-15, and / or recombinant human IL-7.
[0048] In some embodiments, the method further comprises incubating the composition containing the transduced cells, hi some embodiments, the incubation is carried out for at or about 24 hours ± 6 hours, 48 hours ± 6 hours, or 72 hours ± 6 hours.
[0049] In some embodiments, the method further comprises adding a competitor or free binding agent to a composition containing stimulated T cells, thereby disrupting the reversible binding. In some embodiments, the method further comprises adding a competitor or free binding agent to a composition containing transduced T cells, thereby disrupting the reversible binding. In some embodiments, the method further comprises adding a competitor or free binding agent to a composition containing cultured T cells, thereby disrupting the reversible binding. In some embodiments, the method further comprises adding a competitor or free binding agent to a composition containing engineered cells, optionally transduced T cells, optionally under conditions for dissociating one or more stimulatory agents from the oligomeric stimulating reagents in the composition. In some embodiments, the method further comprises adding a competitor or free binding agent to a composition containing incubated T cells, optionally under conditions for dissociating one or more stimulatory agents from the oligomeric stimulating reagents in the composition. In some embodiments, the method further comprises adding a competitor or free binding agent to the composition containing the cultured T cells, optionally under conditions to dissociate one or more stimulatory agents from the oligomeric stimulating reagents in the composition. In some embodiments, the step of adding the competitor or free binding agent is performed prior to harvesting.
[0050] In some embodiments, the competitor or free binder is not detrimental to the T cells, and / or addition of the agent does not reduce the percentage of surviving T cells to less than 90%, less than 80%, less than 70%, less than 60%, or less than 50% compared to incubation of T cells under equivalent or identical conditions without the competitor or free binder. In some embodiments, the disruption terminates or reduces the stimulatory signal in the T cells. In some embodiments, the competing reagent and the free binder independently comprise a molecule selected from the group consisting of a streptavidin-binding molecule; biotin; D-biotin; a biotin analog; a biotin analog that specifically binds to streptavidin or a streptavidin analog having the amino acid sequence Val44-Thr45-Ala46-Arg47 or Ile44-Gly45-Ala46-Arg47 at sequence positions corresponding to positions 44-47 of wild-type streptavidin; or the competing reagent and the free binder independently comprise a metal chelator, optionally EDTA or EGTA. In some embodiments, the competing reagent or the free binder is D-biotin, optionally 1 mM D-biotin. In some embodiments, the method further comprises washing the cells, optionally reducing or removing the stimulating reagent and / or the one or more stimulating substances in the composition. In some embodiments, the washing is performed prior to harvesting.
[0051] In some embodiments, the T cells comprise antigen-specific T cells or populations thereof, T helper cells or populations thereof, cytotoxic T cells or populations thereof, memory T cells or populations thereof, or regulatory T cells or populations thereof. In some embodiments, the T cells comprise CD3+ T cells, or comprise CD4+ and / or CD8+ T cells.
[0052] In some embodiments, the method includes selecting a T cell subset from stimulated T cells of the composition, followed by an introducing step, where a recombinant nucleic acid molecule is introduced into the selected T cell subset. In some embodiments, the method includes selecting a T cell subset from a composition containing transduced cells, followed by an incubation step, where the selected T cell subset is incubated under conditions for viral integration. In some embodiments, the method includes selecting a T cell subset from a composition containing engineered cells, followed by a culturing step, where the selected T cell subset is cultured under conditions for T cell expansion. In some embodiments, the method includes selecting a T cell subset from a composition containing engineered cells, followed by a harvesting step, where the selected T cell subset is harvested to generate an output population of engineered T cells. In some embodiments, the T cell subset is naive-like T cells, or the T cells surface-positive for markers expressed on naive-like T cells are CCR7+CD45RA+, CD27+CCR7+, or CD62L-CCR7+. In some embodiments, the naive-like T cells comprise CD27+CCR7+ T cells. In some embodiments, the naive-like T cells comprise CCR7+CD45RA+ T cells. In some embodiments, the T cell subset expresses a recombinant protein, optionally a chimeric antigen receptor. In some embodiments, the step of selecting the T cell subset is carried out by affinity column chromatography.
[0053] In some embodiments, the method further comprises formulating the harvested cells for cryopreservation and / or administration to a subject, optionally in the presence of a pharmaceutically acceptable excipient. In some embodiments, the harvested cells are formulated in the presence of a cryoprotectant. In some embodiments,
[0054] In some embodiments, the stationary phase is or comprises a chromatography matrix. In some embodiments, the stationary phase has a binding capacity, optionally a static or dynamic capacity, of about 75 million to about 125 million T cells per mL of stationary phase. In some embodiments, (a) the stationary phase is about 20 mL; and / or (b) the stationary phase has a binding capacity of 2 billion ± 500 million cells. In some embodiments, the method includes two stationary phases. In some embodiments, the two stationary phases are arranged in parallel. In some embodiments, the two stationary phases are arranged sequentially.
[0055] An article of manufacture for on-column stimulation of T cells is provided, comprising a first stimulatory substance and a second stimulatory substance capable of stimulating T cells by specifically binding to a first molecule and a second molecule, respectively, on the surface of the T cells, and a stationary phase comprising a selection substance capable of immobilizing T cells on the stationary phase by specifically binding to a selection marker on the T cells. In some embodiments, the stationary phase further comprises the first stimulatory substance and the second stimulatory substance. In some embodiments, the first stimulatory substance, the second stimulatory substance, and the selection substance are indirectly bound to the stationary phase via a selection reagent. In some embodiments, the article further comprises a stimulation reagent to which the first stimulatory substance and the second stimulatory substance are reversibly bound or can be reversibly bound. In some embodiments, the stimulation reagent is an oligomeric stimulation reagent. In some embodiments, the selection substance is indirectly bound to the stationary phase via a selection reagent.
[0056] In some embodiments, the stationary phase is or comprises a chromatography matrix, and the article of manufacture further comprises a container containing all or a portion of the chromatography matrix. In some embodiments, the article of manufacture comprises two stationary phases. In some embodiments, the two stationary phases are arranged in parallel. In some embodiments, the two stationary phases are arranged sequentially.
[0057] Devices comprising the above-described articles of manufacture and embodiments thereof are provided. In some embodiments, the device further comprises a fluid inlet fluidly connected to one or more components of the device and / or a fluid outlet fluidly connected to one or more components of the device. In some embodiments, the device is in a closed system or a sterile system. In some embodiments, the system is both a closed and sterile system.
[0058] Apparatus and / or articles of manufacture are provided for use in any of the methods provided herein (including aspects thereof) that may be performed automatically. [The present invention 1001] A method for on-column stimulation of T cells, comprising the steps of: adding an oligomeric stimulatory reagent capable of delivering a stimulatory signal in a T cell to a stationary phase comprising a plurality of immobilized T cells, thereby initiating incubation of the stimulatory reagent with the one or more T cells; the stationary phase comprises a selection agent that specifically binds to a selection marker on the surface of one or more T cells or subsets thereof; the oligomeric stimulatory reagent comprises one or more stimulatory agents including (i) a first stimulatory agent that is an anti-CD3 antibody and (ii) a second stimulatory agent that is an anti-CD28 antibody; process; and Harvesting one or more of the plurality of T cells from the stationary phase by gravity flow within 24 hours of the start of incubation, thereby producing a composition comprising stimulated T cells. [The present invention 1002] A method for on-column stimulation of T cells, comprising the steps of: (a) incubating a plurality of T cells immobilized on a stationary phase with one or more stimulatory agents to deliver a stimulatory signal in one or more T cells of the plurality of T cells, wherein the stationary phase comprises a selection agent that specifically binds to a selection marker on the surface of the one or more T cells, and specific binding of the selection agent to the selection marker expressed by the one or more T cells immobilizes the one or more T cells on the stationary phase; and (b) harvesting the one or more T cells from the stationary phase by gravity flow within 24 hours of the start of incubation, thereby producing a composition comprising stimulated T cells. [The present invention 1003] The method of the present invention 1002, wherein the immobilized phase comprises at least one of one or more stimulatory substances capable of delivering a stimulatory signal in one or more T cells or is immobilized together with at least one of said one or more stimulatory substances. [The present invention 1004] The method of the present invention 1002, wherein the one or more stimulating substances are a first stimulating substance and a second stimulating substance, and prior to incubation, a stimulating reagent containing a second stimulating substance capable of enhancing, attenuating or modifying the stimulating signal of the first stimulating substance is added to the stationary phase. [The present invention 1005] The method of claim 1002, further comprising the step of adding a stimulating reagent comprising at least one of the one or more stimulating substances to the stationary phase prior to incubating. [The present invention 1006] The method of the present invention 1005, wherein at least one stimulating substance is a first stimulating substance, and the one or more stimulating substances further comprise a second stimulating substance having the ability to enhance, attenuate or modify the stimulating signal of the first stimulating substance. [The present invention 1007] Any of the methods of claims 1002 to 1006, wherein at least one of the one or more stimulatory agents, optionally the first stimulatory agent, is capable of delivering a stimulatory signal, the stimulatory signal being a stimulatory signal via a TCR / CD3 complex in a T cell, a CD3-containing complex in a T cell, and / or an ITAM-containing molecule in a T cell. [The present invention 1008] The method of any of claims 1004, 1006 and 1007, wherein the second stimulatory agent has the ability to specifically bind to one or more costimulatory molecules on T cells. [The present invention 1009] A method for on-column stimulation of T cells, comprising the steps of: (a) adding a sample comprising a plurality of T cells to a stationary phase, wherein the stationary phase comprises a selection agent that binds to a selection marker on the surface of one or more of the plurality of T cells, thereby immobilizing the one or more of the plurality of T cells on the stationary phase; (b) adding a stimulatory reagent to the stationary phase, the stimulatory reagent comprising one or more stimulatory substances capable of delivering a stimulatory signal in one or more of the plurality of T cells, thereby initiating incubation of the stimulatory reagent with the one or more T cells; and (c) harvesting one or more of the plurality of T cells from the stationary phase by gravity flow within 24 hours of the start of incubation, thereby producing a composition comprising stimulated T cells. [The present invention 1010] A method for on-column stimulation of T cells, comprising the steps of: (1) mixing (a) a sample comprising a plurality of T cells with (b) a stationary phase comprising a selection agent capable of specifically binding to a selection marker expressed on the surface of one or more of the plurality of T cells, wherein the specific binding of the selection agent to the selection marker immobilizes the one or more of the plurality of T cells to the stationary phase; (2) adding a stimulatory reagent to the stationary phase, the stimulatory reagent comprising one or more stimulatory substances capable of delivering a stimulatory signal in T cells, thereby initiating incubation of the stimulatory reagent with the one or more T cells; and (3) harvesting one or more of the plurality of T cells from the stationary phase by gravity flow within 24 hours of the start of incubation, thereby producing a composition comprising stimulated T cells. [The present invention 1011] A method for on-column stimulation of T cells, comprising the steps of: adding an oligomeric stimulating reagent to a stationary phase comprising a plurality of immobilized T cells, thereby initiating incubation of the stimulating reagent with one or more T cells of the plurality of immobilized T cells; the stationary phase comprises a selection agent that specifically binds to a selection marker on the surface of one or more T cells, and specific binding of the selection agent to the selection marker expressed by the one or more T cells immobilizes the one or more T cells to the stationary phase; The oligomeric stimulatory reagent comprises (i) a plurality of streptavidin or streptavidin mutein molecules and (ii) one or more stimulatory substances capable of delivering a stimulatory signal in one or more T cells, and the size of the oligomeric stimulatory reagent is (i) greater than 50 nm in radius, (ii) at least 5×10 6 g / mol and / or (iii) at least 100 streptavidin tetramers or streptavidin mutein tetramers per oligomeric stimulation reagent; Process. [The present invention 1012] The method of claim 1011, further comprising the step of collecting one or more of the plurality of T cells from the stationary phase by gravity flow within 24 hours of the start of incubation, thereby producing a composition comprising stimulated T cells. [The present invention 1013] Any of the methods of 1001 to 1010 or 1012 of the present invention, wherein harvesting one or more of the plurality of T cells from the stationary phase occurs within about 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 hours from the start of incubation. [The present invention 1014] Harvesting one or more of the plurality of T cells from the stationary phase may occur within about 2-24, 3-24, 4-24, 5-24, 6-24, 7-24, 8-24, 9-24, 10-24, 11-24, 12-24, 13-24, 14-24, 15-24, 16-24, 17-24, 18-24, 19-24, 20-24, 21-24, 22-24, 23-24, 24-24, 25-24, 26-24, 27-24, 28-24, 29-30, 30-30, 31-31, 32-32, 33-33, 34-34, 35-35, 36-36, 37-37, 38-38, 39-40, 41-42, 42-43, 43-44, 44-45, 45-46, 46-47, 47-48, 48-49, 49-50, 51-52, 53-54, 54-55, 55-56, 56-57, 57-58, 58-59, 59-60, 61-62, 63-64, 64-65, 65-66, 66-67, 67-68, 68-69, 69-70, 71-71, 72-73, 73-74, 74-75, 75-76, 76-77, 77-78, 78-79, 2 to 4, 22 to 24, 23 to 24, 2 to 23, 2 to 22, 2 to 21, 2 to 20, 2 to 19, 2 to 18, 2 to 17, 2 to 16, 2 to 15, 2 to 14, 2 to 13, 2 to 12, 2 to 11, 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, 2 to 4, or 2 to 3 hours. [The present invention 1015] Any of the methods of 1001 to 1010 or 1012 to 1014 of the present invention, wherein harvesting one or more of the plurality of T cells from the stationary phase occurs within about 12, 10, 8, 6, 4, or 2 hours from the start of incubation. [The present invention 1016] 10. The method of any of claims 1001 to 1010 or 1012 to 1015, wherein harvesting one or more of the plurality of T cells from the stationary phase occurs within 5 hours of initiating incubation. [The present invention 1017] Any of the methods of 1001 to 1010 or 1012 to 1016 of the present invention, wherein harvesting one or more of the plurality of T cells from the stationary phase occurs within 4.5 hours or about 4.5 hours from the start of incubation. [The present invention 1018] 10. The method of any of claims 1001 to 1010 or 1012 to 1017, wherein harvesting one or more of the plurality of T cells from the stationary phase occurs within 4 hours of initiating incubation. [The present invention 1019] Any of the methods of inventions 1001, 1009, 1010 and 1013 to 1017, wherein the incubation with the stimulating reagent is initiated within 10 minutes or within about 10 minutes, 20 minutes or within about 20 minutes, 30 minutes or within about 30 minutes, 45 minutes or within about 45 minutes, 60 minutes or within about 60 minutes, 90 minutes or within about 90 minutes, or 120 minutes or within about 120 minutes after adding the sample containing the plurality of T cells to or mixing with the stationary phase. [The present invention 1020] Any of the methods of 1001, 1009, 1010 and 1013-1019, wherein the initiation of incubation with the stimulating reagent is performed within 60 minutes or within about 60 minutes after adding or mixing the sample containing the plurality of T cells with the stationary phase. [The present invention 1021] Any of the methods of claims 1009 to 1020, wherein at least one of the one or more stimulatory substances is capable of delivering a stimulatory signal, the stimulatory signal being a stimulatory signal via a TCR / CD3 complex in a T cell, a CD3-containing complex in a T cell, and / or an ITAM-containing molecule in a T cell. [The present invention 1022] The method of the present invention 1021, wherein at least one stimulating substance is a first stimulating substance and the stimulating reagent further comprises one or more second stimulating substances capable of enhancing, attenuating or modifying the stimulating signal of the first stimulating substance. [The present invention 1023] The method of any of claims 1004, 1006, 1007 and 1022, wherein the second stimulatory agent has the ability to specifically bind to one or more costimulatory molecules on T cells. [The present invention 1024] The method of claim 1008 or claim 1023, wherein the costimulatory molecule is selected from among CD28, CD90 (Thy-1), CD95 (Apo- / Fas), CD137 (4-1BB), CD154 (CD40L), ICOS, LAT, CD27, OX40 or HVEM. [The present invention 1025] The method of invention 1008, invention 1023 or invention 1024, wherein the second stimulatory agent has the ability to specifically bind to CD28 and / or the costimulatory molecule is CD28. [The present invention 1026] The method of any one of claims 1014, 1006, 1007, 1008 and 1020 to 1023, wherein the first stimulatory agent specifically binds to CD3 and the second stimulatory agent specifically binds to CD28. [The present invention 1027] the one or more stimulatory substances are, or comprise, independently, substances selected from the group consisting of antibody fragments, monovalent antibody fragments, proteinaceous binding molecules with immunoglobulin-like function, molecules containing Ig domains, cytokines, chemokines, aptamers, MHC molecules, MHC-peptide complexes; receptor ligands; and binding fragments thereof; Any of the methods 1001 to 1026 of the present invention. [The present invention 1028] the first stimulatory agent and the second stimulatory agent are, or comprise, independently, a substance selected from the group consisting of an antibody fragment, a monovalent antibody fragment, a proteinaceous binding molecule with immunoglobulin-like function, an Ig domain-containing molecule, a cytokine, a chemokine, an aptamer, an MHC molecule, an MHC-peptide complex; a receptor ligand; and binding fragments thereof; Any of the methods of the present invention 1004, 1006, 1007, 1008 or 1013 to 1020, 1022 to 1264. [The present invention 1029] The method of any of claims 1001 to 1027, wherein the one or more stimulatory agents comprises a monovalent antibody fragment. [The present invention 1030] The method of any of claims 1001, 1004, 1006, 1007, 1008, 1013-1020, 1022-1026 and 1028, wherein the first stimulatory agent and the second stimulatory agent independently comprise a monovalent antibody fragment. [The present invention 1031] Any of the methods of inventions 1001, 1004, 1006, 1007, 1008, 1013 to 1020, 1022 to 1026, 1028 and 1030, wherein the first stimulatory agent comprises a monovalent antibody fragment that binds to CD3 and the second stimulatory agent comprises a monovalent antibody fragment that binds to CD28. [The present invention 1032] 1032. The method of any of claims 1027 to 1031, wherein the monovalent antibody fragment is selected from the group consisting of a Fab fragment, an Fv fragment and a single chain Fv fragment (scFv). [The present invention 1033] Any of the methods of inventions 1001, 1004, 1006, 1007, 1008, 1013 to 1020, 1022 to 1026, 1028 and 1030 to 1032, wherein the first stimulatory substance is anti-CD3 Fab and the second stimulatory substance is anti-CD28 Fab. [The present invention 1034] A method for on-column stimulation of T cells, comprising the steps of: adding an oligomeric stimulatory reagent capable of delivering a stimulatory signal in a T cell to a stationary phase comprising a plurality of immobilized T cells, thereby initiating incubation of the stimulatory reagent with the one or more T cells; the stationary phase comprises a selection agent capable of specifically binding to a selection marker on the surface of one or more T cells or a subset thereof, wherein specific binding of the selection agent to the selection marker expressed by the one or more T cells or a subset thereof immobilizes the at least a plurality of T cells to the stationary phase, and the selection agent is a Fab fragment capable of specifically binding to a selection marker selected from the group consisting of CD3, CD4 and CD8; the oligomeric stimulatory reagent comprises (i) a plurality of streptavidin mutein molecules, (ii) a first stimulatory agent that is a Fab fragment capable of specifically binding to CD3 and capable of delivering a stimulatory signal in one or more T cells, and (iii) a second stimulatory agent that is a Fab fragment capable of specifically binding to CD28 and capable of enhancing, attenuating, or modifying the stimulatory signal, and the size of the oligomeric stimulatory reagent is (i) greater than 50 nm in radius, (ii) at least 5×10 6 g / mol, and / or (iii) at least 100 streptavidin tetramers or streptavidin mutein tetramers per oligomeric stimulation reagent; process; and Harvesting one or more of the plurality of T cells from the stationary phase by gravity flow within 24 hours of the start of incubation, thereby producing a composition comprising stimulated T cells. [This invention 1035] The method of any of claims 1001 to 1034, wherein the T cells are derived from a sample that is or comprises a whole blood sample, a buffy coat sample, a peripheral blood mononuclear cell (PBMC) sample, an unfractionated T cell sample, a lymphocyte sample, a leukocyte sample, an apheresis product, or a leukocyte apheresis product. [The present invention 1036] 1036. The method of any of claims 1035, wherein the sample is an apheresis product or a leukapheresis product. [This invention 1037] 1036. Any of the methods of claim 1036, wherein the apheresis product or leukapheresis product has previously been cryofrozen. [The present invention 1038] The method of any of claims 1002-1027 and 1029, wherein incubating with the one or more stimuli causes one or more of the plurality of immobilized T cells to release from the stationary phase. [This invention 1039] 1028, 1030-1038, wherein incubating with the first stimulatory agent and the second stimulatory agent releases one or more of the plurality of immobilized T cells from the stationary phase. [The present invention 1040] a biotin analogue in which one or more stimulatory agents reversibly bind to biotin, streptavidin, or avidin; TIFF0007582940000013.tif48168 Any of the methods of claims 1001 to 1027, 1029 and 1035 to 1028, further comprising a streptavidin-binding peptide selected from the group consisting of: a calmodulin-binding peptide that reversibly binds to calmodulin; a FLAG peptide that reversibly binds to an antibody that binds to the FLAG peptide; and an oligohistidine tag that reversibly binds to an antibody that binds to the oligohistidine tag. [The present invention 1041] One or more stimulants TIFF0007582940000014.tif47165 The method of any one of claims 1001 to 1027, 1029 and 1035 to 1040, further comprising a streptavidin-binding peptide selected from the group consisting of: [The present invention 1042] One or more stimuli are TIFF0007582940000015.tif4128 The method of any one of claims 1001 to 1027, 1029 and 1035 to 1041, further comprising a streptavidin-binding peptide having the formula: [This invention 1043] the first stimulatory agent and the second stimulatory agent are biotin analogs that independently reversibly bind to biotin, streptavidin, or avidin; TIFF0007582940000016.tif48169 any one of methods 1001, 1004, 1006, 1007, 1008, 1013 to 1020, 1022 to 1026, 1028, and 1030 to 1039, further comprising a streptavidin-binding peptide selected from the group consisting of: a calmodulin-binding peptide that reversibly binds to calmodulin; a FLAG peptide that reversibly binds to an antibody that binds to the FLAG peptide; and an oligohistidine tag that reversibly binds to an antibody that binds to the oligohistidine tag. [This invention 1044] Each of the first stimulus substance and the second stimulus substance is TIFF0007582940000017.tif48168 The method of any one of claims 1001, 1004, 1006, 1007, 1008, 1013 to 1020, 1022 to 1026, 1028, 1030 to 1039 and 1043, further comprising a streptavidin-binding peptide selected from the group consisting of: [This invention 1045] Each of the first stimulus substance and the second stimulus substance has the sequence TIFF0007582940000018.tif4128 1028, 1030 to 1039, 1043, and 1044, further comprising a streptavidin-binding peptide having the formula: [The present invention 1046] Any of the methods of claims 1001 to 1045, wherein the selected substance is or comprises a substance selected from the group consisting of an antibody fragment, a monovalent antibody fragment, a proteinaceous binding molecule with immunoglobulin-like function, a molecule containing an Ig domain, a cytokine, a chemokine, an aptamer, an MHC molecule, an MHC-peptide complex; a receptor ligand; and binding fragments thereof. [This invention 1047] The selection marker is a T cell coreceptor; the selectable marker is or comprises a member of the T cell antigen receptor complex; the selection marker is or comprises a CD3 chain, the selection marker is or comprises the CD3 zeta chain, the selection marker is or comprises CD8; the selection marker is or comprises CD4, the selection marker is or comprises CD45RA; the selection marker is or comprises CD27; the selection marker is or comprises CD28, and / or the selection marker is or comprises CCR7; Any of the methods of 1001 to 1046 of the present invention. [This invention 1048] The method of any of claims 1001 to 1047, wherein the selection marker is selected from the group consisting of CD3, CD4 and CD8. [This invention 1049] The method of any one of claims 1001 to 1048, wherein the selection marker is CD3. [The present invention 1050] the selective agent is a biotin analogue that reversibly binds to biotin, streptavidin, or avidin; TIFF0007582940000019.tif49169 Any of the methods of claims 1001 to 1049, further comprising a streptavidin-binding peptide selected from the group consisting of: a calmodulin-binding peptide that reversibly binds to calmodulin; a FLAG peptide that reversibly binds to an antibody that binds to the FLAG peptide; and an oligohistidine tag that reversibly binds to an antibody that binds to the oligohistidine tag. [This invention 1051] the selective agent is a biotin analogue that reversibly binds to biotin, streptavidin, or avidin; TIFF0007582940000020.tif48168 The method of any one of claims 1001 to 1050, further comprising a streptavidin-binding peptide selected from the group consisting of: [This invention 1052] The selected substance has the sequence TIFF0007582940000021.tif4128 The method of any one of claims 1001 to 1051, further comprising a streptavidin-binding peptide having the formula: [This invention 1053] Any of the methods of inventions 1001 to 1052, wherein the specific binding between the selection substance and the selection marker does not induce a signal to the T cell, or does not induce any of a stimulatory signal, an activation signal, and a proliferation signal to the T cell. [This invention 1054] The method of any of claims 1001 to 1053, wherein the selection agent comprises a monovalent antibody fragment that binds to CD3, CD8 or CD4. [This invention 1055] The method of any of claims 1001 to 1054, wherein the selection agent is an anti-CD3 Fab, an anti-CD8 Fab, or an anti-CD4 Fab. [This invention 1056] The method of any one of claims 1001 to 1055, wherein the selection agent is an anti-CD3 Fab. [This invention 1057] The stimulation reagent is an oligomeric stimulation reagent comprising a plurality of streptavidin molecules or streptavidin mutein molecules, and the size of the oligomeric particle reagent is: (i) a radius of greater than 50 nm; (ii) at least 5×10 6 g / mol and / or (iii) at least 100 streptavidin tetramers or streptavidin mutein tetramers per oligomeric stimulation reagent. [This invention 1058] The oligomeric stimulation reagent comprises a plurality of streptavidin or streptavidin mutein molecules, and the size of the oligomeric particle reagent is: (i) greater than 50 nm in radius; (ii) at least 5×10 6 g / mol and / or (iii) at least 100 streptavidin tetramers or streptavidin mutein tetramers per oligomeric stimulation reagent. [This invention 1059] The method of any one of claims 1001 and 1011 to 1058, wherein the oligomer stimulating reagent is soluble. [The present invention 1060] the oligomeric stimulation reagent is not, and is not bound to or associated with, a solid support, stationary phase, bead, microparticle, magnetic particle and / or matrix; and / or the reagent is flexible, does not contain a metallic or magnetic core, is composed entirely or primarily of organic polymers, and / or is not rigid; Any of methods 1001, 1011 to 1059 of the present invention. [The present invention 1061] The method of any of claims 1011 to 1060, wherein the streptavidin molecule or streptavidin mutein molecule reversibly binds or has the ability to reversibly bind to biotin, a biotin analogue, or a streptavidin-binding peptide. [This invention 1062] The streptavidin mutein has the amino acid sequence Ile at a sequence position corresponding to positions 44 to 47 in streptavidin in the amino acid sequence shown in SEQ ID NO: 1. 44 -Gly 45 -Ala 46 -Arg 47 Contains, or The streptavidin mutein has the amino acid sequence Val at a sequence position corresponding to positions 44 to 47 in streptavidin in the amino acid sequence shown in SEQ ID NO: 1. 44 -Thr 45 -Ala 46 -Arg 47 Including, Any of the methods of the present invention 1011 to 1061. [This invention 1063] Streptavidin-binding peptides TIFF0007582940000022.tif48169 1063. The method of any of claims 1061 or 1062, wherein the method is selected from the group consisting of: [The present invention 1064] The oligomer stimulating reagent is Radius greater than 60nm, greater than 70nm, greater than 80nm or greater than 90nm Any of the methods of the present inventions 1001 and 1011 to 1063, comprising: [This invention 1065] The oligomer stimulating reagent is a radius between 50 nm and 150 nm, between 75 nm and 125 nm, between 80 nm and 115 nm, or between 90 nm and 110 nm, inclusive; or Radius of 90nm±15nm or 95nm±20~25nm Any of the methods of the present inventions 1001 and 1011 to 1064, comprising: [The present invention 1066] 1165. Any of the methods of claim 1164, wherein said radius is a hydrodynamic radius. [This invention 1067] The oligomer stimulating reagent is At least 5 x 10 7 g / mol or at least 1×10 8 g / mol, and / or 5×10 7 g / mol ~ 5 × 10 8 g / mol, 1×10 8 g / mol ~ 5 × 10 8 g / mol, or 1×10 8 g / mol~2×10 8 g / mol The method of any one of 1001 and 1011 to 1066 of the present invention, which includes a molecular weight of [The present invention 1068] The oligomer stimulating reagent is at least 500 streptavidin tetramers or streptavidin mutein tetramers, at least 1,000 streptavidin tetramers or streptavidin mutein tetramers, at least 1,500 streptavidin tetramers or streptavidin mutein tetramers, or at least 2,000 streptavidin tetramers or streptavidin mutein tetramers, and / or 1,000 to 20,000 streptavidin tetramers or streptavidin mutein tetramers, 1,000 to 10,000 streptavidin tetramers or streptavidin mutein tetramers, or 2,000 to 5,000 streptavidin tetramers or streptavidin mutein tetramers Any of the methods of the present inventions 1001 and 1011 to 1067, comprising: [This invention 1069] The method of any of claims 1001 and 1011 to 1068, wherein the oligomeric stimulating reagent is added to the stationary phase at a concentration of about 1 to about 2 µg / million cells. [The present invention 1070] The method of any of claims 1001 to 1069, wherein the selection agent is directly or indirectly bound to the stationary phase. [This invention 1071] The method of any of claims 1001 to 1070, wherein the selection substance is indirectly bound to the stationary phase via a selection reagent to which the selection substance reversibly binds. [This invention 1072] 1072. The method of claim 1070 or 1071, wherein the selection reagent is or comprises streptavidin; avidin; a mutein of streptavidin that reversibly binds to biotin, a biotin analogue or a biologically active fragment thereof; an avidin or mutein of streptavidin that reversibly binds to a streptavidin-binding peptide; a reagent comprising at least two chelating groups K, wherein the at least two chelating groups are capable of binding to a transition metal ion; a substance capable of binding to an oligohistidine affinity tag; a substance capable of binding to glutathione-S-transferase; calmodulin or an analogue thereof; a substance capable of binding to calmodulin-binding peptide (CBP); a substance capable of binding to a FLAG peptide; a substance capable of binding to an HA tag; a substance capable of binding to maltose-binding protein (MBP); a substance capable of binding to an HSV epitope; a substance capable of binding to a myc epitope; or a substance capable of binding to a biotinylated carrier protein. [This invention 1073] the selection reagent is or comprises a streptavidin or avidin mutein that reversibly binds biotin or a biologically active fragment; the stimulating reagent is or comprises a streptavidin or avidin mutein that reversibly binds to a biotin analog or biologically active fragment; and / or the stimulating reagent is or comprises a streptavidin mutein or avidin mutein that reversibly binds to a streptavidin-binding peptide; Any of the methods of 1070 to 1072 of the present invention. [This invention 1074] 1074. A method according to claim 1072 or claim 1073, wherein the streptavidin molecule or streptavidin mutein molecule reversibly binds or has the ability to reversibly bind to biotin, a biotin analogue or a streptavidin-binding peptide. [This invention 1075] The streptavidin mutein has the amino acid sequence Ile at a sequence position corresponding to positions 44 to 47 in streptavidin in the amino acid sequence shown in SEQ ID NO: 1. 44 -Gly 45 -Ala 46 -Arg 47 Contains, or The streptavidin mutein has the amino acid sequence Val at a sequence position corresponding to positions 44 to 47 in streptavidin in the amino acid sequence shown in SEQ ID NO: 1. 44 -Thr 45 -Ala 46 -Arg 47 Including, Any of methods 1072 to 1074 of the present invention. [This invention 1076] Streptavidin-binding peptides TIFF0007582940000023.tif48169 Any of the methods of 1072 to 1075 of the present invention, selected from the group consisting of: [This invention 1077] The streptavidin-binding peptide has the sequence TIFF0007582940000024.tif4128 Any of the methods of claims 1072 to 1076 of the present invention. [This invention 1078] Any of the methods of claims 1001-1010 or 1012-1077, wherein collecting by gravity flow comprises adding to the stationary phase a medium that does not contain a competitor or a free binding agent for eluting the T cells from the stationary phase. [This invention 1079] The method of any of claims 1001 to 1010 and 1012 to 1078, wherein the composition comprising stimulated T cells does not comprise a competitor or a free binder. [The present invention 1080] 1079. The method of any one of claims 1078 to 1079, wherein the competitor or free binder is or comprises biotin or a biotin analogue, and optionally the biotin analogue is D-biotin. [This invention 1081] The method of any of claims 1001 to 1078, further comprising the step of introducing a recombinant nucleic acid molecule encoding a recombinant protein into stimulated T cells of said composition, thereby producing a composition comprising engineered T cells, optionally a composition comprising transduced T cells. [This invention 1082] 1081. The method of claim 1081, wherein the recombinant protein is an antigen receptor. [This invention 1083] The method of claim 1081 or claim 1082, wherein the recombinant protein is a chimeric antigen receptor. [This invention 1084] The method of claim 1083, wherein the chimeric antigen receptor (CAR) comprises an extracellular antigen recognition domain that specifically binds to a target antigen and an intracellular signaling domain comprising an ITAM. [This invention 1085] 1084. The method of claim 1084, wherein the intracellular signaling domain comprises the intracellular domain of the CD3 zeta (CD3ζ) chain. [The present invention 1086] The method of claim 1084 or claim 1085, further comprising a transmembrane domain connecting the extracellular domain and the intracellular signaling domain. [This invention 1087] 1086. The method of claim 1086, wherein the transmembrane domain comprises the transmembrane portion of CD28. [This invention 1088] The method of any of claims 1084 to 1087, wherein the intracellular signaling domain further comprises an intracellular signaling domain of a T cell costimulatory molecule. [This invention 1089] The method of claim 1088, wherein the T cell costimulatory molecule is selected from the group consisting of CD28 and 41BB. [The present invention 1090] 1089. The method of any of claims 1081 to 1089, wherein said nucleic acid further comprises a promoter operably linked to the nucleic acid encoding the recombinant antigen receptor. [This invention 1091] 1090. The method of any one of claims 1081 to 1090, wherein the introduction of the recombinant nucleic acid is achieved by transduction using a viral particle. [This invention 1092] 1091. The method of claim 1091, wherein the viral particle is a retroviral vector particle. [This invention 1093] 1093. The method of claim 1091 or 1092, wherein the viral particle is a lentiviral vector particle. [This invention 1094] Any of the methods of claims 1081 to 1093, further comprising the step of incubating the composition comprising the transduced cells under conditions for viral integration, optionally at a temperature of 37°±2°C or about 37°±2°C. [This invention 1095] 1094. The method of claim 1094, wherein the step of incubating the composition comprising the transduced cells is carried out for up to 96 hours after transfection. [This invention 1096] 1094. The method of claim 1094, wherein the step of incubating the composition comprising the transduced cells is carried out for up to 72 hours after transfection. [This invention 1097] 1094. The method of claim 1094, wherein the step of incubating the composition comprising the transduced cells is carried out for up to 48 hours after transfection. [This invention 1098] 1094. The method of claim 1094, wherein the step of incubating the composition comprising the transduced cells is carried out for up to 24 hours after transfection. [This invention 1099] 199. The method of any one of claims 1094 to 1098, wherein the step of incubating the composition comprising the transduced cells is carried out for at least 18 hours after transfection. [The present invention 1100] The method of any of claims 1081 to 1099, further comprising culturing the composition comprising the engineered cells, and optionally the composition comprising the transduced cells, under conditions for expanding T cells. [The present invention 1101] The method of claim 1100, wherein the culturing step is carried out for a period of 14 days or less, 12 days or less, 10 days or less, 8 days or less, 6 days or less, or 5 days or less. [The present invention 1102] The method of any of claims 1081 to 1101, further comprising the step of harvesting the engineered T cells, thereby producing an output population of engineered T cells. [The present invention 1103] Any of the methods of claims 1081 to 1099, further comprising the step of harvesting the engineered T cells at a time point between 48 and 120 hours, inclusive, after initiation of exposure to the stimulatory reagent. [The present invention 1104] The method of any of claims 1081 to 1099 and 1103, wherein the collection is performed within 120 hours after the start of exposure to the irritant. [This invention 1105] The method of any of claims 1081 to 1099 and 1103, wherein the collection is performed within 96 hours after the start of exposure to the irritant. [The present invention 1106] The method of any of claims 1081 to 1099 and 1105, wherein the collection is performed within 72 hours after the start of exposure to the irritant. [This invention 1107] The method of any of claims 1081 to 1099 and 1106, wherein the collection is performed within 48 hours after the start of exposure to the irritant. [This invention 1108] Any of the methods of 1102 to 1107, wherein the percentage of naive-like cells is greater than or greater than about 60% of the total T cells in the population, the total CD4+ T cells in the population, or the total CD8+ T cells or recombinant protein-expressing cells thereof in the population at the time of collection. [This invention 1109] The method of claim 1108, wherein the naive-like T cells comprise CD27+CCR7+ cells. [The present invention 1110] 1094. The method of any of claims 1081 to 1093, wherein the introduction is carried out in serum-free medium. [The present invention 1111] 1099. The method of any of claims 1094 to 1099, wherein the incubating step is carried out in serum-free medium. [The present invention 1112] The method of claim 1100 or claim 1101, wherein the culturing step is carried out in a serum-free medium. [The present invention 1113] Serum-free medium, In the basal medium, 0.5 mM to 5 mM dipeptide-type L-glutamine, 0.5mM to 5mM L-glutamine, and Optionally, at least one protein 1113. The method of any one of claims 1110 to 1112, wherein the medium is serum-free. [This invention 1114] The method of any of claims 1110 to 1113, wherein the serum-free medium comprises a recombinant cytokine selected from among IL-2, IL-15 and IL-7, optionally recombinant human IL-2, recombinant human IL-15 and / or recombinant human IL-7. [This invention 1115] The method of any of claims 1110 to 1114, wherein the serum-free medium does not contain a recombinant cytokine selected from among IL-2, IL-15 and IL-7, optionally recombinant human IL-2, recombinant human IL-15 and / or recombinant human IL-7. [The present invention 1116] The method of any of claims 1081 to 1093, further comprising adding a competitor or free binder to the composition comprising the engineered cells, optionally a composition comprising the transduced T cells, optionally wherein the agent is added under conditions to dissociate one or more stimulatory agents from the oligomeric stimulatory reagents in the composition. [This invention 1117] Any of the methods of claims 1094 to 1099, further comprising adding to the composition comprising the incubated T cells, optionally under conditions to dissociate one or more stimulatory agents from the oligomeric stimulatory reagents in the composition, a competitor or free binder. [This invention 1118] 1102. The method of any of claims 1100-1101, further comprising adding to the composition comprising the cultured T cells, optionally a competitor or free binder, under conditions to dissociate one or more stimulatory agents from the oligomeric stimulatory reagent in the composition. [This invention 1119] The method of any of claims 1116 to 1118, wherein the step of adding a competitor or free binder is carried out prior to harvesting. [The present invention 1120] Any of the methods of inventions 1116 to 1119, wherein the competitor or free binding agent is not harmful to T cells and / or addition of the agent does not reduce the percentage of surviving T cells to less than 90%, less than 80%, less than 70%, less than 60% or less than 50% compared to incubation of T cells under equivalent or identical conditions without the use of either the competitor or the free binding agent. [This invention 1121] The method of any of claims 1116 to 1120, wherein said dissociation terminates or reduces a stimulatory signal in the T cell. [This invention 1122] The competing reagent and the free binder are independently a streptavidin-binding molecule; biotin; D-biotin; a biotin analog; streptavidin; or a sequence containing the amino acid sequence Val at a sequence position corresponding to positions 44-47 of wild-type streptavidin. 44 -Thr 45 -Ala 46 -Arg 47 Or Ile 44 -Gly 45 -Ala 46 -Arg 47 or a molecule from the group consisting of a biotin analogue that specifically binds to a streptavidin analogue having the competing reagent and the free binder independently comprise a metal chelator, optionally EDTA or EGTA; Any of the methods of the present invention 1116 to 1121. [This invention 1123] The method of any of claims 1116 to 1122, wherein the competitive reagent and the free binder independently comprise D-biotin, optionally 1 mM D-biotin. [This invention 1124] The method of any of claims 1081 to 1123, further comprising a step of washing the cells, optionally wherein said washing step reduces or removes the stimulating reagent and / or one or more stimulating substances in the composition. [Invention 1125] The method of claim 1124, wherein a washing step is performed before harvesting. [The present invention 1126] Any of the methods of the present inventions 1001 to 1125, wherein the T cells include antigen-specific T cells or a population thereof, T helper cells or a population thereof, cytotoxic T cells or a population thereof, memory T cells or a population thereof, or regulatory T cells or a population thereof. [This invention 1127] The method of any of claims 1001 to 1126, wherein the T cells comprise CD3+ T cells, or comprise CD4+ and / or CD8+ T cells. [This invention 1128] Any of the methods of present inventions 1001 to 1127, comprising a step of selecting a T cell subset from T cells stimulated with the composition, followed by introduction of any of present inventions 1081 to 1093, and introducing a recombinant nucleic acid molecule into the selected T cell subset. [This invention 1129] The method of any of claims 1001 to 1128, comprising the step of selecting a T cell subset from a composition comprising transduced cells, followed by the incubation of any of claims 1094 to 1099, wherein the selected T cell subset is incubated under conditions for viral integration. [The present invention 1130] Any of the methods of claims 1001 to 1129, comprising a step of selecting a T cell subset from a composition comprising engineered cells, followed by a culture step of any of claims 1100 to 1101, and culturing the selected T cell subset under conditions for expanding T cells. [This invention 1131] 11. The method of any of claims 1001 to 1130, comprising the step of selecting a T cell subset from a composition comprising the engineered cells, followed by the harvesting of any of claims 1102 to 1109, and harvesting the selected T cell subset to produce an output population of engineered T cells. [This invention 1132] Any of the methods of the present inventions 1129 to 1131, wherein the T cell subset is a naive-like T cell, or the T cells that are surface-positive for a marker expressed on a naive-like T cell are CCR7+CD45RA+, CD27+CCR7+ or CD62L-CCR7+. [This invention 1133] The method of claim 1129 or claim 1132, wherein the naive-like T cells comprise CD27+CCR7+ T cells. [This invention 1134] The method of claim 1129 or claim 1132, wherein the naive-like T cells comprise CCR7+CD45RA+ T cells. [This invention 1135] 1135. The method of any of claims 1129 to 1134, wherein the T cell subset expresses a recombinant protein, optionally a chimeric antigen receptor. [This invention 1136] 1136. The method of any of claims 1129 to 1135, wherein the step of selecting a T cell subset is carried out by affinity column chromatography. [This invention 1137] Any of the methods of claims 1102-1108, 1125 and 1129-1136, further comprising formulating the harvested cells, optionally in the presence of a pharmaceutically acceptable excipient, for cryopreservation and / or administration to a subject. [This invention 1138] The method of any of claims 1102 to 1108, 1125 and 1129 to 1137, wherein the harvested cells are formulated in the presence of a cryoprotectant. [This invention 1139] The method of any one of claims 1001 to 1138, wherein the stationary phase is or comprises a chromatographic matrix. [This invention 1140] 1139. The method of any of claims 1001 to 1139, wherein the stationary phase has a binding capacity, optionally a static binding capacity or a dynamic binding capacity, of about 75 million to about 125 million T cells per mL of stationary phase. [This invention 1141] (a) the stationary phase is about 20 mL; and / or (b) the stationary phase has a binding capacity of 2 billion ± 500 million cells; Any of the methods of 1001 to 1140 of the present invention. [This invention 1142] 1001-1141. The method of any one of claims 1001-1141, comprising two stationary phases. [This invention 1143] The method of claim 1142, wherein the two stationary phases are arranged in parallel. [This invention 1144] The method of claim 1142, wherein the two stationary phases are arranged sequentially. [Invention 1145] (a) a first stimulatory agent and a second stimulatory agent capable of stimulating a T cell by specifically binding to a first molecule and a second molecule, respectively, on the surface of the T cell; (b) a stationary phase comprising a selection agent capable of immobilizing T cells on the stationary phase by specifically binding to a selection marker on the T cells; 1. An article of manufacture for on-column stimulation of T cells, comprising: [Invention 1146] 1145. The article of manufacture of claim 1145, wherein the stationary phase further comprises a first stimulant and a second stimulant. [This invention 1147] 1145 or 1146, wherein the first stimulus agent, the second stimulus agent, and the selection agent are indirectly bound to the stationary phase via the selection reagent. [Invention 1148] 1145. The article of manufacture of claim 1145, further comprising a stimulating reagent, wherein the first stimulating substance and the second stimulating substance are reversibly bound or have the ability to be reversibly bound. [This invention 1149] 1145. The article of manufacture of claim 1145, wherein the selection substance is indirectly bound to the stationary phase via the selection reagent. [This invention 1150] 1149. The article of manufacture of any one of claims 1145 to 1149, wherein the stationary phase is or comprises a chromatography matrix, and said article of manufacture further comprises a vessel containing all or a portion of said chromatography matrix. [This invention 1151] 11. The article of manufacture of any one of claims 1145 to 1150, comprising two stationary phases. [This invention 1152] 1151. An article of manufacture of claim 1151, wherein two stationary phases are arranged in parallel. [This invention 1153] 1151. An article of manufacture of claim 1151, wherein two stationary phases are arranged sequentially. [This invention 1154] An apparatus comprising any one of the articles of manufacture of the present inventions 1145 to 1153. [Invention 1155] The device of the present invention 1154 further comprising a fluid inlet fluidly connected to one or more components of the device and / or a fluid outlet fluidly connected to one or more components of the device. [Invention 1156] A device of either invention 1154 or 1155 in a closed system or in a sterile system. [This invention 1157] Any of the devices of the present inventions 1154 to 1156 or any of the articles of the present inventions 1145 to 1153 for use in any of the methods of the present inventions 1001 to 1144, which may be carried out automatically. [Brief explanation of the drawings]
[0059] [Figure 1]FIG. 1 is a schematic diagram of an exemplary embodiment of a process for stimulating and selecting target cells. Here, stimulation is performed by incubation of cells, which occurs at least in part in the presence of a support 6 (depicted here as a stationary phase). A component of a selection reagent 1 for cell selection is immobilized on the support (Panel A). The selection reagent 1 has a binding site for a selection agent 2, which is capable of binding to a molecule (selection marker) 4 present on some or all of the target cells. The selection agent 2 is added to the support on which the selection reagent 1 is immobilized under conditions such that the reagent and agent reversibly bind, e.g., via the binding site, to form an oligomeric complex on which the agent multimerizes (Panel B). The selection agent can include two or more agents. Alternatively, a reversibly bound agent-reagent complex can be added as a complex to the stationary phase for immobilization. As shown, cells 3, including target cells, are mixed with the stationary phase and the multimerized selection agent complex. This causes the target cells to become reversibly immobilized to support 6 via selection agent 2 and reagent (selection reagent) 1 (Panel C). Optionally, unbound cells are removed prior to or after addition of the stimulator. A complex containing multimerized stimulator 5 reversibly bound to oligomeric stimulator reagent 7 is added under conditions such that stimulator 5 specifically binds to a molecule on the target cells, thereby inducing or modulating a signal in the immobilized target cells expressing the marker (Panel D). [Figure 2] Figures 2A and 2B show the results of WST metabolic assays of T cells from three different donors incubated with anti-CD3 / anti-CD28 multimerized on different batches of oligomeric reagents. Figure 2A summarizes the WST metabolic activity for all tested batches (pools) compared to reference batches containing anti-CD3 / anti-CD28 multimerized on oligomeric backbones with average hydrodynamic radii of 36 nm or 101 nm. Figure 2B shows the average WST metabolic activity in T cells from different donors for each tested batch and reference reagent. [Figure 3] Figure 3 shows the effect of 24-hour on-column stimulation with anti-CD3 / anti-CD28 oligomer stimulating reagent on the surface expression of each molecule when CD3, CD4, and CD8 were each used as selection markers to immobilize cells on the stationary phase of a chromatography column. The surface expression pattern is compared to a control condition without on-column stimulation with anti-CD3 / anti-CD28 oligomer stimulating reagent. Cells were isolated from apheresis samples applied to the stationary phase. [Figure 4] Figure 4 shows exemplary kinetics of downregulation and re-expression of TCR / CD3 complexes upon on-column stimulation with anti-CD3 / anti-CD28 oligomer stimulation reagents, when CD3 was used as a selection marker to immobilize cells on the column. Cells were isolated from apheresis samples applied to the stationary phase. CD3 / TCR complexes were assessed using antibodies against the alpha-beta TCR chain. [Figure 5A] Figures 5A-5B show the phenotypic and functional characteristics of cultured T cells spontaneously detached during on-column stimulation with anti-CD3 / anti-CD28 oligomer stimulating reagent. Figure 5A shows T cell size and CD3, CD69, and CD25 expression 24 hours and 5 days after on-column stimulation. Figure 5B shows the proliferative potential of spontaneously detached cultured T cells. Cells were isolated from apheresis samples applied to the stationary phase and collected using a washing procedure. [Figure 5B] See legend to Figure 5A. [Figure 6] Figures 6A-6D show exemplary effects of incubating T cells with anti-CD3 / anti-CD28 oligomer stimulatory reagent in the presence or absence of compound 63 on mTor signaling and viability and growth kinetics. Figure 6A shows pS6 expression by memory subsets in live CD8+ T cells. Figure 6B shows mean fluorescence intensity (mfi) of total CD8 T cells with the indicated treatments. Figures 6C-6D show viability and total T cell numbers, respectively, over time (shown in days, e.g., d1) in culture after the start of stimulation ("input"). [Figure 7]Figures 7A-7F show exemplary functional and phenotypic characteristics of cryopreserved CAR-T cells generated using a method employing incubation with anti-CD3 / anti-CD28 oligomer stimulating reagents in the presence or absence of compound 63. Figure 7A shows intracellular expression of caspases at the time of thawing. Figures 7B and 7D show phenotypic profiles of CD8 and CD4 CAR-T cells, respectively, by CD27 and / or CCR7 subset expression. Figures 7C and 7E show intracellular IL2, IFNg, or TNF (left panel) or a combination of IL2 and / or IFNg or TNF (right panel) in CD8 and CD4 CAR-T cells, respectively, stimulated with antigen-bearing targets. Figure 7F shows 12-day expansion and survival (left panel) and the total expansion metric (calculated by area under the curve) for CAR-T cells stimulated with anti-CAR beads. [Figure 8A] Figure 8A shows CD3+, CD4+, and CD8+ T cell yields after cell selection using the on-column stimulation process or an alternative process described in Example 5. Figures 8B-8C show the total number of cells (Figure 8B) and percentage of viable cells (Figure 8C) recovered after using the on-column stimulation process or an alternative process described in Example 5. [Figure 8B] See legend to Figure 8A. [Figure 8C] See legend to Figure 8A. [Figure 9A] Figures 9A-9D represent the percentage of viable cells (e.g., purity; Figure 9A), the percentage of viable cells expressing an exemplary CAR (Figure 9B), the percentage of viable cells expressing CD4 at selection and at day 8 of the process (Figure 9C), and the distribution (percentage) of T cell phenotypes for each donor at day 5 of culture (from the beginning of the process to day 8) for the on-column stimulation process described in Example 5 or an alternative process. [Figure 9B] See legend to Figure 9A. [Figure 9C]See legend to Figure 9A. [Figure 9D] See legend to Figure 9A. [Figure 10] Figure 10 depicts CD19+ HEK cell lysis over time during culture with anti-CD19 CAR T cells engineered using the on-column stimulation process described in Example 5 or an alternative process, and under control conditions. [Figure 11A] Figures 11A-11C depict antigen-specific CAR T cell production of IFNg (Figure 11A), IL-2 (Figure 11B), and TNF-a (Figure 11C) for CD4 and CD8 T cells engineered using the on-column stimulation process described in Example 5 or an alternative process. [Figure 11B] See legend to Figure 11A. [Figure 11C] See legend to Figure 11A. [Figure 12A] Figures 12A-12C show the CD4:CD8 ratio (Figure 12A), transduction efficiency (CD4 and CD8 cells combined; Figure 12B), and percentage of viable cells (Figure 12C) of engineered T cells generated using the on-column stimulation process or an alternative process described in Example 5. Three production runs are shown for each process. [Figure 12B] See legend to Figure 12A. [Figure 12C] See legend to Figure 12A. [Figure 13] FIG. 13 depicts tumor size by mean radiance in treatment groups 6 days after mice were injected (iv) with a B-cell lymphoma cell line (Raji). [Figure 14] Figure 14 depicts tumor burden in mice injected with a B cell lymphoma cell line (Raji) over time for each treatment group. The effect of CAR T cell treatment is shown for the on-column stimulation process described in Example 5 or the alternative process, and for each of the three manufacturing runs (see Figures 12A-12C). DETAILED DESCRIPTION OF THE INVENTION
[0060] Detailed Description Provided herein are methods for selecting cells from a sample containing target cells (e.g., T cells, CD3+, CD4+, CD8+ T cells), immobilizing the target cells on a stationary phase of a chromatography column, stimulating the immobilized cells on the stationary phase (also referred to herein as on-column stimulation), and collecting and / or eluting the selected and stimulated cells that spontaneously detach from the stationary phase without using a competitor or free binder to promote detachment. Some of the provided methods involve selecting cells from a sample containing target cells (e.g., T cells, CD3+, CD4+, CD8+ T cells), immobilizing the target cells on a stationary phase of a chromatography column, stimulating the immobilized cells on the stationary phase, and collecting and / or eluting the selected and stimulated cells by gravity flow. In provided embodiments, stimulating the target cells (e.g., CD3+, CD4+, or CD8+ T cells) on the stationary phase of the chromatography column promotes downregulation of the molecule used for cell selection (i.e., the selection marker), resulting in the spontaneous detachment or release of the cells from the stationary phase. The release or detachment of the cells can occur without any additional steps or reagents. In some aspects, the cells can be collected by gravity flow, such as by adding media or other solutions to a chromatography column. In certain embodiments, the added media or other solutions do not contain competitors or free-binding agents to promote the release of the cells from the stationary phase.
[0061] In some embodiments, the selected and stimulated cells are a composition containing stimulated T cells, in which T cells have been selected from a biological sample (e.g., an apheresis sample or a whole blood sample) containing a plurality of T cells. In some embodiments, collection and / or elution of selected and stimulated cells that spontaneously detach from the stationary phase is accomplished by gravity flow, e.g., during a wash step. In the methods provided herein, cell selection, stimulation, and collection and / or elution steps are integrated, and no separate steps are required to facilitate detachment of the selected and stimulated cells from the stationary phase or to remove agents used to facilitate detachment (e.g., competitors and / or free binders). Thus, the methods reduce the number of processing steps required to produce a composition of selected and stimulated cells suitable for downstream processing (e.g., genetic manipulation, expansion, subsequent incubation, stimulation, and / or selection (e.g., initial selection and / or polishing)), thereby reducing production time, minimizing potential cell stress, and reducing the possibility of contamination.
[0062] In certain embodiments, the method generates an output composition of selected and stimulated cells suitable for downstream processing within a period of time, e.g., within 24 hours. In certain embodiments, the method generates an output composition of selected and stimulated cells suitable for downstream processing within a period of time, e.g., within or about 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 hours. In certain embodiments, the method generates an output composition of selected and stimulated cells suitable for downstream processing within a period of time, e.g., within or about 6, 5, 4, 3, or 2 hours. In some embodiments, the method generates an output composition of selected and stimulated cells suitable for downstream processing within a period of time, e.g., within about 6 hours or less than about 6 hours. In some embodiments, the method generates an output composition of selected and stimulated cells suitable for downstream processing within a period of time, e.g., within or about 5.5 hours or less. In some embodiments, the method generates an output composition of selected and stimulated cells suitable for downstream processing within a period of time, e.g., about 5 hours or less. In some embodiments, the method generates an output composition of selected and stimulated cells suitable for downstream processing within a period of time, e.g., about 4.5 hours or less. In some embodiments, the method generates an output composition of selected and stimulated cells suitable for downstream processing within a period of time, e.g., about 4 hours or less. In some embodiments, the method generates an output composition of selected and stimulated cells suitable for downstream processing within a period of time, e.g., about 3 hours or less. In some embodiments, the method generates an output composition of selected and stimulated cells suitable for downstream processing within a period of time, e.g., about 3-6 hours or less. In some embodiments, the method generates an output composition of selected and stimulated cells suitable for downstream processing within a period of time, e.g., about 4-6 hours or less.In some embodiments, the methods produce an output composition of selected and stimulated cells suitable for downstream processing within a period of time, e.g., within about 5-6 hours or less than about 5-6 hours. In some embodiments, the methods produce an output composition of selected and stimulated cells suitable for downstream processing within a period of time, e.g., within about 4-5 hours or less than about 4-5 hours. In some embodiments, the methods provided herein produce a composition of engineered T cells (e.g., a therapeutic cell composition) within 5 days. In some embodiments, the methods provided herein produce a composition of engineered T cells (e.g., a therapeutic cell composition) in 4-5 days or about 4-5 days. In some embodiments, the processes provided herein result in a manufacturing process that is 4 or 5 days in length. In some embodiments, the processes provided herein result in a manufacturing process that is about 4-5 days in length. In some embodiments, the processes provided herein result in a manufacturing process that is 4 days or about 4 days or 96±6 hours in length.
[0063] The provided methods include methods for selecting cells, e.g., CD3+, CD4+, and CD8+ T cells, from other components, e.g., other cells in a sample, and immobilizing the cells on a stationary phase of a chromatography column; stimulating the selected cells immobilized on the stationary phase; and collecting the selected and stimulated cells in the absence of processing steps to detach the cells from the stationary phase and to remove from the output composition of the selected and stimulated cells any agents (e.g., competitors or free binders) used to promote detachment. In particular embodiments, the provided methods include methods for selecting cells, e.g., CD3+, CD4+, and CD8+ T cells, from other components, e.g., other cells in a sample, and immobilizing the cells on a stationary phase of a chromatography column; stimulating the selected cells immobilized on the stationary phase; and eluting and / or collecting the selected and stimulated cells by gravity flow.
[0064] In certain aspects, the methods provided herein are an improvement over many existing methods that include one or more additional steps after cell selection (e.g., immunoaffinity-based selection) and prior to stimulating the cells to generate engineered cells (e.g., T cells), such as for cell therapy. In some embodiments, the one or more additional steps present in existing methods can include one or more elution steps using competitive or free-binding agents to recover or harvest the selected cells and / or steps to remove reagents used for selection (e.g., magnetic bead reagents or antibodies). In some embodiments, such additional steps may lengthen the process for genetically engineering cells for cell therapy and / or may result in manipulation of the cells during the process that can impact the differentiation state, viability, or cell number of the cells. In certain aspects, the methods provided generate a population of selected and stimulated cells in a reduced amount of time compared to methods that include separate selection and stimulation steps, requiring additional steps to detach the cells from the stationary phase and additional steps to remove agents used to promote detachment.
[0065] In certain aspects, the methods produce an output population (also referred to as an output composition) of selected and stimulated cells suitable for downstream processing (e.g., genetic manipulation, expansion, and / or subsequent incubation, stimulation, and / or selection rounds (e.g., polishing)) within 24 hours of initiating on-column stimulation, also referred to herein as on-column stimulation. In some embodiments, the methods produce an output population (e.g., an output composition) of selected and stimulated cells suitable for downstream processing (e.g., genetic manipulation, expansion, and / or subsequent incubation, stimulation, and / or selection rounds (e.g., polishing)) within or about 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 hours of initiating on-column stimulation. In some embodiments, the methods generate an output population of selected and stimulated cells suitable for downstream processing (e.g., genetic manipulation, expansion, and / or subsequent incubation, stimulation, and / or selection rounds (e.g., polishing)) within or about 6, 5, 4, 3, or 2 hours. In some embodiments, the methods generate an output population of selected and stimulated cells suitable for downstream processing (e.g., genetic manipulation, expansion, and / or subsequent incubation, stimulation, and / or selection rounds (e.g., polishing)) within or about 3-6 hours. In some embodiments, the methods generate an output population of selected and stimulated cells suitable for downstream processing (e.g., genetic manipulation, expansion, and / or subsequent incubation, stimulation, and / or selection rounds (e.g., polishing)) within or about 4-6 hours. In some embodiments, the method produces an output population of selected and stimulated cells suitable for downstream processing (e.g., genetic manipulation, expansion and / or subsequent incubation, stimulation and / or selection rounds (e.g., polishing)) within or about 5-6 hours.In some embodiments, the method generates an output population of selected and stimulated cells suitable for downstream processing (e.g., genetic manipulation, expansion, and / or subsequent incubation, stimulation, and / or selection rounds (e.g., polishing)) within 4 to 5 hours or about 4 to 5 hours. In some embodiments, the method generates an output population of selected and stimulated cells suitable for downstream processing (e.g., genetic manipulation, expansion, and / or subsequent incubation, stimulation, and / or selection rounds (e.g., polishing)) within 6 hours or about 6 hours. In some embodiments, the method generates an output population of selected and stimulated cells suitable for downstream processing (e.g., genetic manipulation, expansion, and / or subsequent incubation, stimulation, and / or selection rounds (e.g., polishing)) within 5.5 hours or about 5.5 hours. In some embodiments, the method generates an output population of selected and stimulated cells suitable for downstream processing (e.g., genetic manipulation, expansion, and / or subsequent incubation, stimulation, and / or selection rounds (e.g., polishing)) within 5 hours or about 5 hours. In some embodiments, the method produces an output population of selected and stimulated cells suitable for downstream processing (e.g., genetic manipulation, expansion, and / or subsequent incubation, stimulation, and / or selection rounds (e.g., polishing)) within 4.5 hours or about 4.5 hours. In some embodiments, the method produces an output population of selected and stimulated cells suitable for downstream processing (e.g., genetic manipulation, expansion, and / or subsequent incubation, stimulation, and / or selection rounds (e.g., polishing)) within 4 hours or about 4 hours. In some embodiments, the method produces an output population of selected and stimulated cells suitable for downstream processing (e.g., genetic manipulation, expansion, and / or subsequent incubation, stimulation, and / or selection rounds (e.g., polishing)) within 3 hours or about 3 hours.
[0066] In some embodiments, the method involves the use of a stimulatory agent capable of delivering a stimulatory signal to cells by binding to a molecule on the surface of the cells. In some embodiments, the stimulatory agent is included in an oligomeric stimulatory reagent (e.g., a streptavidin mutein oligomer conjugated to an anti-CD3 Fab and an anti-CD28 Fab) that can be added to the stationary phase. In some embodiments, the stimulation results in the spontaneous detachment of selected cells from the stationary phase, thereby allowing for collection and / or elution of the selected, stimulated cells without additional processing steps to detach the cells from the stationary phase and to remove the agent used to promote detachment from the stimulated cell output composition. In some embodiments, the stimulation results in the spontaneous detachment or release of selected cells from the stationary phase, thereby allowing for collection and / or elution of selected, stimulated cells by gravity flow. In some embodiments, gravity flow relies on collecting or eluting cells that have spontaneously detached from a column (e.g., a stationary phase). In some embodiments, a wash step may be used, e.g., in combination with gravity flow, to elute spontaneously detached cells from the column (e.g., a stationary phase). In some embodiments, the washing step can simply involve adding cell culture medium (e.g., serum-free medium) to the column, e.g., the same medium that is present in the cell input composition before adding or immobilizing the cells to the stationary phase. In certain aspects, the method successfully produces an uncontaminated (e.g., free of agents used for detachment (e.g., competitors, free binders) and / or selection agents) composition of selected, stimulated cells suitable for further processing, e.g., genetic manipulation, expansion, incubation, or subsequent stimulation and / or selection rounds (e.g., polishing), within 24 hours of initiating on-column stimulation. Articles of manufacture and devices thereof are also provided.
[0067] A variety of methods are available for generating cell populations suitable for use in cell therapy (e.g., selected (enriched), stimulated cells engineered to express a recombinant protein (e.g., a chimeric antigen receptor)). However, in some aspects, these methods can require long or relatively long times to generate the cells, at least in part due to the need to perform multiple processing steps. Multiple processing steps can also result in cellular stress, thus affecting the usefulness of the cells for downstream processing. Additional methods for generating cell compositions are needed.
[0068] In certain aspects, provided methods are based on the discovery that selecting and stimulating target cells (e.g., CD3+, CD4+, or CD8+ T cells) on a stationary phase of a chromatography column promotes downregulation of the molecule (i.e., selection marker) used for cell selection, resulting in spontaneous detachment of the cells from the stationary phase. In some embodiments, the stationary phase of the chromatography column is functionalized with an agent (e.g., a selection agent) capable of specifically binding to a molecule (e.g., a selection marker) on the surface of the target cells. In this manner, when a sample containing target cells bearing a selection marker (e.g., CD3, CD4, CD8) is mixed with the stationary phase (e.g., adding the sample to the stationary phase), the target cells (e.g., CD3+, CD4+, CD8+ T cells) are indirectly immobilized to the stationary phase. In certain aspects, the target cells (e.g., T cells) are stimulated while immobilized on the stationary phase (e.g., on-column stimulation), for example, by adding a stimulatory agent, a stimulatory reagent containing the stimulatory agent, and / or via a stimulatory agent directly or indirectly coupled to the stationary phase. In particular embodiments, the stimulatory agent comprises an agent that activates or stimulates T cells, e.g., an anti-CD3 / anti-CD28 antibody (e.g., Fab) agent. Thus, in some aspects, the provided methods and other embodiments are advantageous in that they simplify multiple processing steps (e.g., selection and stimulation) and / or eliminate processing steps (e.g., steps to remove selection reagents and / or selection agents used to promote detachment), allowing the simplified process to occur in the same container and / or the same closed system, which can result in improved efficiency and sterility.
[0069] In certain aspects, the method involves the use of an oligomeric stimulatory reagent comprising a stimulatory substance capable of delivering a stimulatory signal to target cells (e.g., T cells). Exemplary oligomeric reagents include streptavidin mutein oligomers reversibly bound or conjugated to one or more antibodies or fragments thereof capable of delivering a stimulatory signal to target cells, e.g., T cells. In some embodiments, the oligomeric stimulatory reagent is a streptavidin mutein oligomer conjugated to an anti-CD3 Fab and an anti-CD28 Fab. Existing reagents used to stimulate T cells in vitro, for example, in the absence of exogenous growth factors or in the presence of small amounts of exogenous growth factors, are known (see, for example, U.S. Patent No. 6,352,694 (B1) and European Patent EP0700430B1). Generally, such reagents use beads with a diameter of more than 1 μm, e.g., magnetic beads, to which various binding agents (e.g., anti-CD3 antibodies and / or anti-CD28 antibodies) are immobilized. However, such magnetic beads can be difficult to incorporate into methods for stimulating cells, for example, under conditions required for clinical trials or therapeutic purposes, because it is necessary to ensure that these magnetic beads are substantially or completely removed before administering engineered T cells to a subject. In some aspects, such removal, for example, by exposing the cells to a magnetic field, can reduce the yield of viable cells available for cell therapy. In certain instances, such reagents, e.g., stimulation reagents containing magnetic beads, must be incubated with cells for a minimum time to allow for the detachment of a sufficient number of T cells from the stimulation reagent. Furthermore, reagents such as beads are not easily compatible with column chromatography due to their physical properties.
[0070] The provided methods utilize oligomeric stimulating reagents (e.g., streptavidin mutein oligomers conjugated to anti-CD3 and anti-CD28 antibodies, e.g., Fabs) to overcome such potential limitations. For example, in some embodiments, the provided methods include adding a soluble oligomeric reagent that is not bound to a solid support (e.g., beads) to the stationary phase to initiate stimulation. In some embodiments, the provided methods can include steps to reduce or minimize the amount of residual oligomeric stimulating reagent that may be present at the end of the overall process of engineering cells for cell therapy. In some embodiments, the use of oligomeric reagents reduces or avoids the risk of residual reagent in output cells, e.g., engineered cells, produced or generated by the methods. This is because the addition of a competing reagent or free binding agent can be used to dissociate (e.g., disrupt binding to) the oligomeric stimulating reagent from the stimulatory agent in the cell-containing composition. In some embodiments, because the oligomeric stimulating reagent is soluble, for example, adding a competing reagent or free binding agent is not necessary; it may be sufficient to simply reduce or remove the oligomeric stimulating reagent from the cells in the composition by one or more wash steps. In some embodiments, this also means that a process that complies with GMP standards can be more easily established compared to other methods, such as methods that require additional measures to ensure that the final population for administration is bead-free. Thus, in some aspects, removal or separation of the oligomeric stimulating reagent from the cells, such as by adding a competitor or free binder or one or more washing steps, results in little or no cell loss compared to removal or separation of a bead-based stimulating reagent. In some aspects, the timing of reduction, removal, or separation of the stimulating reagent or oligomeric stimulating reagent is unlimited or less restrictive than removal or separation of a bead-based stimulating reagent. Thus, in some aspects, the stimulating reagent or oligomeric stimulating reagent can be reduced, removed, or separated from the cells at any time or step during the provided methods.
[0071] In certain aspects, the duration of the provided methods can be measured from the time when cells, e.g., T cells of an input cell population or input cell sample, are first contacted or exposed to stimulatory conditions (e.g., those described herein, e.g., in Section IC) (also referred to herein as the initiation of incubation with a stimulator or under stimulatory conditions), e.g., exposure to a stimulatory reagent, is initiated. In some embodiments, the duration for collecting an output population (also referred to herein as an output composition) containing stimulated target cells (e.g., CD3+, CD4+, CD8+ T cells) is measured from the initiation of incubation of the target cells with the stimulatory reagent (e.g., addition of or exposure to the stimulatory reagent), i.e., from the time the stimulatory reagent is added to the column. In some embodiments, the collecting step is performed by gravity flow of the cells from the column at a point after the initiation of incubation, which in some instances can include one or more washes of the column to ensure recovery of cells that have spontaneously released from the column. In particular embodiments, the duration of incubation before the cells are harvested from the column is 24 hours, 23 hours, 22 hours, 21 hours, 20 hours, 19 hours, 18 hours, 17 hours, 16 hours, 15 hours, 14 hours, 13 hours, 12 hours, 11 hours, 10 hours, 9 hours, 8 hours, 7 hours, 6 hours, 5 hours, 4 hours, 3 hours, or 2 hours, or about 24 hours, 23 hours, 22 hours, 21 hours, 20 hours, 19 hours, 18 hours, 17 hours, 16 hours, 15 hours, 14 hours, 13 hours, 12 hours, 11 hours, 10 hours, 9 hours, 8 hours, 7 hours, 6 hours, 5 hours, 4 hours, 3 hours, or 2 hours. hours, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 hours, or less than 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 hours.In some embodiments, the duration of incubation before the cells are eluted from the column and / or collected is 12 hours, 11 hours, 10 hours, 9 hours, 8 hours, 7 hours, 6 hours, 5 hours, 4 hours, 3 hours, or 2 hours, or less than about 12 hours, 11 hours, 10 hours, 9 hours, 8 hours, 7 hours, 6 hours, 5 hours, 4 hours, 3 hours, or 2 hours, or less than 12 hours, 11 hours, 10 hours, 9 hours, 8 hours, 7 hours, 6 hours, 5 hours, 4 hours, 3 hours, or 2 hours. In some embodiments, the duration of incubation before the cells are eluted from the column and / or collected is 6 hours, about 6 hours, or less than 6 hours. In some embodiments, the duration of incubation before the cells are eluted from the column and / or collected is 5 hours, about 5 hours, or less than 5 hours. In some embodiments, the duration of incubation before the cells are eluted from the column and / or collected is 4.5 hours, about 4.5 hours, or less than 4.5 hours. In some embodiments, the duration of incubation before the cells are eluted from the column and / or collected is 4 hours, about 4 hours, or less than 4 hours. In some embodiments, the duration of incubation before the cells are eluted from the column and / or collected is 3 hours, about 3 hours, or less than 3 hours. In some embodiments, the duration of incubation before the cells are eluted from the column and / or collected is 3 to 6 hours or about 3 to 6 hours. In some embodiments, the duration of incubation before the cells are eluted from the column and / or collected is 4 to 6 hours or about 4 to 6 hours. In some embodiments, the duration of incubation before the cells are eluted from the column and / or collected is at or about 4-5 hours.In some embodiments, the duration of incubation with a stimulation reagent provided prior to collection from the column, e.g., for purposes of generating an output composition of selected and stimulated cells for use in connection with a process of genetically engineering the cells with a recombinant receptor, e.g., by transduction, is at, or about, less than, or 75%, 60%, 50%, 40%, 30%, 25%, 15%, or 10% of an alternative or existing process, e.g., an alternative process in which selection and stimulation are performed separately and / or stimulation is not performed on a column.
[0072] It is contemplated herein that the output composition of selected and stimulated cells can be further processed. For example, the output cells can be genetically engineered to express a recombinant protein such as a chimeric antigen receptor, and / or the output cells can be subjected to further incubation, stimulation, expansion, selection (e.g., polishing), and / or formulation. In some embodiments, the output composition of selected and stimulated cells can be further processed (e.g., manipulated, polished) to produce an output composition of engineered cells, e.g., a therapeutic cell composition useful for treating a disease in a patient.
[0073] In certain embodiments, the provided methods are performed on a sample, such as, for example, an apheresis sample, buffy coat, or whole blood. In some embodiments, the sample is a biological sample. In some embodiments, the biological sample is collected from a human subject. In some embodiments, the biological sample is collected from a patient suffering from a disease or condition. In some embodiments, the method is performed on a population of cells previously isolated, enriched, or selected from the sample, such as a population of CD3+ T cells. In some embodiments, the method is performed on a population of cells previously isolated, enriched, or selected from the sample, such as a population of CD4+ T cells and CD8+ T cells. In some embodiments, the sample or cells isolated from the sample may be cryopreserved.
[0074] Also provided are cells and populations, e.g., pharmaceutical populations and pharmaceutical formulations, prepared by the methods, as well as kits, systems, and devices for carrying out the methods. Methods of using the cells and populations prepared by the methods, e.g., therapeutic methods, such as methods of adoptive cell therapy, and pharmaceutical populations for administration to a subject, are further provided.
[0075] All publications mentioned in this application, including patent documents, scientific articles, and databases, are incorporated herein in their entirety for all purposes to the same extent as if each individual publication was individually incorporated herein by reference. To the extent that a definition set forth herein conflicts or is otherwise inconsistent with a definition set forth in a patent, patent application, published patent application, or other publication incorporated herein by reference, the definition set forth herein shall take precedence over the definition incorporated herein by reference.
[0076] The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described.
[0077] I. Methods for Selecting, Stimulating, and Manipulating Cells Provided herein are methods for producing an output population (also referred to as an output composition) of cells, e.g., selected and stimulated T cells, e.g., CD3+ T cells, CD4+ T cells, and CD8+ T cells, comprising steps for cell selection, stimulation, and collection. In some embodiments, the output population of stimulated and selected cells is suitable for producing a therapeutic cell composition. In certain aspects, the methods integrate the selection and stimulation steps, allowing for collection and / or elution of selected and stimulated cells that spontaneously detach from the stationary phase without the use of competitors or free binders to promote detachment. Thus, the methods provided herein integrate cell selection, stimulation, and collection / elution steps, eliminating the need for separate steps to promote detachment of selected and stimulated cells from the stationary phase or purification steps to remove agents used to promote detachment (e.g., competitors and / or free binders). Thus, the present methods reduce the number of processing steps required to produce an output composition of selected and stimulated cells suitable for downstream processing (e.g., genetic manipulation, expansion, subsequent incubation, stimulation, and / or selection (e.g., polishing)), thereby reducing production time, minimizing potential cell stress, and reducing the possibility of contamination. In particular embodiments, the present methods produce a composition of selected and stimulated cells suitable for downstream processing within a period of time, e.g., within 24 hours. In some embodiments, the output population of selected and stimulated cells is used as, or is a source for use as, an input population for a subsequent step, such as the genetic manipulation described in Section IE.
[0078] In certain embodiments, the methods provided herein are used in connection with the manufacture, production, or production of cellular therapeutics. In some embodiments, methods for producing or generating an output composition, e.g., a method for producing or generating selected and stimulated T cells, include one or more steps for isolating cells from a subject and incubating the cells under stimulatory conditions. In some aspects, the output composition is used as a source of input cells for downstream processes to produce a cellular therapeutic, e.g., for genetically engineering the cells. In some embodiments, the method includes sequential processing steps in which cells, e.g., primary CD3+, CD4+, and CD8+ T cells, are isolated, e.g., selected or separated, from a biological sample in a single step, incubated under stimulatory conditions, collected or eluted, then genetically engineered to introduce a recombinant polynucleotide encoding a recombinant receptor into the cells, e.g., by transduction or transfection, and then collected, harvested, or packaged into a container, e.g., a bag or vial, as an output population of engineered cells. In some embodiments, the cells of the output population of engineered cells (e.g., a therapeutic cell composition) are reintroduced into the same subject, optionally after cryopreservation and storage of the cells. In some embodiments, the output population of engineered cells is suitable for use in therapy, e.g., autologous cell therapy.
[0079] In particular embodiments, the provided methods are used in connection with generating an output population of engineered cells expressing a recombinant receptor from an initial or input population of cells. In certain embodiments, the input population is produced, generated, and / or created by providing, mixing, and / or pooling cells collected as an output composition of selected and stimulated cells by the provided methods. In some embodiments, the input population of cells contains enriched T cells, enriched CD3+ T cells, enriched CD4+ T cells, and / or enriched CD8+ T cells (hereinafter also referred to as an enriched population of T cells, an enriched population of CD3+ T cells, an enriched population of CD4+ T cells, and an enriched population of CD8+ T cells, respectively). In some embodiments, the input population of cells is a population of CD4+ T cells or CD8+ T cells, or a mixed, blended, and / or pooled population of CD4+ T cells and CD8+ T cells. In some embodiments, the input population of cells is a population of CD3+ cells. In certain embodiments, the provided methods are used in connection with genetically manipulating the selected and stimulated cells, e.g., by introducing a polynucleotide encoding a recombinant protein by transduction or transfection. In certain embodiments, the methods can be used to isolate or select and stimulate cells from a biological sample, e.g., a biological sample collected, harvested, and / or obtained from a subject (e.g., whole blood, apheresis), to generate an input population of stimulated enriched T cells. In some embodiments, the provided methods can further include harvesting, collecting, and / or formulating the population of enriched T cells after manipulating, transducing, and / or culturing the cells.
[0080] In certain embodiments, the methods provided herein are carried out in connection with introducing a heterologous or recombinant polynucleotide into a cell, e.g., transducing or transfecting the cell, e.g., by a method described herein, such as in Section IE. In certain embodiments of the provided methods, the cells are incubated during or after genetic engineering of the cells for a time sufficient to allow integration of a heterologous or recombinant polynucleotide, e.g., encoding a recombinant protein, or to allow expression of the recombinant protein. In certain embodiments, the cells are incubated for a fixed or defined period of time, e.g., more than 18 hours or less than 4 days. In some embodiments, the manipulation step is initiated or commenced within a fixed period of time from when the stimulation step is initiated or commenced, e.g., within 24 hours from when the cells are exposed to a stimulating substance. In some embodiments, the manipulation step is initiated or commenced within 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours or within about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours from when the cells are exposed to a stimulating substance. In some embodiments, the manipulation step is initiated or commenced within 2, 3, 4, 5, or 6 hours or about 2, 3, 4, 5, or 6 hours of the time the cells are exposed to the stimulus. In some embodiments, the manipulation step is initiated or commenced within 3 or 6 hours or about 3 or 6 hours of the time the cells are exposed to the stimulus. In some embodiments, the manipulation step is initiated or commenced within 4 or 6 hours or about 4 or 6 hours of the time the cells are exposed to the stimulus. In some embodiments, the manipulation step is initiated or commenced within 4 or 5 hours or about 4 or 5 hours of the time the cells are exposed to the stimulus. In some embodiments, the manipulation step is initiated or commenced within 6 hours or about 6 hours of the time the cells are exposed to the stimulus. In some embodiments, the manipulation step is initiated or commenced within 5 hours or about 5 hours of the time the cells are exposed to the stimulus. In some embodiments, the manipulation step is initiated or commenced within 4.5 hours or about 4.5 hours of the time the cells are exposed to the stimulus.In some embodiments, the manipulation step is initiated or commenced within 4 hours or about 4 hours of the time the cells are exposed to the stimulus. In some embodiments, the manipulation step is initiated or commenced within 3 hours or about 3 hours of the time the cells are exposed to the stimulus. In some embodiments, the incubation in the presence of a heterologous or recombinant polynucleotide, optionally contained in a virus (e.g., a viral vector), continues for a duration of 1 hour, about 1 hour, or at least 1 hour. In some embodiments, the one or more processes are carried out at least in part in serum-free medium. In some embodiments, the serum-free medium is a defined or well-defined cell culture medium. In certain embodiments, the serum-free medium is a controlled culture medium that has been processed, e.g., filtered to remove inhibitory factors and / or growth factors. In some embodiments, the serum-free medium contains protein. In certain embodiments, the serum-free medium may contain serum albumin, hydrolysates, growth factors, hormones, carrier proteins, and / or attachment factors. In some embodiments, the serum-free medium comprises cytokines. In some embodiments, the serum-free medium comprises a cytokine or recombinant cytokine. In some embodiments, the serum-free medium comprises recombinant IL-2, IL-15, and / or IL-7. In some embodiments, the serum-free medium comprises glutamine. In some embodiments, the serum-free medium comprises glutamine and recombinant IL-2, IL-15, and IL-7.
[0081] In some embodiments, the provided methods are carried out such that one, more, or all steps in preparing cells for clinical use, such as in adoptive cell therapy, are carried out without exposing the cells to non-sterile conditions. In some embodiments, cell selection, stimulation, transduction, washing, and formulation are all carried out within a closed, sterile system or device. In some embodiments, one or more of the steps are carried out outside of a closed system or device. In some such embodiments, the cells are transferred from a closed system or device under sterile conditions to another closed system, e.g., by aseptic transfer.
[0082] In particular embodiments, a sample and / or an isolated portion of a sample, such as a cell-containing sample in connection with one or more steps of the invention (e.g., buffy coat, a population of enriched T cells), can be collected, formulated for cryoprotection, frozen (e.g., cryoprotected), and / or stored below 0° C., below −20° C., or −70° C. or −80° C., or below −70° C. or −80° C., before, during, or after any stage or step of the methods provided herein. In some embodiments, the cells can be stored for less than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days, or for less than 1, 2, 3, 4, 5, 6, 7, 8 weeks, or for a period of at least 1, 2, 3, 4, 5, 6, 7, or 8 weeks, or for more than 8 weeks. After storage, the sample of cells or an isolated portion of the sample can be thawed, and processing according to the method can be resumed from the same point in the process. In certain embodiments, the cultured and / or formulated population of enriched T cells (e.g., engineered T cells) are cryoprotected and stored prior to administration to a subject, e.g., as an autologous cell therapy.
[0083] In particular embodiments, a portion of cells can be sampled or collected at any stage or step in the process; for example, cells can be collected from a population of cells (e.g., a population of T cells) while the population remains in a closed system. In certain embodiments, such cells can be analyzed for markers, traits, or characteristics, including but not limited to, viability, apoptosis, activation, stimulation, growth, and / or exhaustion. In some embodiments, cells are sampled or collected by an automated process (see, e.g., Section IE-3a). In some embodiments, analysis of sampled or collected cells is automated. In particular embodiments, analysis is performed in a closed system under sterile conditions.
[0084] In some embodiments, cells or populations of cells produced and / or processed by the provided methods may be compared to cells or populations of cells processed or produced by exemplary and / or alternative processes. In certain embodiments, the alternative and / or exemplary processes may differ in one or more specific aspects but otherwise include similar or identical features, aspects, steps, stages, reagents, or conditions as the embodiment or aspect of the provided methods to which the exemplary or alternative processes are being compared. For example, selected and stimulated cells produced by the provided methods, e.g., the output composition of selected and stimulated cells, may be compared to cells produced by a process involving separate selection and stimulation steps that require the use of a competitor or free binder to release the selected cells from the stationary phase. In some embodiments, unless otherwise specified, the provided methods and exemplary or alternative processes will otherwise be similar and / or identical, e.g., will involve similar or identical steps of selection, enrichment, stimulation, manipulation, transfection, transduction, culture, and / or formulation. In some embodiments, unless otherwise specified, the provided methods and alternative processes select and / or enrich cells from the same or similar type of biological sample and / or process cells and / or input cells of the same cell type.
[0085] The methods provided herein reduce the time required to produce an engineered cell output composition (e.g., a therapeutic cell composition). In some embodiments, the time required to produce an engineered cell output composition (e.g., a therapeutic cell composition) is at least 40%, 50%, 60%, 70%, 80%, or 90% less than the time required by alternative processes. In some embodiments, the methods provided herein provide an engineered cell output composition (e.g., a therapeutic cell composition) in less than 5 days. In some embodiments, the methods provided herein provide an engineered cell output cell composition (e.g., a therapeutic cell composition) in at or about 4 days, or in at or about 96 hours. In some embodiments, the methods provided herein provide an engineered cell output cell composition (e.g., a therapeutic cell composition) in at or about 4-5 days, or in at or about 96-120 hours.
[0086] A. Sample and Cell Preparation In certain embodiments, the provided methods include selecting and / or enriching cells from a biological sample. In some embodiments, the provided methods include selecting cells or populations thereof from a biological sample, e.g., a biological sample obtained or derived from a subject, such as a subject with a particular disease or condition, in need of cell therapy, or to whom cell therapy is administered. In some aspects, the subject is a human, e.g., a patient in need of a particular therapeutic intervention, such as adoptive cell therapy, for which cells are isolated, processed, and / or manipulated. Thus, the cells, in some embodiments, are primary cells, e.g., primary human cells. Samples include tissues, body fluids, and other samples taken directly from a subject. Biological samples can be samples obtained directly from a biological source or samples that are processed. Biological samples include, but are not limited to, body fluids, e.g., blood, plasma, serum, cerebrospinal fluid, synovial fluid, urine, and sweat, tissue, and organ samples, as well as processed samples derived therefrom.
[0087] In some aspects, the sample is a blood or blood-derived sample, or derived from an apheresis or leukapheresis product. Exemplary samples include whole blood, peripheral blood mononuclear cells (PBMCs), white blood cells, bone marrow, thymus, tissue biopsy, tumor, leukemia, lymphoma, lymph node, gut-associated lymphoid tissue, mucosa-associated lymphoid tissue, spleen, other lymphoid tissue, liver, lung, stomach, intestine, colon, kidney, pancreas, breast, bone, prostate, cervix, testis, ovary, tonsil, or other organ, and / or cells derived therefrom. Samples include samples from autologous and allogeneic sources in the context of cell therapy, e.g., adoptive cell therapy.
[0088] In some examples, cells from the subject's circulating blood are obtained, for example, by apheresis or leukapheresis. The sample, in some aspects, contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and / or platelets, and in some aspects, contains cells other than red blood cells and platelets.
[0089] In some embodiments, blood cells collected from a subject are washed, e.g., to remove the plasma fraction and to place the cells in an appropriate buffer or medium for subsequent processing steps. In some embodiments, the cells are washed with phosphate-buffered saline (PBS). In some embodiments, the wash solution lacks calcium and / or magnesium and / or many or all divalent cations. In some aspects, the wash step is accomplished by a semi-automated "flow-through" centrifuge (e.g., Cobe 2991 cell processor, Baxter) according to the manufacturer's instructions. In some aspects, the wash step is accomplished by tangential flow filtration (TFF) according to the manufacturer's instructions. In some embodiments, the cells are washed after washing, e.g., with a solution containing calcium. ++ / Mg ++ In certain embodiments, the components of the blood cell sample are removed and the cells are resuspended directly in culture medium.
[0090] In some embodiments, the cell-containing sample (e.g., an apheresis product or leukapheresis product) is washed to remove one or more anticoagulants, such as heparin, that were added during apheresis or leukapheresis.
[0091] In some embodiments, a cell-containing sample (e.g., a whole blood sample, a buffy coat sample, a peripheral blood mononuclear cell (PBMC) sample, an unfractionated T cell sample, a lymphocyte sample, a white blood cell sample, an apheresis product, or a leukapheresis product) is cryopreserved and / or cryoprotected (e.g., frozen) and then thawed prior to any step for isolating, selecting, activating, stimulating, manipulating, transducing, transfecting, incubating, culturing, harvesting, formulating a population of cells, and / or administering the formulated cell population to a subject.
[0092] In some embodiments, a sample containing autologous peripheral blood mononuclear cells (PBMCs) from a subject is collected in a manner suitable for ensuring adequate manufacturing quality. In one aspect, the sample containing PBMCs is derived from fractionated whole blood. In some embodiments, whole blood from a subject is fractionated by leukapheresis using centrifugal force to exploit density differences between cell phenotypes, whereby autologous mononuclear cells (MNCs) are preferentially enriched while other cell phenotypes, such as red blood cells, are reduced in the collected cell composition. In some embodiments, autologous plasma is collected simultaneously during MNC collection, which in some aspects can enable extended stability of the leukapheresis product. In one aspect, autologous plasma is added to the leukapheresis product to improve the buffering capacity of the leukapheresis product matrix. In some aspects, the total volume of whole blood processed to generate the leukapheresis product is or is about 2 L, 4 L, 6 L, 8 L, 10 L, 12 L, 14 L, 16 L, 18 L, or 20 L, or any value between any of the foregoing. In some embodiments, the volume of collected autologous plasma is or is about 10 mL, 50 mL, 100 mL, 150 mL, 200 mL, 250 mL, or 300 mL or more, or any value between any of the foregoing. In some embodiments, the leukapheresis product is subjected to procedures, e.g., washing and formulation for in-process cryopreservation, within about 48 hours of completing the leukapheresis collection. In some embodiments, the leukapheresis product is subjected to one or more washing steps, e.g., within about 2, 6, 12, 18, 24, 36, or 48 hours of completing the leukapheresis collection. In some aspects, the one or more washing steps remove anticoagulant during the leukapheresis collection, cellular waste products that may accumulate in the leukapheresis product, residual platelets, and / or cellular debris. In some embodiments, one or more buffer exchanges are performed between the one or more washing steps.
[0093] In certain embodiments, the apheresis product or leukapheresis product is cryopreserved and / or cryoprotected (e.g., frozen), as described below, and then thawed before being subjected to a cell selection or isolation step (e.g., a T cell selection or isolation step). In some embodiments, after the cryopreserved and / or cryoprotected apheresis product or leukapheresis product is subjected to a T cell selection or isolation step, no additional cryopreservation and / or cryoprotection step is performed during or between any subsequent steps, such as activating, stimulating, manipulating, transducing, transfecting, incubating, culturing, harvesting, formulating, and / or administering the formulated cell population to a subject. For example, T cells selected from a thawed cryopreserved and / or cryoprotected apheresis product or leukapheresis product are not again cryopreserved and / or cryoprotected before being thawed for downstream processing, such as transduction.
[0094] In certain embodiments, the cryopreserved and / or cryoprotected apheresis or leukapheresis product is banked (e.g., without cell selection prior to freezing the sample), which, in some aspects, can provide more flexibility in subsequent manufacturing steps. In some aspects, the cryopreserved and / or cryoprotected apheresis or leukapheresis product is divided into multiple cryopreservation containers (e.g., bags) that can each be used individually or in combination in processing the product. In one aspect, banking cells before selection can increase cell yield in downstream processes, and banking cells earlier can mean that they are healthier and may be easier to meet manufacturing success criteria. In another aspect, once thawed, the cryopreserved and / or cryoprotected apheresis or leukapheresis product can be subjected to one or more different selection methods. The advantage of this approach is, among other things, enhancing the availability, efficacy, and / or other aspects of cells in cell therapy for the treatment of a disease or condition of interest, such as in the sample donor and / or another recipient.
[0095] In some embodiments, the sample (e.g., an apheresis or leukapheresis sample) is collected after the donor has been diagnosed with a disease or condition, either before cell selection or without prior cell selection (e.g., without prior T cell selection, such as chromatographic selection), and cryopreserved and / or cryoprotected. In some aspects, the time of cryopreservation is also before the donor receives one or more of any initial treatment for the disease or condition, any targeted therapy or any therapy designated for treatment of the disease or condition, or any therapy other than radiation and / or chemotherapy. In some embodiments, the sample is collected after the first recurrence of the disease after initial treatment for the disease and before the donor or subject receives subsequent treatment for the disease. The initial treatment and / or subsequent treatment can be a therapy other than cell therapy. In some embodiments, the collected cells may be used for cell therapy after the initial treatment and / or subsequent treatment. In one aspect, cryopreserved and / or cryoprotected samples without prior cell selection can help reduce initial costs, such as those associated with untreated patients in randomized clinical trials who may cross over and later require treatment.
[0096] In some embodiments, the sample (e.g., an apheresis or leukapheresis sample) is collected, cryopreserved, and / or cryoprotected, either before or without prior cell selection (e.g., without prior T cell selection, such as by chromatographic selection), at a time point after second-line treatment for the disease and after a second recurrence of the disease before the donor or subject receives subsequent treatment for the disease. In some embodiments, the patient is identified as likely to relapse after second-line treatment, for example, by assessing certain risk factors. In some embodiments, the risk factors are based on disease type and / or genetic traits, such as double-hit lymphoma, primary refractory cancer, or activated B-cell lymphoma. In some embodiments, the risk factors are based on clinical features, such as early recurrence after first-line treatment or other poor prognostic indicators after treatment (e.g., an IPI (International Prognostic Index) > 2).
[0097] In some embodiments, a sample (e.g., an apheresis or leukapheresis sample) is collected and cryopreserved and / or cryoprotected before cell selection or without prior cell selection (e.g., without prior T cell selection, such as chromatographic selection) at a time before the donor or subject is diagnosed with any disease. In some aspects, the donor or subject may be determined to be at risk of developing any disease. In some aspects, the donor or subject may be a healthy subject. In certain cases, the donor or subject may never be considered at risk of developing or being diagnosed with any disease, but may choose to bank or preserve the cells in case cell therapy is needed at a later stage in life. In some embodiments, the donor or subject may be considered at risk of developing any disease based on factors such as gene mutations, gene abnormalities, gene disruptions, family history, protein abnormalities (such as defects in protein production and / or processing), and lifestyle choices that may increase the risk of developing any disease. In some embodiments, the cells are collected as a prophylactic.
[0098] In some embodiments, cryopreserved and / or cryoprotected samples of cells (e.g., apheresis or leukapheresis samples), e.g., samples of cells that have not been subjected to prior cell selection (e.g., without prior T cell selection, such as chromatographic selection), are stored or banked for a period of more than 12 hours, more than 24 hours, more than 36 hours, or more than 48 hours, or a period equal to 12, 24, 36, or 48 hours. In some embodiments, samples are stored or banked for a period of more than 1 week, more than 2 weeks, more than 3 weeks, or more than 4 weeks, or a period equal to 1 week, 2 weeks, 3 weeks, or 4 weeks. In some embodiments, samples are stored or banked long-term. In some aspects, the sample is greater than 1 month, greater than 2 months, greater than 3 months, greater than 4 months, greater than 5 months, greater than 6 months, greater than 7 months, greater than 8 months, greater than 9 months, greater than 10 months, greater than 11 months, greater than 1 year, greater than 2 years, greater than 3 years, greater than 4 years, greater than 5 years, greater than 6 years, greater than 7 years, greater than 8 years, greater than 9 years, greater than 10 years, greater than 11 years, greater than 12 years, greater than 13 years, greater than 14 years, greater than 15 years, greater than 16 years, greater than 17 years, greater than 18 years, greater than 19 years, greater than 20 years, greater than 25 years, greater than 30 years, greater than 35 years, greater than 36 years, greater than 37 years, greater than 38 years, greater than 39 years, greater than 40 years, greater than 41 years, greater than 42 years, greater than 43 years, greater than 44 years, greater than 45 years, greater than 46 years, greater than 47 years, greater than 48 years, greater than 49 years, greater than 50 years, greater than 51 years, greater than 52 years, greater than 53 years, greater than 54 years, greater than 55 years, greater than 56 years, greater than 57 years, greater than 58 years, greater than 59 years, greater than 60 years, greater than 61 years, greater than 62 years, greater than 63 years, greater than 64 years, greater than 65 years, greater than 66 years, greater than 67 years, greater than 68 years, greater than 69 years, greater than 70 years, greater than 71 years, greater than 72 years, greater than 73 years, greater than 74 years, greater than 75 years, greater than 7 years, greater than 40 years or more, or a period equal to 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years, 17 years, 18 years, 19 years, 20 years, 25 years, 30 years, 35 years, 40 years or more.
[0099] In some embodiments, apheresis or leukapheresis samples collected from donors are transported to a storage or processing facility in a refrigerated environment and / or cryogenically stored at a storage facility or processed at a processing facility. In some embodiments, the sample is processed prior to transport, e.g., by selecting T cells, such as CD4+ and / or CD8+ T cells. In some embodiments, such processing is performed after transport and before cryogenic storage of the sample. In some embodiments, processing is performed after thawing the sample following cryogenic storage.
[0100] By allowing a donor, and thus their cells, to store their cells at a stage when they have not received extensive treatment for a disease and / or before the onset or diagnosis of a disease or condition, such cells may have certain advantages for use in cell therapy compared to cells collected after one or more treatments. For example, cells collected before one or more treatments may be healthier, may exhibit higher levels of specific cellular activity, may proliferate more rapidly, and / or may be more amenable to genetic manipulation than cells that have undergone several treatments. Another example of an advantage of the embodiments described herein may include convenience. For example, by collecting, optionally processing, and storing a donor's cells before they are needed for cell therapy, the cells are readily available if a recipient later needs them. This increases the capacity of apheresis laboratories and provides technicians with greater flexibility in scheduling the apheresis collection process.
[0101] Exemplary methods and systems for cryogenically storing and processing cells from a sample, such as an apheresis sample, may include those described in International Published Application No. WO2018170188. In some embodiments, the methods and systems involve collecting an apheresis sample before a patient requires cell therapy, then cryopreserving the apheresis sample for later use in a process to engineer cells (e.g., T cells) with a recombinant receptor (e.g., a CAR). In some cases, such a process may include a process described herein. In some embodiments, an apheresis sample is collected from a subject and cryopreserved prior to subsequent T cell selection, activation, stimulation, manipulation, transduction, transfection, incubation, culture, harvesting, formulation, and / or administration of the formulated cell population to the subject. In such examples, the cryopreserved apheresis sample is thawed before subjecting the sample to one or more selection steps, such as any described herein.
[0102] In some embodiments, a cryopreserved and / or cryoprotected sample of cells (e.g., an apheresis or leukapheresis sample), e.g., a sample of cells that has not been subjected to prior cell selection (e.g., without prior T cell selection, such as chromatographic selection), is thawed prior to use in downstream processes to manufacture a cell population for cell therapy, e.g., a T cell population containing CAR+ T cells. In some embodiments, such a cryopreserved and / or cryoprotected sample of cells (e.g., an apheresis or leukapheresis sample) is used in connection with the processes provided herein for engineered T cell therapy, such as CAR+ T cell therapy. In certain examples, no further step of cryopreservation is performed prior to or during the harvesting / formulation step.
[0103] B. Chromatographic cell selection In aspects of the methods provided herein, cells of a sample, such as T cells, are selected by chromatographic isolation, for example, by column chromatography such as affinity chromatography or gel permeation chromatography. In some embodiments, the method uses a selection agent that binds to a selection marker located on the surface of target cells, such as cells to be isolated, selected, or enriched. Such methods are sometimes referred to as (traceless) cell affinity chromatography technology (CATCH), and may include any of the methods or techniques described in PCT applications WO2013124474 and WO2015164675, which are incorporated herein by reference in their entirety.
[0104] In some embodiments, a cryopreserved and / or cryoprotected apheresis product or leukapheresis product is thawed. In some embodiments, the thawed cell composition is subjected to dilution (e.g., dilution with serum-free medium) and / or washing (washing with serum-free medium), which can remove or reduce unwanted or undesirable components in some cases. Optionally, dilution and / or washing removes or reduces the presence of cryoprotectants, such as DMSO, contained in the thawed sample. Otherwise, cryoprotectants can adversely affect cell viability, yield, and recovery when exposed to room temperature for extended periods of time. In some embodiments, dilution and / or washing allows the medium of the thawed cryopreserved product to be replaced with a serum-free medium, such as that described in Section III of this specification or PCT / US2018 / 064627, which is incorporated herein by reference.
[0105] In some embodiments, the serum-free medium comprises a basal medium supplemented with one or more supplements (e.g., OpTmizer™ T-Cell Expansion Basal Medium (ThermoFisher). In some embodiments, the one or more supplements are serum-free. In some embodiments, the serum-free medium comprises a basal medium supplemented with one or more additional components for the maintenance, expansion, and / or activation of cells (e.g., T cells), such as those provided by additional supplements (e.g., OpTmizer™ T-cell Expansion Supplement (ThermoFisher)). In some embodiments, the serum-free medium comprises a serum replacement supplement, such as an immune cell serum replacement, e.g., ThermoFisher, #A2596101, CTS™ Immune Cell Serum Replacement, or Smith et al. Clin Transl Immunology. 2015 Jan;4(1):e31. In some embodiments, the serum-free medium further comprises a free amino acid, such as L-glutamine. In some embodiments, the serum-free medium further comprises a dipeptide form of L-glutamine (e.g., L-alanyl-L-glutamine), such as the dipeptide in Glutamax™ (ThermoFisher). In some embodiments, the serum-free medium further comprises one or more recombinant cytokines, such as recombinant human IL-2, recombinant human IL-7, and / or recombinant human IL-15.
[0106] In some embodiments, cells, e.g., target cells, have or express a selectable marker described herein on the cell surface, such that the cells to be isolated, selected, or enriched are defined by the presence of at least one common specific receptor molecule. In some embodiments, the sample containing the target cells may also contain excess cells that lack the selectable marker. For example, in some embodiments, T cells are selected, isolated, or enriched from a sample containing multiple cell types, e.g., red blood cells or B cells.
[0107] In some embodiments, the selection agent is included in the chromatography column, e.g., directly or indirectly bound to the chromatography matrix (e.g., stationary phase). In some embodiments, the selection agent is present on the chromatography matrix (e.g., stationary phase) when the sample is applied to the column. In some embodiments, the selection agent is capable of being indirectly bound to the chromatography matrix (e.g., stationary phase) via a reagent, e.g., a selection reagent described herein, e.g., in Section II-A. In some embodiments, the selection agent is covalently or non-covalently bound to the column stationary phase. In some embodiments, the selection agent is reversibly immobilized on the chromatography matrix (e.g., stationary phase). Optionally, the selection agent is immobilized on the chromatography matrix (e.g., stationary phase) by a covalent bond. In some aspects, the selection agent is reversibly immobilized on the chromatography matrix (e.g., stationary phase) by a non-covalent bond.
[0108] In some embodiments, the selection agent can be present at the time the sample is added to the chromatography column (e.g., stationary phase), bound directly (e.g., covalently or non-covalently) or indirectly via a selection reagent, for example. Thus, upon addition of the sample, target cells can be bound by the selection agent and immobilized on the chromatography matrix (e.g., stationary phase) of the column. Alternatively, in some embodiments, a selection agent can be added to the sample. The selection agent then binds to target cells (e.g., T cells) in the sample, and the sample can then be added to a chromatography matrix (e.g., stationary phase) containing a selection agent. In this case, the selection agent already bound to the target cells binds to the selection agent, thereby immobilizing the target cells on the chromatography matrix (e.g., stationary phase). In some embodiments, the selection agent binds to a selection agent, e.g., as described herein in Sections II-A and II-B, via a binding partner C, as described herein, included in the selection agent.
[0109] In some aspects, a selection agent is added to the sample. In certain embodiments, the selection agent has a binding site B that specifically binds to a receptor molecule (e.g., a selection marker) on the surface of a cell, e.g., a target cell. See, e.g., Section II-B et seq. In some aspects, the selection agent also includes a binding partner C that can specifically and reversibly bind to binding site Z of the selection reagent.
[0110] In certain aspects, the selection reagent may also contain two or more binding sites Z, which may be bound by a binding partner C, thereby resulting in multimerization of the receptor-binding reagent. Thus, the selection reagent as used herein may also be a multimerization reagent. The selection reagent may be, for example, streptavidin, a streptavidin mutein, avidin, an avidin mutein, or a mixture thereof. In some aspects, different chromatographic matrices may be coupled to different selection reagents and layered into columns to form a multicomponent system for separation.
[0111] In some embodiments, two or more selection agents are associated, e.g., reversibly or irreversibly bound, to the selection reagent, e.g., via one or more binding sites Z present on the selection reagent. In some cases, this results in the selection agents being spaced closely together such that an avidity effect can occur when a target cell bearing (at least two copies of) a cell surface molecule (e.g., a selection marker) is contacted with a selection agent that can bind to that molecule (e.g., a selection marker).
[0112] In some embodiments, two or more different selection substances, i.e., having the same selection marker binding specificity, can be reversibly bound to the selection reagent. In some embodiments, it is possible to use at least two different selection substances, and in some cases three or four different selection substances, that bind to different selection markers. In some aspects, each of the at least two selection substances can bind to a different molecule (e.g., selection marker), e.g., a first molecule, a second molecule, etc. In some cases, the different molecules (e.g., selection markers), e.g., different cell surface molecules, can be present on the same target cell. In another example, the different molecules (e.g., selection markers), e.g., different cell surface molecules, can be present on different target cells present in the same cell population. In some cases, a third, fourth, etc. selection substance can be associated with the same reagent, each of which further contains a different binding site.
[0113] In some embodiments, the two or more different selection substances contain the same binding partner C. In some embodiments, the two or more different selection substances contain different binding partners. In some aspects, the first selection substance can have a binding partner C1 capable of specifically binding to binding site Z1 present on the selection reagent, and the second selection substance can have a binding partner C2 capable of specifically binding to binding site Z1 or binding site Z2 present on the selection reagent. Thus, in some examples, the multiple binding sites Z contained in the selection reagent include binding sites Z1 and Z2, which are capable of reversibly binding to binding partners C1 and C2 contained in the selection substance, respectively. In some embodiments, C1 and C2 are the same, and / or Z1 and Z2 are the same. In another aspect, one or more of the multiple binding sites Z can be different. In another example, one or more of the multiple binding partners C can be different. It is within the level of skill in the art to select any combination of different binding partners C that are compatible with a selection reagent containing binding site Z, as long as each of the binding partners C can interact with, e.g., specifically bind to, one of the binding sites Z.
[0114] In certain embodiments, a sample, e.g., a sample containing cells and a selection agent, is added to or contacted with a chromatography matrix containing an attached or immobilized selection reagent. In certain aspects, the selection agent has multiple binding sites Z that specifically bind to the selection agent's binding partner C. In certain aspects, the selection agent binds to the selection agent through an interaction between the binding partner C and binding site Z. Thus, in some embodiments, cells, e.g., target cells, are immobilized on the chromatography matrix via a complex formed by one or more binding sites Z of the selection agent and the binding site Z of the selection agent. In further aspects, cells, e.g., target cells, can be depleted from the sample, e.g., by rinsing, releasing, or washing away the remaining sample from the chromatography matrix. In certain aspects, the selection agent can be included in the cell-containing sample or can be applied to or contacted with the chromatography matrix, e.g., before adding the sample, to bind to the attached selection or multimerization reagent.
[0115] In some embodiments, the reversible bond formed between binding partner C and binding site Z can be disrupted by a competitor and / or free binder. In some embodiments, the competitor and / or free binder can be biotin, a biotin derivative, a biotin analog, or a streptavidin-binding peptide capable of competing with binding partner C for binding to one or more binding sites Z. In some embodiments, binding partner C and the competitor and / or free binder differ, such that the competitor and / or free binder exhibits a higher binding affinity for one or more binding sites Z than the affinity of the binding partner. In certain aspects of any of the methods provided herein, the addition of a competitor and / or free binder to the stationary phase of a chromatography column to disrupt binding of the selection agent to the selection reagent is not necessary to desorb target cells (T cells) from the chromatography matrix (e.g., the stationary phase).
[0116] In some embodiments, cells, e.g., target cells of a sample, can be depleted from a sample, e.g., by rinsing, releasing, or washing away remaining sample from a chromatography matrix (e.g., a stationary phase). In some embodiments, one or more (e.g., 2, 3, 4, 5, 6) washing steps are used to remove unbound cells and debris from the chromatography matrix (e.g., a stationary phase). In some embodiments, at least two washing steps are performed. In some embodiments, the sample is allowed to penetrate the matrix for at least or about 5, 10, 15, 16, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, or 120 minutes before performing one or more washing steps. In some embodiments, a wash step is performed at, or about, or at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, or 120 minutes after application of the sample to the chromatography column (e.g., stationary phase). In some embodiments, a wash step is performed at, or about, or at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 minutes after application of the sample to the chromatography column (e.g., stationary phase). In some embodiments, one or more wash steps are performed within or about 120, 100, 90, 80, 70, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, or 5 minutes following application of the sample to the chromatography column (e.g., stationary phase).In some embodiments, one or more wash steps are performed within or about 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, or 5 minutes following addition of the sample to the chromatography column (e.g., stationary phase). In some embodiments, one or more wash steps are performed within or about 5 to 60 minutes following addition of the sample to the chromatography column (e.g., stationary phase). In some embodiments, one or more wash steps are performed within or about 5 to 50 minutes following addition of the sample to the chromatography column (e.g., stationary phase). In some embodiments, one or more wash steps are performed within or about 5 to 40 minutes following addition of the sample to the chromatography column (e.g., stationary phase). In some embodiments, one or more wash steps are performed within 5-30 minutes or within about 5-30 minutes following addition of the sample to the chromatography column (e.g., the stationary phase). In some embodiments, one or more wash steps are performed within 5-20 minutes or within about 5-20 minutes following addition of the sample to the chromatography column (e.g., the stationary phase). In some embodiments, one or more wash steps are performed within 5-10 minutes or within about 5-10 minutes following addition of the sample to the chromatography column (e.g., the stationary phase). In some embodiments, one or more wash steps are performed within 10-60 minutes or within about 10-60 minutes following addition of the sample to the chromatography column (e.g., the stationary phase). In some embodiments, one or more wash steps are performed within 20-60 minutes or within about 20-60 minutes following addition of the sample to the chromatography column (e.g., the stationary phase). In some embodiments, one or more wash steps are performed within 30-60 minutes or within about 30-60 minutes following addition of the sample to the chromatography column (e.g., the stationary phase). In some embodiments, one or more wash steps are performed within or about 40-60 minutes following application of the sample to the chromatography column (eg, stationary phase).In some embodiments, one or more wash steps are performed within or about 50-60 minutes following application of the sample to the chromatography column (eg, stationary phase).
[0117] In some embodiments, multiple rounds of cell selection steps are performed, where a fraction positively or negatively selected in one step is subjected to another selection step, e.g., subsequent positive or negative selection. In certain embodiments, methods, techniques, and reagents for selection, isolation, and enrichment are described, for example, in PCT application WO2015164675, which is incorporated herein by reference in its entirety.
[0118] In some embodiments, a single selection step can be used to isolate target cells (e.g., CD3+ T cells) from a sample. In some embodiments, the single selection step can be performed on a single chromatography column. In some examples, a single selection step can simultaneously deplete cells expressing multiple markers. Similarly, multiple cell types can be simultaneously positively selected. In certain embodiments, a selection step is repeated and / or performed more than once, where the positively or negatively selected fraction from a step is subjected to the same selection step, e.g., repeated positive or negative selection. In some examples, a single selection step is repeated and / or performed more than once, e.g., to increase the purity of selected cells and / or to further remove and / or deplete negatively selected cells from the negatively selected fraction. In certain embodiments, one or more selection steps are performed 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 times. In certain embodiments, the one or more selection steps are performed and / or repeated 1 to 10 times, 1 to 5 times, or 3 to 5 times. In some embodiments, two selection steps are performed.
[0119] Cell selection can be performed using one or more chromatography columns. In some embodiments, the one or more chromatography columns are contained within a closed system. In some embodiments, the closed system is an automated closed system, e.g., requiring little or no user (e.g., human) input. In some embodiments, cell selection is performed sequentially (e.g., sequential selection techniques). In some embodiments, one or more chromatography columns are arranged sequentially. For example, a first column can be oriented such that the column output (e.g., eluate) is fed to a second chromatography column, e.g., through connected tubing. In some embodiments, multiple chromatography columns can be arranged sequentially. In some embodiments, cell selection is achieved by performing sequential positive and negative selection steps, with subsequent steps subjecting positive and / or negative fractions from the previous step to further selection, and the entire process can be performed in the same tube or set of tubing. In some embodiments, a sample containing target cells is subjected to sequential selections, where a first selection is performed to enrich for one of the CD4+ or CD8+ populations, and a second selection is performed to enrich for the other of the CD4+ or CD8+ populations, using cells not selected in the first selection as a cell source. In some embodiments, a subpopulation of one or both of the CD4+ or CD8+ populations, e.g., central memory T (T CMOne or more further selections can be performed to enrich for CD3+ cells, naive T cells, and / or cells that are positive for or express high levels of one or more surface markers, e.g., CD28+, CD62L+, CCR7+, CD27+, CD127+, CD4+, CD8+, CD45RA+, and / or CD45RO+. In some embodiments, a first selection is performed to enrich for a CD3+ population, and a second selection to enrich for a CD3+ population involves subjecting a sample containing target cells to sequential selections in which the selected cells are used as the cell source. In some embodiments, a first selection is performed to enrich for a CD3+ population on a first stationary phase (e.g., in a first chromatographic column), and a second selection to enrich for a CD3+ population on a second stationary phase (e.g., in a second chromatographic column) involves subjecting a sample containing target cells to sequential selections in which the flow-through fraction containing unbound cells is used as the cell source, where the first and second stationary phases are sequentially arranged. In some embodiments, a subpopulation of the CD3+ population, such as central memory T (T CM One or more further selections can be performed to enrich for CD3+CD4+ cells, naive T cells, and / or cells that are positive for or express high levels of one or more surface markers, e.g., CD28+, CD62L+, CCR7+, CD27+, CD127+, CD4+, CD8+, CD45RA+, and / or CD45RO+. In some embodiments, the sample containing the target cells is subjected to sequential selections, where a first selection is performed to enrich for the CD3+ population and a second selection is performed to enrich for the CD4+ population, with the selected cells being used as the cell source. In some embodiments, a subpopulation of the CD3+CD4+ population, e.g., central memory T (T CMOne or more further selections can be performed to enrich for CD3+CD8+ cells, naive T cells, and / or cells that are positive for or express high levels of one or more surface markers, e.g., CD28+, CD62L+, CCR7+, CD27+, CD127+, CD4+, CD8+, CD45RA+, and / or CD45RO+. In some embodiments, the sample containing the target cells is subjected to sequential selections, where a first selection is performed to enrich for the CD3+ population and a second selection is performed to enrich for the CD8+ population, with the selected cells being used as the cell source. In some embodiments, a subpopulation of the CD3+CD8+ population, e.g., central memory T (T CM One or more further selections can be performed to enrich for CD3+ T cells, naive T cells, and / or cells that are positive for or express high levels of one or more surface markers, e.g., CD28+, CD62L+, CCR7+, CD27+, CD127+, CD4+, CD8+, CD45RA+, and / or CD45RO+. In some aspects, it is contemplated that specific subpopulations of T cells (e.g., CD3+ cells), e.g., cells that are positive for or express high levels of one or more surface markers, e.g., CD28+, CD62L+, CCR7+, CD27+, CD127+, CD4+, CD8+, CD45RA+, and / or CD45RO+ T cells, are selected by sequential positive or negative selection techniques.
[0120] In some embodiments, cell selection is performed in parallel (e.g., parallel selection techniques). In some embodiments, one or more chromatography columns are arranged in parallel. For example, two or more columns can be arranged so that a sample is loaded onto two or more columns simultaneously via a tube, which allows the sample to be added to each column without the need for the sample to pass through the first column. For example, using parallel selection techniques, cell selection can be achieved by simultaneously performing positive and / or negative selection steps, e.g., in a closed system where the entire process occurs within the same tube or set of tubes. In some embodiments, a sample containing target cells is subjected to parallel selection, in which the sample is loaded onto two or more chromatography columns, each column achieving selection of a cell population. In some embodiments, two or more chromatography columns independently achieve selection of CD3+, CD4+, or CD8+ populations. In some embodiments, two or more chromatography columns, including affinity chromatography or gel permeation chromatography, independently achieve selection of the same cell population. For example, two or more chromatography columns may achieve selection of CD3+ cells. In some embodiments, two or more chromatography columns, including affinity chromatography or gel permeation chromatography, independently achieve the selection of different cell populations. For example, two or more chromatography columns may independently achieve the selection of CD3+ cells, CD4+ cells, and CD8+ cells. In some embodiments, one or more additional rounds of selection, e.g., using sequential selection techniques, can be achieved to enrich for subpopulations of one or all of the cell populations selected via parallel selection. For example, the selected cells can be enriched for central memory T (T CM) cells, naive T cells, and / or cells positive for or expressing high levels of one or more surface markers (e.g., CD28+, CD62L+, CCR7+, CD27+, CD127+, CD4+, CD8+, CD45RA+, and / or CD45RO+). In some embodiments, the sample containing the target cells is subjected to parallel selection performed on two or more columns to enrich for the CD3+ population. In some embodiments, one or more additional rounds of selection are performed to enrich for a subpopulation of the CD3+ population, such as central memory T (T CM ) cells, naive T cells, and / or cells positive for or expressing high levels of one or more surface markers (e.g., CD28+, CD62L+, CCR7+, CD27+, CD127+, CD4+, CD8+, CD45RA+, and / or CD45RO+). In some embodiments, a sample containing target cells is subjected to parallel selection, where selection is accomplished independently on two or more columns to enrich for CD3+ and CD4+ populations. In some embodiments, one or more additional rounds of selection are performed to enrich for subpopulations of the CD3+ and CD4+ populations, such as central memory T (T CM ) cells, naive T cells, and / or cells positive for or expressing high levels of one or more surface markers (e.g., CD28+, CD62L+, CCR7+, CD27+, CD127+, CD4+, CD8+, CD45RA+, and / or CD45RO+). In some embodiments, a sample containing target cells is subjected to parallel selections that are performed to enrich for CD3+ and CD8+ populations. In some embodiments, one or more additional rounds of selection are performed to enrich for subpopulations of the CD3+ and CD8+ populations, such as central memory T (T CM) cells, naive T cells, and / or cells positive for or expressing high levels of one or more surface markers (e.g., CD28+, CD62L+, CCR7+, CD27+, CD127+, CD4+, CD8+, CD45RA+, and / or CD45RO+). In some embodiments, a sample containing target cells is subjected to parallel selections that are performed to enrich for CD4+ and CD8+ populations. In some embodiments, one or more additional rounds of selection are performed to enrich for subpopulations of the CD4+ and CD8+ populations, such as central memory T (T CM ) cells, naive T cells, and / or cells positive for or expressing high levels of one or more surface markers (e.g., CD28+, CD62L+, CCR7+, CD27+, CD127+, CD4+, CD8+, CD45RA+, and / or CD45RO+). In some aspects, it is envisioned that specific subpopulations of T cells (e.g., CD3+, CD4+, CD8+ T cells), for example, cells positive for or expressing high levels of one or more surface markers (e.g., CD28+, CD62L+, CCR7+, CD27+, CD127+, CD4+, CD8+, CD45RA+, and / or CD45RO+ T cells), are selected by positive or negative parallel selection techniques. In some embodiments, a combination of serial and parallel selection techniques can be used.
[0121] In some embodiments, two columns are used for parallel selection. In some embodiments, the two columns select for the same cell type (e.g., the same selection marker). In some embodiments, the two columns each select for CD3+ T cells.
[0122] Generally, the binding capacity of a stationary phase (e.g., a selection resin) affects the amount of stationary phase required to select a certain number of target moieties, e.g., target cells such as T cells. Binding capacity, e.g., the number of target cells that can be immobilized per mL of stationary phase (e.g., a selection resin), can be used to determine or control the number of target cells captured in one or more columns. One or more chromatography columns can be used for the on-column cell selection and cell stimulation disclosed herein. When multiple columns are used, they can be arranged sequentially, in parallel, or in any suitable combination thereof. Thus, the binding capacity of a stationary phase (e.g., a selection resin) can be used to standardize the amount of reagents in a single-column approach or for each column in a multi-column approach.
[0123] In some embodiments, the binding capacity of a stationary phase, as used herein, is the maximum number of target cells that will bind to the stationary phase under given solvent and cell concentration conditions when an excess amount of target cells is loaded onto the stationary phase. In some embodiments, the binding capacity is 100 million ± 25 million target cells (e.g., T cells) or about 100 million ± 25 million target cells per mL of stationary phase. In some embodiments, the static binding capacity of a stationary phase (e.g., a selection resin) disclosed herein is in the range of about 75 million to about 125 million target cells per mL of stationary phase. In one aspect, the binding capacity of a stationary phase used herein for on-column cell selection and cell stimulation is the static binding capacity. In some embodiments, the static binding capacity is the maximum amount of cells that can be immobilized on the stationary phase under, for example, a given solvent and cell concentration condition. In some embodiments, the static binding capacity of a stationary phase (e.g., a selection resin) disclosed herein is in the range of about 50 million to about 100 million target cells per mL of stationary phase. In some embodiments, the static binding capacity is at or about 100 million ± 25 million target cells (e.g., T cells) per mL of stationary phase. In some embodiments, the static binding capacity of the stationary phases (e.g., selection resins) disclosed herein ranges from about 75 million to about 125 million target cells per mL of stationary phase. In some embodiments, the static binding capacity of the stationary phase (e.g., selection resin) is about 10 million to about 20 million target cells per mL of stationary phase, about 20 million to about 30 million, about 30 million to about 40 million, about 40 million to about 50 million, about 50 million to about 60 million, about 60 million to about 70 million, about 70 million to about 80 million, about 80 million to about 90 million, about 90 million to about 100 million, or about 100 million to about 150 million target cells per mL of stationary phase. billion, about 110 million to about 120 million, about 120 million to about 130 million, about 130 million to about 140 million, about 140 million to about 150 million, about 150 million to about 160 million, about 160 million to about 170 million, about 170 million to about 180 million, about 180 million to about 190 million, or about 190 million to about 200 million.
[0124] In some embodiments, the binding capacity of a stationary phase, as used herein, is the number of target cells that bind to the stationary phase under given flow conditions before significant breakthrough of unbound target cells occurs. In one aspect, the binding capacity of a stationary phase, as used herein with respect to on-column cell selection and cell stimulation, is the dynamic binding capacity, i.e., the binding capacity under operating conditions in a packed chromatography column during sample application. In some embodiments, the dynamic binding capacity is determined by loading a sample containing a known concentration of target cells and monitoring the flow-through fraction. Target cells bind to the stationary phase up to a certain breakthrough point, after which unbound target cells will flow through the column. In some embodiments, the dynamic binding capacity is 100 million ± 25 million target cells (e.g., T cells) per mL of stationary phase, or about 100 million ± 25 million target cells (e.g., T cells) per mL of stationary phase. In some embodiments, the dynamic binding capacity of a stationary phase (e.g., a selection resin) disclosed herein is 75 million to about 125 million target cells, or about 75 million to about 125 million target cells per mL of stationary phase. In some embodiments, the dynamic binding capacity of the stationary phase (e.g., selection resin) disclosed herein is in the range of about 50 million to about 100 million target cells per mL of stationary phase. In some embodiments, the dynamic binding capacity of the stationary phase (e.g., selection resin) is in the range of about 10 million to about 20 million target cells per mL of stationary phase, about 20 million to about 30 million target cells, about 30 million to about 40 million target cells, about 40 million to about 50 million target cells, about 50 million to about 60 million target cells, about 60 million to about 70 million target cells, about 70 million to about 80 million target cells, about 80 million to about 90 million target cells, about 90 million to about 100 million target cells, or about 100 million to about 100 million target cells per mL of stationary phase. billion, about 110 million to about 120 million, about 120 million to about 130 million, about 130 million to about 140 million, about 140 million to about 150 million, about 150 million to about 160 million, about 160 million to about 170 million, about 170 million to about 180 million, about 180 million to about 190 million, or about 190 million to about 200 million.
[0125] In some embodiments, the stationary phase is 20 mL. In some embodiments, the stationary phase has a binding capacity of 2 billion ± 500 million cells.
[0126] Any material may be used as a chromatography matrix (e.g., stationary phase). Generally, suitable chromatography materials are essentially non-toxic, i.e., not detrimental to cell viability, when used under desired conditions, e.g., as a packed chromatography column. In some embodiments, the stationary phase remains in a predetermined location, e.g., a predetermined position, even as the position of the sample changes. Thus, in some embodiments, the stationary phase is the portion of the chromatography system through which the mobile phase flows (either by flow-through mode or batch mode), and partitioning of components contained in the liquid phase (dissolved or dispersed) between the phases occurs.
[0127] In some embodiments, the chromatography matrix is in the form of a solid or semi-solid phase, while the sample containing the target cells to be isolated / separated is in the fluid phase. The chromatography matrix can be a particulate material (of any suitable size and shape) or a monolithic chromatography material including a paper substrate or paper membrane. Thus, in some aspects, the chromatography can be column chromatography or planar chromatography. In some embodiments, not only standard chromatography columns but also columns capable of bidirectional flow, such as PhyTip® columns available from PhyNexus, Inc. (San Jose, California, USA), can be used in column-based / flow-through mode-based methods. Thus, in some cases, pipette tips or columns capable of bidirectional flow are also included as chromatography columns useful in the present methods. In some cases, for example, when certain matrix materials are used, the particulate matrix can have an average particle size of, for example, about 5 μm to about 200 μm, or about 5 μm to about 400 μm, or about 5 μm to about 600 μm. In some aspects, the chromatography matrix can be or include, for example, a polymeric resin or a metal oxide or semi-metal oxide. In some aspects, for example, when planar chromatography is used, the matrix material can be any material suitable for planar chromatography, such as a conventional cellulose-based or organic polymer-based membrane (e.g., a paper membrane, a nitrocellulose membrane, or a polyvinylidene difluoride (PVDF) membrane) or a silica-coated glass plate. In one embodiment, the chromatography matrix / stationary phase is a non-magnetic or non-magnetizable material.
[0128] In some embodiments, nonmagnetic or nonmagnetizable chromatographic stationary phases suitable for the present methods include derivatized silica or cross-linked gels. In some aspects, the cross-linked gels can be based on natural polymers, e.g., classes of polymers found in nature. For example, natural polymers that can serve as the basis for chromatographic stationary phases are polysaccharides. In some cases, each polysaccharide is typically cross-linked. Examples of polysaccharide matrices include, but are not limited to, agarose gels (e.g., Superflow™ agarose or Sepharose® materials, such as Superflow™ Sepharose®, which are commercially available in a variety of bead and pore sizes) or cross-linked dextran gels. A further example is a particulate cross-linked agarose matrix to which dextran is covalently attached, which is commercially available as Sephadex® or Superdex®, both from GE Healthcare (in a variety of bead and pore sizes). Another example of such a chromatographic material is Sephacryl®, also commercially available from GE Healthcare in a variety of bead and pore sizes.
[0129] In some embodiments, the cross-linked gel can be based on synthetic polymers, such as polymer classes that do not exist in nature. In some aspects, such synthetic polymers that form the basis of chromatographic stationary phases have polar monomer units and are therefore themselves polar polymers. Thus, in some cases, such polar polymers are hydrophilic. Hydrophilic molecules are also called lipophilic, and in some aspects, contain moieties that can form dipole-dipole interactions with water molecules. In general, hydrophobic molecules, also called lipophilic, tend to move away from water.
[0130] Generally, the chromatography method is fluid chromatography, typically liquid chromatography. In some aspects, chromatography can be performed in a flow-through mode, where a fluid sample containing cells, e.g., target cells, is applied to one end of a column containing a chromatography matrix by gravity flow or by a pump, and the fluid sample exits the column at the other end. In addition, chromatography can be performed in an "up and down" mode, where a fluid sample containing cells to be isolated is applied to one end of a column containing a chromatography matrix packed in a pipette tip, for example, by a pipette, and the fluid sample enters the chromatography matrix / pipette tip and exits the other end of the column. Alternatively, chromatography can also be performed in a batch mode, where a chromatography material (stationary phase) is incubated with a sample containing cells, for example, under shaking, rotation, or repeated contact, and the fluid sample is removed, for example, using a pipette.
[0131] In some aspects, any material suitable for chromatographic isolation, e.g., cell selection, may be utilized as a chromatographic matrix in the context of the present invention. In certain aspects, suitable chromatographic materials are at least non-toxic or essentially non-toxic, e.g., not detrimental to cell viability when used in a packed chromatographic column under the desired conditions for cell isolation and / or cell separation. In some aspects, the chromatographic matrix remains in a predetermined location, typically in a predetermined position, while the location of the sample to be separated and the components contained therein changes. Thus, in some aspects, the chromatographic matrix is a "stationary phase."
[0132] Typically, each chromatography matrix has a solid or semi-solid phase, while the sample containing the target cells to be isolated / separated is in a fluid phase. The mobile phase used to accomplish the chromatographic separation is also a fluid phase. The chromatography matrix can be a particulate material (of any suitable size and shape) or a monolithic chromatography material, including a paper substrate or membrane. Thus, chromatography can be both column chromatography and planar chromatography. In addition to standard chromatography columns, columns or pipette tips that allow bidirectional flow can be used for column-based / flow-through mode-based chromatographic separation of cells as described herein. In some aspects, particulate matrix materials are used, and the particulate matrix materials can have an average particle size of, for example, about 5 μm to about 200 μm, or about 5 μm to about 400 μm, or about 5 μm to about 600 μm. In some aspects, planar chromatography is used, and the matrix material can be any material suitable for planar chromatography, such as a conventional cellulosic or organic polymeric membrane (e.g., a paper membrane, a nitrocellulose membrane, or a polyvinylidene difluoride (PVDF) membrane) or a silica-coated glass plate.
[0133] In some aspects, the chromatography matrix / stationary phase is a non-magnetic or non-magnetizable material. Such materials can include derivatized silica or cross-linked gels. Cross-linked gels (typically manufactured in bead form) can be based on natural polymers such as cross-linked polysaccharides. Suitable examples include, but are not limited to, agarose gels or cross-linked dextran gels. Cross-linked gels can also be based on synthetic polymers, i.e., polymer classes that do not exist in nature. Typically, such synthetic polymers that form the basis of chromatographic stationary phases for cell separation are polymers that have polar monomer units and are therefore polar themselves.
[0134] Examples of suitable synthetic polymers are polyacrylamide, styrene-divinylbenzene gel, and copolymers of acrylates and diols or acrylamide and diols. An example is polymethacrylate gel commercially available as Fractogel®. A further example is copolymers of ethylene glycol and methacrylate commercially available as Toyopearl®. In some embodiments, the chromatographic stationary phase can also include natural and synthetic polymeric components, such as composite matrices or composites or copolymers of polysaccharides and agarose or polysaccharides and N,N'-methylenebisacrylamide, e.g., polyacrylamide / agarose composites. An example of a copolymer of dextran and N,N'-methylenebisacrylamide is the Sephacryl® series of materials mentioned above. Derivatized silica can include silica particles coupled to synthetic or natural polymers. Examples of such embodiments include, but are not limited to, polysaccharide-grafted silica, polyvinylpyrrolidone-grafted silica, polyethylene oxide-grafted silica, poly(2-hydroxyethylaspartamide) silica, and poly(N-isopropylacrylamide)-grafted silica.
[0135] In some embodiments, the chromatography matrix utilized in the present invention is a gel filtration (also known as size exclusion) matrix. Gel filtration can be characterized by its design property of being at least essentially free from interaction with the cells to be separated. Thus, gel filtration matrices enable separation of cells or other biological entities, as defined herein, primarily based on their size. Each chromatography matrix is typically a particulate porous material, as described above. The chromatography matrix can have a specific exclusion limit, typically defined in terms of molecular weight, above which molecules are completely blocked from entering the pores. The molecular weight defining the size exclusion limit can be selected to be below the weight corresponding to the weight of the target cells (or biological entities) to be isolated. In such embodiments, the target cells are prevented from entering the pores of the size exclusion chromatography matrix. Similarly, the stationary phase, which is an affinity chromatography matrix, can have pores that are smaller than the size of the selected target cells. In exemplary embodiments, the affinity chromatography matrix and / or gel filtration matrix has an average pore size of 0 to about 500 nm.
[0136] Other components present in the sample, such as stimulating substances and / or stimulating reagents (e.g., oligomeric stimulating reagents), may have sizes below the exclusion limit of the pores and thus can enter the pores of the size-exclusion chromatography matrix. Among those components that can partially or completely enter the pore volume, larger molecules with less access to the pore volume will typically elute first, while the smallest molecules will typically elute last. In some embodiments, the exclusion limit of the size-exclusion chromatography matrix is selected to be below the maximum width of the target cells. Therefore, components that can access the pore volume will typically remain in / on the size-exclusion chromatography matrix longer than the target cells. In this way, the target cells can be collected in the eluate of the chromatography column separately from other objects / components of the sample. Therefore, components such as stimulating reagents elute from the gel filtration matrix at a later time than the target cells. This separation effect can be further enhanced if the gel permeation matrix contains (usually covalently bound thereto) a selection reagent containing a binding moiety, such as binding moiety Z, that can bind to a reagent, such as a selection reagent and / or a competitive reagent, present in the sample. The selection agent and / or competing reagent will be bound by binding site Z of the affinity reagent, thereby immobilizing it on a gel permeation matrix. This method is typically performed on a removal cartridge, and in some embodiments, the methods, combinations, and kits of the invention include and / or use such a gel filtration matrix. Thus, in each method, cells are separated on the basis of size.
[0137] The chromatography matrix used in the present invention may also include a magnetically attractable object, such as one or more magnetically attractable particles or magnetic fluids. Each magnetically attractable particle may include a selection reagent having a binding site (e.g., a selection substance) capable of binding to and immobilizing target cells on the chromatography matrix. The magnetically attractable particles may include diamagnetic, ferromagnetic, paramagnetic, or superparamagnetic materials. Superparamagnetic materials generate an induced magnetic field in response to a magnetic field but do not become permanently magnetized. Iron oxide-based magnetic particles are commercially available, for example, from Dynal Biotech as Dynabeads®, Miltenyi Biotec as magnetic MicroBeads, CPG Inc. as magnetic porous glass beads, and from various other sources, such as Roche Applied Science, BIOCLON, BioSource International Inc., micromod, AMBION, Merck, Bangs Laboratories, Polysciences, or Novagen Inc., to name just a few. Magnetic nanoparticles based on superparamagnetic Co and FeCo and ferromagnetic Co nanocrystals are described, for example, in Huetten, A. et al. (J. Biotech. (2004), 112, 47-63), although in some embodiments the chromatography matrix used in the present invention does not contain any magnetically attractable objects.
[0138] Selected Substances As noted above, in certain aspects, the methods provided herein employ a selection agent. In some embodiments, the agent described in Section II-B is a selection agent. In some embodiments, the selection agent binds to a molecule on the cell surface, e.g., a cell surface molecule. In some examples, the cell surface molecule is a selection marker. In some embodiments, the selection agent has the ability to specifically bind to a selection marker expressed by one or more cells in the sample. In some embodiments, specific binding to a molecule, such as a cell surface molecule or cell surface receptor, throughout this disclosure does not necessarily mean that the agent binds exclusively to such molecule. For example, an agent that specifically binds to a molecule may also bind other molecules, generally with much lower affinity, as determined, for example, by immunoassay, BIAcore®, KinExA3000 instrument (Sapidyne Instruments, Boise, Idaho), or other assay. In some cases, the ability of the agent to bind to a target molecule under specific binding conditions is such that its affinity or avidity is at least 5 times, e.g., at least 10, 20, 30, 40, 50, 100, 250, or 500 times, or even at least 1000 times, the average affinity or avidity of the agent for a collection of random peptides or polypeptides of sufficient statistical size.
[0139] In some embodiments, cells, e.g., target cells (e.g., T cells), have or express a molecule, e.g., a selection marker, on their cell surface such that the cells to be selected are defined by the presence of at least one common specific molecule (e.g., selection marker). In some embodiments, a sample containing target cells may also contain excess cells that lack the molecule (e.g., selection marker). For example, in some embodiments, T cells may be selected from a sample containing multiple cell types, e.g., red blood cells or B cells. The terms selection marker and receptor molecule may be used interchangeably herein to refer to cell surface molecules.
[0140] In some embodiments, a selection marker (e.g., a receptor molecule) located on a cell surface, e.g., on a target cell surface, can be any molecule as long as it remains covalently or non-covalently bound to the cell surface during the chromatographic separation process in the methods of the present invention. A selection marker (e.g., a receptor molecule) is a molecule that can be targeted by a selection agent. In some embodiments, a selection marker is a peptide or protein, e.g., a membrane receptor protein. In some embodiments, a selection marker is a lipid, polysaccharide, or nucleic acid. A selection marker (e.g., a receptor molecule) that is a protein can be a peripheral membrane protein or an integral membrane protein, which in some embodiments can have one or more membrane-spanning domains. In certain embodiments, a selection marker is an immune cell surface protein, e.g., CD3, CD4, or CD8. In some embodiments, a selection marker can be an antigen that defines a desired cell population or cell subpopulation, e.g., a population or subpopulation of blood cells, e.g., lymphocytes (e.g., T cells, CD4+ T cells, or CD8+ T cells).
[0141] In some aspects, the cell surface molecule, e.g., a selection marker, can be an antigen that defines a desired cell population or cell subpopulation, e.g., a population or subpopulation of blood cells, such as lymphocytes (e.g., T cells, T helper cells, e.g., CD3+ T cells, CD8 T cells, CD4+ T helper cells, B cells, or natural killer cells), monocytes, or stem cells, e.g., CD34-positive peripheral stem cells or Nanog- or Oct-4-expressing stem cells. In some embodiments, the selection marker can be a marker expressed on the surface of T cells or T cell subsets, e.g., CD25, CD28, CD62L, CCR7, CD27, CD127, CD3, CD4, CD8, CD45RA, and / or CD45RO. Examples of T cells include CMV-specific CD8+ T lymphocytes, cytotoxic T cells, memory T cells, and regulatory T cells (Tregs). Specific examples of Tregs include CD4 CD25 CD45RA Treg cells, and specific examples of memory T cells include CD62L CD8+ specific central memory T cells.
[0142] As noted above, in some embodiments, the selection agent has or contains binding site B. In certain embodiments, binding site B is monovalent. In some aspects, monovalent binding site B is or contains a monovalent antibody fragment or a proteinaceous binding molecule with immunoglobulin-like function, an aptamer, or an MHC molecule. Examples of monovalent antibody fragments include, but are not limited to, Fab fragments, Fv fragments, and single-chain Fv fragments (scFv), including bivalent single-chain Fv fragments. Examples of (recombinant) antibody fragments are Fab fragments, Fv fragments, single-chain Fv fragments (scFv), bivalent antibody fragments such as (Fab)2' fragments, diabodies, triabodies (Iliades, P., et al., FEBS Lett (1997) 409, 437-441), decabodies (Stone, E., et al., Journal of Immunological Methods (2007) 318, 88-94) and other domain antibodies (Holt, LJ, et al., Trends Biotechnol. (2003), 21, 11, 484-490). In some embodiments, one or more binding sites of the selection agent may be a bivalent proteinaceous artificial binding molecule, such as a dimeric lipocalin mutein, also known as "duocalin". In some embodiments, the receptor-binding reagent may have a single second binding site, i.e., it may be monovalent. Examples of monovalent receptor-binding reagents include, but are not limited to, monovalent antibody fragments, proteinaceous binding molecules with antibody-like binding properties, or MHC molecules.
[0143] Further examples of suitable proteinaceous binding molecules include EGF-like domains, Kringle domains, fibronectin type I domains, fibronectin type II domains, fibronectin type III domains, PAN domains, Gla domains, SRCR domains, Kunitz / bovine pancreatic trypsin inhibitor domains, tendamistat, Kazal-type serine protease inhibitor domains, trefoil (P-type) domains, von Willebrand factor type C domains, anaphylatoxin-like domains, CUB domains, thyroglobulin type I lipids, and the like. nucleotide, LDL receptor class A domain, sushi domain, link domain, thrombospondin type I domain, immunoglobulin domain or immunoglobulin-like domain (e.g., domain antibody or camel heavy chain antibody), C-type lectin domain, MAM domain, von Willebrand factor type A domain, somatomedin B domain, WAP-type 4 disulfide core domain, F5 / 8-type C domain, hemopexin domain, SH2 domain, SH3 domain, laminin-type EGF-like domain, C2 domain, "kappa body" (Ill.et al., Protein Eng (1997) 10, 949-57, so-called "minibodies" (Martin et al., EMBO J (1994) 13, 5303-5309), diabodies (Holliger et al., PNAS USA (1993) 90, 6444-6448), so-called "Janusis" (Traunecker et al., EMBO J (1991) 10, 3655-3659 or Traunecker et al., Int J Cancer (1992) Suppl 7, 51-52), nanobodies, microbodies, affilins, affibodies, knottins, ubiquitin, zinc finger proteins, autofluorescent proteins, or leucine-rich repeat proteins. One example of a nucleic acid molecule with antibody-like function is an aptamer. Aptamers fold into a defined three-dimensional motif and exhibit high affinity for a given target structure.
[0144] In certain aspects, the selection agent contains a binding partner C. In some aspects, the binding partner C included in the selection agent may be, for example, hydrocarbon-based (including polymeric) and may contain nitrogen, phosphorus, sulfur, carbene, halogen, or pseudohalogen groups. It may be an alcohol, organic acid, inorganic acid, amine, phosphine, thiol, disulfide, alkane, amino acid, peptide, oligopeptide, polypeptide, protein, nucleic acid, lipid, sugar, oligosaccharide, or polysaccharide. As a further example, it may be a cation, anion, polycation, polyanion, polycation, electrolyte, polyelectrolyte, carbon nanotube, or carbon nanofoam. Generally, such binding partners have a higher affinity for the binding site of the selection agent or multimerization agent than other entities. Examples of respective binding partners include, but are not limited to, crown ethers, immunoglobulins, fragments thereof, and proteinaceous binding molecules with antibody-like functions.
[0145] In some embodiments, the binding partner C included in the selection agent comprises biotin, and the selection reagent comprises a streptavidin analog or an avidin analog that reversibly binds to biotin. In some embodiments, the binding partner C included in the selection agent comprises a biotin analog that reversibly binds to streptavidin or avidin, and the selection reagent comprises streptavidin, avidin, a streptavidin analog, or an avidin analog that reversibly binds to the respective biotin analog. In some embodiments, the binding partner C included in the selection agent comprises a streptavidin-binding peptide or an avidin-binding peptide, and the selection reagent comprises streptavidin, avidin, a streptavidin analog, or an avidin analog that reversibly binds to the respective streptavidin-binding peptide or avidin-binding peptide.
[0146] In some embodiments, the binding partner included in the selection agent can comprise a streptavidin-binding peptide. In some embodiments, the peptide sequence contains a sequence of the general formula His-Pro-Xaa (wherein Xaa is glutamine, asparagine, or methionine), e.g., the sequence set forth in SEQ ID NO:9. In some embodiments, the peptide sequence has the general formula set forth in SEQ ID NO:11, e.g., the general formula set forth in SEQ ID NO:12. In one example, the peptide sequence is Trp-Arg-His-Pro-Gln-Phe-Gly-Gly (also known as Strep-tag® and set forth in SEQ ID NO:7). In one example, the peptide sequence is Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (also known as Strep-tag® II and set forth in SEQ ID NO:8), which is described, e.g., in U.S. Patent No. 6,103,493 and commercially available under the trademark Strep-Tactin®. The streptavidin-binding peptide may be, for example, a single peptide, such as the "Strep-tag" described in U.S. Pat. No. 5,506,121, or may be a streptavidin-binding peptide comprising two or more individual binding modules arranged in series, such as those described in WO 02 / 077018 or U.S. Pat. No. 7,981,632.
[0147] In some embodiments, the binding partner C of the selection agent comprises a moiety known to those skilled in the art as an affinity tag. In such embodiments, the selection reagent comprises a corresponding binding partner, e.g., an antibody or antibody fragment, known to bind to the affinity tag. Binding partners included in the selection agent can include dinitrophenol or digoxigenin, oligohistidine, polyhistidine, immunoglobulin domains, maltose binding protein, glutathione-S-transferase (GST), chitin-binding protein (CBP) or thioredoxin, calmodulin-binding peptide (CBP), FLAG'-peptide, HA tag, VSV-G tag, HSV tag, T7 epitope, maltose-binding protein (MBP), HSV epitope of the sequence of herpes simplex virus glycoprotein D, "myc" epitope of the transcription factor c-myc of the sequence of V5 tag, or glutathione-S-transferase (GST), to name a few examples of known affinity tags. In such embodiments, the complex formed between one or more binding sites of the selection reagent, in this case an antibody or antibody fragment, and the antigen can be competitively disrupted by adding free antigen, i.e., a free peptide (epitope tag) or free protein (such as MBP or CBP). The affinity tag can be an oligonucleotide tag. Such an oligonucleotide tag can be used, for example, to hybridize to an oligonucleotide with a complementary sequence linked to or contained in the selection reagent.
[0148] Consistent with co-pending International Patent Application PCT / EP2012 / 063969, published as WO 2013 / 011011 (the entire contents of which are incorporated herein by reference for all purposes), the strength of binding between the selection agent and the selection marker on the target cell may not be critical to the reversibility of binding of the target cell to the selection agent via the selection agent. Rather, the reversibility of binding may be independent of the strength of binding, i.e., the dissociation constant (K D ) but K D For example, about 10-3 ~about 10 -7 low affinity in the M range or K D For example, about 10 -7 ~Approx. 1×10 -10 Regardless of whether the binding between the selective substance and the receptor molecule is of high affinity in the range of M or M, the target cells can be reversibly stained as long as the dissociation of the binding between the selective substance and the receptor molecule via binding site B occurs sufficiently fast. In this regard, the dissociation rate constant (k off ) is approximately 3 × 10 -5 sec -1 or greater (this dissociation rate constant characterizes the dissociation reaction of the complex formed between binding site B of the selection substance and the selection marker on the surface of the target cell). The association rate constant (k on ) can have any value. To ensure sufficient reversible binding between the selection marker and the selection agent, the k off The value is about 3 x 10 -5 sec -1 That's about 5 x 10 -5 sec -1 or more, for example, 1×10 -4 sec -1 That's it, 5 x 10 -4 sec -1 That's it, 1 x 10 -3 sec -1 That's it, 5 x 10 -3 sec -1 That's it, 1 x 10 -2 sec -1 That's it, 1 x 10 -1 sec -1 or more or 5 x 10 -1 sec -1 or more, or about 1 x 10 -4 sec -1 That's it, 5 x 10 -4 sec -1 That's it, 1 x 10 -3 sec -1 That's it, 5 x 10 -3 sec -1 That's it, 1 x 10 -2 sec -1That's it, 1 x 10 -1 sec -1 or more or 5 x 10 -1 sec -1 It is advantageous to select the kinetic constants to have values equal to or greater than 1.013 bar and 25° C. It should be noted that the values of the kinetic constants and thermodynamic constants used herein refer to conditions of atmospheric pressure, i.e., 1.013 bar, and room temperature, i.e., 25° C.
[0149] In some embodiments, the selection agent has a single (monovalent) binding site B capable of specifically binding to the selection marker. In some embodiments, the selection agent has at least two (i.e., a plurality of binding sites comprising three, four, or five identical binding sites B) capable of binding to the selection marker. In any of these embodiments, binding of the selection marker via (each of) binding sites B is greater than or equal to about 3×10 -5 sec -1 More than k off Thus, the selection agent can be monovalent (e.g., a monovalent antibody fragment or a monovalent artificial binding molecule (proteinaceous or otherwise), such as a mutein based on a polypeptide of the lipocalin family (also known as "Anticalin®"), or a bivalent molecule, such as an antibody or fragment in which both binding sites are retained, e.g., an F(ab')2 fragment. In some embodiments, the selection marker is k off Speed is 3x10 -5 sec -1 If it is more than this, it may be a multivalent molecule such as a pentameric IgE molecule.
[0150] In some embodiments of the present invention, the reversible cell affinity chromatography techniques described herein allow for the (traceless) isolation of biological materials by a molecular level of approximately 3×10 binding sites of a selection agent to a selection marker on a target cell via at least one binding site B. -5 sec -1 (more than)k offRather, and as described, for example, in U.S. Pat. No. 7,776,562 or International Patent Application WO 02 / 054065, low-affinity binding between the selection marker and binding site B of the selection agent, coupled with the avidity effect mediated by the immobilized selection reagent, allows for reversible and traceless isolation of target cells. In these embodiments, complexes can form between two or more binding sites Z of the selection agent and at least two binding partners C of the selection agent, allowing for reversible immobilization of target cells to the affinity chromatography matrix. As noted above, such low binding affinity is approximately 1.0 × 10 for binding of the selection agent to the selection marker on the target cell surface via binding site B. -3 M ~ approx. 1.0×10 -7 Dissociation constants (K D )
[0151] In some embodiments, the selection marker can be CD4, and the selection agent specifically binds to CD4. In some aspects, the selection agent that specifically binds to CD4 can be selected from the group consisting of an anti-CD4 antibody, a bivalent antibody fragment of an anti-CD4 antibody, a monovalent antibody fragment of an anti-CD4 antibody, and a proteinaceous CD4-binding molecule with antibody-like binding properties. In some embodiments, the anti-CD4 antibody, e.g., a bivalent antibody fragment or a monovalent antibody fragment (e.g., a CD4 Fab fragment), can be derived from the antibody 13B8.2 or a functionally active variant of 13B8.2 that retains specific binding to CD4. For example, exemplary variants of antibody 13B8.2 or m13B8.2 are described in U.S. Patent No. 7,482,000, U.S. Patent Application Publication No. 2014 / 0295458, or International Patent Application WO2013 / 124474, and Bes, C, et al. J Biol Chem 278, 14265-14273 (2003). The mutant Fab fragment, designated "m13B8.2," has the variable domains of the CD4-binding murine antibody 13B8.2 and a constant domain containing a gamma-type constant human CH1 domain for the heavy chain and a kappa-type constant human light chain domain, as described in U.S. Patent No. 7,482,000. In some embodiments, the anti-CD4 antibody, e.g., a variant of antibody 13B8.2, contains the amino acid substitution H91A in the variable light chain, Y92A in the variable light chain, H35A in the variable heavy chain, and / or R53A in the variable heavy chain, each according to the Kabat numbering. In some aspects, compared to the variable domain of the 13B8.2 Fab fragment in m13B8.2, the His residue at position 91 of the light chain (position 93 in SEQ ID NO:30) is mutated to Ala, and the Arg residue at position 53 of the heavy chain (position 55 in SEQ ID NO:29) is mutated to Ala. In some embodiments, the reagent that reversibly binds anti-CD4 or a fragment thereof is commercially available or derived from a commercially available reagent (e.g., catalog number 6-8000-206 or 6-8000-205 or 6-8002-100, IBA GmbH, Goettingen, Germany).In some embodiments, the selection agent comprises an anti-CD4 Fab fragment. In some embodiments, the anti-CD4 Fab fragment comprises a variable heavy chain having the sequence set forth in SEQ ID NO:29 and a variable light chain having the sequence set forth in SEQ ID NO:30. In some embodiments, the anti-CD4 Fab fragment comprises the CDRs of the variable heavy chain having the sequence set forth in SEQ ID NO:29 and the CDRs of the variable light chain having the sequence set forth in SEQ ID NO:30.
[0152] In some embodiments, the selection marker can be CD8, and the selection agent specifically binds to CD8. In some aspects, the selection agent that specifically binds to CD8 can be selected from the group consisting of an anti-CD8 antibody, a bivalent antibody fragment of an anti-CD8 antibody, a monovalent antibody fragment of an anti-CD8 antibody, and a proteinaceous CD8-binding molecule with antibody-like binding properties. In some embodiments, the anti-CD8 antibody, e.g., a bivalent antibody fragment or a monovalent antibody fragment (e.g., a CD8 Fab fragment), can be derived from the antibody OKT8 (e.g., ATCC CRL-8014) or a functionally active variant thereof that retains specific binding to CD8. In some embodiments, a reagent that reversibly binds to anti-CD8 or a fragment thereof is commercially available or derived from a commercially available reagent (e.g., catalog number 6-8003 or 6-8000-201, IBA GmbH, Goettingen, Germany). In some embodiments, the selection agent comprises an anti-CD8 Fab fragment. In some embodiments, the anti-CD8 Fab fragment comprises a variable heavy chain having the sequence set forth in SEQ ID NO: 36 and a variable light chain having the sequence set forth in SEQ ID NO: 37. In some embodiments, the anti-CD8 Fab fragment comprises the CDRs of the variable heavy chain having the sequence set forth in SEQ ID NO: 36 and the CDRs of the variable light chain having the sequence set forth in SEQ ID NO: 37.
[0153] In some embodiments, the selection marker can be CD3, and the selection agent specifically binds to CD3. In some aspects, the selection agent that specifically binds to CD3 can be selected from the group consisting of an anti-CD3 antibody, a bivalent antibody fragment of an anti-CD3 antibody, a monovalent antibody fragment of an anti-CD3 antibody, and a proteinaceous CD3-binding molecule with antibody-like binding properties. In some embodiments, the anti-CD3 antibody, e.g., a bivalent antibody fragment or a monovalent antibody fragment (e.g., a CD3 Fab fragment), can be derived from the antibody OKT3 (e.g., ATCC CRL-8001; see, e.g., Stemberger et al. PLoS One. 2012;7(4):e35798) or a functionally active variant thereof that retains specific binding to CD3. In some embodiments, the reagent that reversibly binds to anti-CD3 or a fragment thereof is commercially available or derived from a commercially available reagent (e.g., catalog number 6-8000-201, 6-8001-100, IBA GmbH, Goettingen, Germany). In some embodiments, the selection agent comprises an anti-CD3 Fab fragment. In some embodiments, the anti-CD3 Fab fragment comprises a variable heavy chain having the sequence set forth in SEQ ID NO:31 and a variable light chain having the sequence set forth in SEQ ID NO:32. In some embodiments, the anti-CD3 Fab fragment comprises the CDRs of the variable heavy chain having the sequence set forth in SEQ ID NO:31 and the CDRs of the variable light chain having the sequence set forth in SEQ ID NO:32.
[0154] In any of the above examples, the bivalent antibody fragment may be a (Fab)2' fragment or a bivalent single-chain Fv fragment, while the monovalent antibody fragment may be selected from the group consisting of a Fab fragment, an Fv fragment, and a single-chain Fv fragment (scFv). In any of the above examples, the proteinaceous binding molecule with antibody-like binding properties may be an aptamer, a mutein based on a polypeptide of the lipocalin family, a glubody, an ankyrin scaffold-based protein, a crystalline scaffold-based protein, an adnectin, and an avimer.
[0155] C. On-column stimulation In the methods provided herein, cell selection by a column chromatography step is integrated with stimulation. Thus, in certain aspects, stimulation is performed during at least a portion of the selection step while the cells are immobilized on the column (e.g., by a selection agent). In some embodiments where two or more columns are used for selection, stimulation is performed on each column. In some embodiments where two or more columns are used for selection, stimulation is performed on fewer columns than the total number of columns. In some embodiments where two or more columns are used for selection, stimulation is performed on at least one column. In some embodiments where parallel selection is used, stimulation is performed on each column. In some embodiments where parallel selection is used, stimulation is performed on at least one column. In some embodiments where sequential selection is used, stimulation is performed on each column. In some embodiments where sequential selection is used, stimulation is performed on at least one column. In some embodiments, the stimulation conditions include stimulating or activating conditions and can deliver a stimulatory signal, e.g., a signal generated from a TCR and / or a costimulatory molecule, in cells, e.g., CD3+, CD4+, or CD8+ T cells. In some embodiments, the stimulatory conditions are or include incubating target cells (e.g., T cells) immobilized on a chromatographic matrix (e.g., a stationary phase) with a stimulatory agent, e.g., an agent that delivers or has the ability to deliver a stimulatory signal, thereby stimulating the selected cells, or with a stimulatory reagent, e.g., an oligomeric stimulatory reagent, that includes the stimulatory agent. In some embodiments, the stimulatory agent binds to and / or activates a TCR and / or costimulatory molecule. In particular embodiments, the stimulatory reagent is an oligomeric stimulatory reagent provided herein, e.g., as described in Section IC-1a. In certain embodiments, stimulating a population of cells under stimulatory conditions generates or creates a population of selected stimulated cells (also referred to herein as a stimulated cell population). The population of selected stimulated cells is sometimes referred to herein as an output population of stimulated selected cells.Optionally, the population of selected and stimulated cells can serve as an input population for downstream processing, for example, for genetic manipulation as described in Section IE.
[0156] In certain embodiments, cells of the sample are selected and stimulated prior to introducing the heterologous or recombinant polynucleotide into the cells, such as by the methods, processes, or techniques described herein, e.g., in Section IE. In some embodiments, the output population of selected and stimulated cells is engineered to express a heterologous or recombinant protein (e.g., a chimeric antigen receptor).
[0157] In some embodiments, stimulation is considered to begin when cells of the population are first stimulated or first exposed to conditions that activate or stimulate the cells and / or conditions that can activate or stimulate signals in the cells, e.g., signals generated from a TCR and / or a coreceptor or costimulatory molecule. In some embodiments, stimulation begins when cells are first contacted with or exposed to a stimulatory agent or a stimulating reagent containing a stimulatory agent, e.g., as described in Sections IC-1a and / or II-A herein, e.g., as described in Sections II-A and / or IC-1b. In certain aspects, the initiation of stimulation (also referred to herein as the initiation of incubation) occurs when target cells (e.g., T cells) of a sample immobilized on a chromatographic matrix (e.g., a stationary phase) are first contacted with or exposed to a stimulatory agent or a stimulating reagent containing a stimulatory agent (e.g., an oligomeric stimulating reagent described in Section IC-1b below). In some embodiments, the cells are allowed to percolate through the column for about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, or 120 minutes prior to addition of the stimulating reagent (e.g., oligomeric stimulating reagent) or stimulating substance. In some embodiments, the column is washed at least one (1, 2, 3, 4, 5) time prior to addition of the stimulating reagent (e.g., oligomeric stimulating reagent) or stimulating substance. In some embodiments, the column is washed at least two times prior to addition of the stimulating substance or stimulating reagent (e.g., oligomeric stimulating reagent) containing the stimulating substance.
[0158] In some embodiments, the stimulating agent or stimulating reagent (e.g., oligomeric stimulating reagent) comprising the stimulating agent is added 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, or 120 minutes after adding the sample to the chromatography column (e.g., stationary phase), or at about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, or 120 minutes after adding the sample to the chromatography column (e.g., stationary phase). In some embodiments, the stimulating agent or stimulating reagent (e.g., oligomeric stimulating reagent) comprising the stimulating agent is added 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, or 120 minutes after adding the sample to the chromatography column (e.g., stationary phase), or at about 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, or 120 minutes after adding the sample to the chromatography column (e.g., stationary phase). In some embodiments, the stimulator or a stimulating reagent comprising the stimulator (e.g., an oligomer stimulating reagent) is added 30, 35, 40, 45, 50, 55, or 60 minutes after, or about, or at least 30, 35, 40, 45, 50, 55, or 60 minutes after adding the sample to the chromatography column (e.g., the stationary phase). In some embodiments, the stimulator or a stimulating reagent comprising the stimulator (e.g., an oligomer stimulating reagent) is added between about 15 and about 120 minutes, inclusive, after adding the sample to the column. In some embodiments, the stimulator or a stimulating reagent comprising the stimulator (e.g., an oligomer stimulating reagent) is added between about 15 and about 100 minutes, inclusive, after adding the sample to the column. In some embodiments, the stimulator or a stimulating reagent comprising the stimulator (e.g., an oligomer stimulating reagent) is added between about 15 and about 90 minutes, inclusive, after adding the sample to the column. In some embodiments, the stimulator or a stimulating reagent containing the stimulator (e.g., an oligomeric stimulating reagent) is added between about 15 and about 80 minutes, inclusive, after the sample is added to the column.In some embodiments, the stimulator or a stimulating reagent comprising the stimulator (e.g., an oligomer stimulating reagent) is added between about 15 and about 70 minutes, inclusive, after the sample is added to the column. In some embodiments, the stimulator or a stimulating reagent comprising the stimulator (e.g., an oligomer stimulating reagent) is added between about 15 and about 60 minutes, inclusive, after the sample is added to the column. In some embodiments, the stimulator or a stimulating reagent comprising the stimulator (e.g., an oligomer stimulating reagent) is added between about 15 and about 50 minutes, inclusive, after the sample is added to the column. In some embodiments, the stimulator or a stimulating reagent comprising the stimulator (e.g., an oligomer stimulating reagent) is added between about 15 and about 40 minutes, inclusive, after the sample is added to the column. In some embodiments, the stimulator or a stimulating reagent comprising the stimulator (e.g., an oligomer stimulating reagent) is added between about 15 and about 30 minutes, inclusive, after the sample is added to the column. In some embodiments, the stimulator or a stimulating reagent comprising the stimulator (e.g., an oligomer stimulating reagent) is added between about 30 and about 120 minutes, inclusive, after adding the sample to the column. In some embodiments, the stimulator or a stimulating reagent comprising the stimulator (e.g., an oligomer stimulating reagent) is added between about 30 and about 100 minutes, inclusive, after adding the sample to the column. In some embodiments, the stimulator or a stimulating reagent comprising the stimulator (e.g., an oligomer stimulating reagent) is added between about 30 and about 90 minutes, inclusive, after adding the sample to the column. In some embodiments, the stimulator or a stimulating reagent comprising the stimulator (e.g., an oligomer stimulating reagent) is added between about 30 and about 80 minutes, inclusive, after adding the sample to the column. In some embodiments, the stimulator or a stimulating reagent comprising the stimulator (e.g., an oligomer stimulating reagent) is added between about 30 and about 70 minutes, inclusive, after adding the sample to the column. In some embodiments, the stimulator or a stimulating reagent containing the stimulator (e.g., an oligomeric stimulating reagent) is added between about 30 and about 60 minutes, inclusive, after the sample is added to the column. In some embodiments, the stimulator or a stimulating reagent containing the stimulator (e.g., an oligomeric stimulating reagent) is added between about 30 and about 50 minutes, inclusive, after the sample is added to the column.In some embodiments, the stimulator or a stimulating reagent containing the stimulator (e.g., an oligomeric stimulating reagent) is added between about 30 and about 40 minutes, inclusive, after the sample is added to the column. In some embodiments, at least one wash step is performed before adding the stimulator or a reagent containing the stimulator (e.g., an oligomeric stimulating reagent) to the column.
[0159] In some embodiments, the stimulation, e.g., incubating the fixed cells under stimulating conditions, is carried out for 1 day, about 1 day, or less than 1 day. In some embodiments, the stimulation, e.g., incubating the fixed cells under stimulating conditions, is carried out for 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 hours, or for less than 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 hours. In some embodiments, stimulation, e.g., incubating selected cells under stimulatory conditions, is performed using a method comprising administering to a subject the method comprises administering to the subject the selected cells under stimulatory conditions. 2-24, 2-22, 2-21, 2-20, 2-19, 2-18, 2-17, 2-16, 2-15, 2-14, 2-13, 2-12, 2-11, 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, or 2-3 hours. In some embodiments, the stimulation, e.g., incubating the fixed cells under stimulating conditions, is carried out for 24 hours, about 24 hours, or less than 24 hours. In some embodiments, the stimulation, e.g., incubating the fixed cells under stimulating conditions, is carried out for 12 hours, about 12 hours, or less than 12 hours.In some embodiments, the stimulation, for example, incubating the fixed cells under stimulating conditions, is carried out for 5 hours, about 5 hours, or less than 5 hours. In some embodiments, the stimulation, for example, incubating the fixed cells under stimulating conditions, is carried out for 4.5 hours, about 4.5 hours, or less than 4.5 hours. In some embodiments, the stimulation, for example, incubating the fixed cells under stimulating conditions, is carried out for 4 hours, about 4 hours, or less than 4 hours. In some embodiments, the stimulation, for example, incubating the fixed cells under stimulating conditions, is carried out for 2 hours, about 2 hours, or less than 2 hours.
[0160] In certain embodiments, 50×10 selected from the sample 6 , 100×10 6 , 150×10 6 , 200×10 6 , 250×10 6 , 300×10 6 , 350×10 6 , 400×10 6 , 450×10 6 , 500×10 6 , 550×10 6 , 600×10 6 , 700×10 6 , 800×10 6 , 900×10 6 , 1,000 x 10 6 , 1250×10 6 , 1500×10 6 , 1750×10 6 , 2000×10 6 , 2250×10 6 , 2500×10 6 , 2750×10 6 , 3000×10 6 3250×10 6 , 3500 10 6 , 3750×10 6 , 4000×10 6 , 4250×10 6 , 4500×10 6 , 4750×10 6 Or 5000 x 10 6pieces, about 50×10 6 , 100×10 6 , 150×10 6 , 200×10 6 , 250×10 6 , 300×10 6 , 350×10 6 , 400×10 6 , 450×10 6 , 500×10 6 , 550×10 6 , 600×10 6 , 700×10 6 , 800×10 6 , 900×10 6 , 1,000 x 10 6 , 1250×10 6 , 1500×10 6 , 1750×10 6 , 2000×10 6 , 2250×10 6 , 2500×10 6 , 2750×10 6 , 3000×10 6 3250×10 6 , 3500 10 6 , 3750×10 6 , 4000×10 6 , 4250×10 6 , 4500×10 6 , 4750×10 6 Or 5000 x 10 6 pieces, or at least 50 x 10 6 , 100×10 6 , 150×10 6 , 200×10 6 , 250×10 6 , 300×10 6 , 350×10 6 , 400×10 6 , 450×10 6 , 500×10 6 , 550×10 6 , 600×10 6 , 700×10 6 , 800×10 6 , 900×10 6 , 1,000 x 10 6 , 1250×106 , 1500×10 6 , 1750×10 6 , 2000×10 6 , 2250×10 6 , 2500×10 6 , 2750×10 6 , 3000×10 6 3250×10 6 , 3500 10 6 , 3750×10 6 , 4000×10 6 , 4250×10 6 , 4500×10 6 , 4750×10 6 Or 5000 x 10 6 A quantity of cells, or any number of cells between any of the above, are stimulated (e.g., incubated under stimulating conditions). In some embodiments, the selected cells are immobilized on a single column (e.g., containing a chromatography matrix). For example, the entire quantity of selected cells from a sample is immobilized on a single column, and the immobilized cells on the single column are incubated under stimulating conditions. In some embodiments, the selected cells are immobilized on two columns (e.g., each containing a chromatography matrix). For example, the entire quantity of selected cells from a sample is immobilized on two columns (e.g., each column (e.g., chromatography matrix) contains half or about half of the total quantity of cells immobilized thereon), and the immobilized cells on the two columns are incubated under stimulating conditions. In certain embodiments, the cells, e.g., selected cells (e.g., T cells), on the chromatography matrix (e.g., stationary phase) are immobilized in an amount of 0.01 x 10 6 cells / mL, 0.1×10 6 cells / mL, 0.5×10 6 cells / mL, 1.0×10 6 cells / mL, 1.5×10 6 cells / mL, 2.0×10 6 cells / mL, 2.5×10 6 cells / mL, 3.0×10 6 cells / mL, 4.0×10 6 cells / mL, 5.0×10 6cells / mL, 10×10 6 cells / mL, 50×10 6 cells / mL, 75×10 6 cells / mL, 100×10 6 cells / mL, 125×10 6 cells / mL, 150×10 6 cells / mL or 200 x 10 6 cells / mL, or approximately 0.01 x 10 6 cells / mL, 0.1×10 6 cells / mL, 0.5×10 6 cells / mL, 1.0×10 6 cells / mL, 1.5×10 6 cells / mL, 2.0×10 6 cells / mL, 2.5×10 6 cells / mL, 3.0×10 6 cells / mL, 4.0×10 6 cells / mL, 5.0×10 6 cells / mL, 10×10 6 cells / mL, 50×10 6 cells / mL, 75×10 6 cells / mL, 100×10 6 cells / mL, 125×10 6 cells / mL, 150×10 6 cells / mL or 200 x 10 6 cells / mL, or at least 0.01 x 10 6 cells / mL, 0.1×10 6 cells / mL, 0.5×10 6 cells / mL, 1.0×10 6 cells / mL, 1.5×10 6 cells / mL, 2.0×10 6 cells / mL, 2.5×10 6 cells / mL, 3.0×10 6 cells / mL, 4.0×10 6 cells / mL, 5.0×10 6 cells / mL, 10×10 6 cells / mL, 50×10 6 cells / mL, 75×10 6 cells / mL, 100×10 6 cells / mL, 125×10 6 cells / mL, 150×106 cells / mL or 200 x 10 6 In certain embodiments, the cells immobilized on the stationary phase, e.g., the selected cells (e.g., T cells), are stimulated or subjected to stimulation at a density of 100 million ± 25 million cells / mL or about 100 million ± 25 million cells / mL and incubated under stimulating conditions, e.g., in the presence of a stimulating substance. In certain embodiments, the cells immobilized on the stationary phase, e.g., the selected cells (e.g., T cells), are stimulated or subjected to stimulation at a density of 3.0 × 10 6 cells / mL, approximately 3.0×10 6 cells / mL or at least 3.0 x 10 6 The cells are stimulated or subjected to stimulation at a density of cells / mL and incubated under stimulatory conditions, such as in the presence of a stimulatory agent. In certain embodiments, the cells selected are viable cells.
[0161] In some embodiments, the stimulator or stimulatory reagent containing the stimulator is 1×10 6 In some embodiments, a stimulator or a stimulation reagent comprising a stimulator is applied to the column containing immobilized cells at a concentration of about, or at least 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3 μg per cell. In some embodiments, a stimulator or a stimulation reagent comprising a stimulator is applied to the column containing immobilized cells at a concentration of about, or at least 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3 μg per cell. 6 In some embodiments, the stimulator or stimulatory reagent containing the stimulator is added at a concentration of about, or at least 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25 μg per cell. 6The stimulating reagent is applied to the column at a concentration of 1-2 μg per cell or about 1-2 μg per cell. In some embodiments, the stimulating reagent is an oligomeric stimulating reagent. In some embodiments, the oligomeric stimulating reagent is applied to the column containing the immobilized cells at a concentration of 1×10 6 In some embodiments, the antibody is added at a concentration of 1-2 μg per cell or about 1-2 μg per cell. 8 of oligomeric stimulation reagent is added to the column containing the immobilized cells. If more than one column contains immobilized cells for stimulation, a concentration or amount of stimulant or stimulation reagent containing a stimulant (e.g., oligomeric stimulation reagent) described herein is added or applied to each column.
[0162] In some embodiments, the conditions for stimulation can include one or more of a specific medium, temperature, oxygen content, carbon dioxide content, time, agents such as nutrients, amino acids, antibiotics, ions and / or stimulatory factors such as cytokines, chemokines, antigens, binding partners, fusion proteins, recombinant soluble receptors, and any other agents designed to activate cells. In some embodiments, the temperature is at or about 37° C. In some embodiments, the oxygen content and carbon dioxide content are managed using gas exchange.
[0163] In certain embodiments, the stimulatory conditions include incubating cells, e.g., selected cells of a sample, with and / or in the presence of one or more cytokines. In certain embodiments, the one or more cytokines are recombinant cytokines. In some embodiments, the one or more cytokines are human recombinant cytokines. In certain embodiments, the one or more cytokines bind to and / or are capable of binding to a receptor expressed by and / or endogenous to the selected cells (e.g., T cells). In certain embodiments, the one or more cytokines are or include members of the four-alpha-helical bundle family of cytokines. In some embodiments, members of the four-alpha-helical bundle family of cytokines include, but are not limited to, interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-7 (IL-7), interleukin-9 (IL-9), interleukin-12 (IL-12), interleukin-15 (IL-15), granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF). In some embodiments, the one or more cytokines are or include IL-15. In certain embodiments, the one or more cytokines are or include IL-7. In certain embodiments, the one or more cytokines are or include IL-2.
[0164] In certain embodiments, the amount or concentration of one or more cytokines is measured and / or quantified using International Units (IU). International units may be used to quantify vitamins, hormones, cytokines, vaccines, blood products, and similar biologically active substances. In some embodiments, IU is or includes a unit of measurement of the potency of a biological preparation by comparison with an international reference standard of a specific weight and strength, such as the WHO First International Standard for Human IL-2, 86 / 504. International units are the only recognized standardized method for reporting biological activity units that are published and obtained from international collaborative research efforts. In certain embodiments, IU for a population, sample, or source of cytokine may be obtained by product comparison testing using a similar WHO standard. For example, in some embodiments, the IU / mg of a population, sample, or source of human recombinant IL-2, IL-7, or IL-15 is compared to a WHO standard IL-2 product (NIBSC code: 86 / 500), a WHO standard IL-17 product (NIBSC code: 90 / 530), and a WHO standard IL-15 product (NIBSC code: 95 / 554), respectively.
[0165] In some embodiments, biological activity in IU / mg is equal to (ED50 in ng / ml) - 1 x 106. In certain embodiments, the ED50 of recombinant human IL-2 or IL-15 is equal to the concentration required for half-maximal stimulation of cell proliferation (XTT cleavage) by CTLL-2 cells. In certain embodiments, the ED50 of recombinant human IL-7 is equal to the concentration required for half-maximal stimulation of proliferation of PHA-activated human peripheral blood lymphocytes. Details regarding assaying and calculating IU for IL-2 are discussed in Wadhwa et al., Journal of Immunological Methods (2013), 379 (1-2): 1-7; and Gearing and Thorpe, Journal of Immunological Methods (1988), 114 (1-2): 3-9; details regarding assaying and calculating IU for IL-15 are discussed in Soman et al. Journal of Immunological Methods (2009) 348 (1-2): 83-94.
[0166] In some embodiments, cells, e.g., selected cells of a sample, are stimulated or subjected to stimulation in the presence of a cytokine, e.g., a recombinant human cytokine, at a concentration of between 1 IU / mL and 1,000 IU / mL, between 10 IU / mL and 50 IU / mL, between 50 IU / mL and 100 IU / mL, between 100 IU / mL and 200 IU / mL, between 100 IU / mL and 500 IU / mL, between 250 IU / mL and 500 IU / mL, or between 500 IU / mL and 1,000 IU / mL.
[0167] In some embodiments, cells, e.g., selected cells of a sample, are stimulated or subjected to stimulation in the presence of recombinant IL-2, e.g., human recombinant IL-2, at a concentration of 1 IU / mL to 500 IU / mL, 10 IU / mL to 250 IU / mL, 50 IU / mL to 200 IU / mL, 50 IU / mL to 150 IU / mL, 75 IU / mL to 125 IU / mL, 100 IU / mL to 200 IU / mL, or 10 IU / mL to 100 IU / mL. In particular embodiments, cells, e.g., selected cells of a sample, contain 50 IU / mL, 60 IU / mL, 70 IU / mL, 80 IU / mL, 90 IU / mL, 100 IU / mL, 110 IU / mL, 120 IU / mL, 130 IU / mL, 140 IU / mL, 150 IU / mL, 160 IU / mL, 170 IU / mL, 180 IU / mL, 190 IU / mL, or 100 IU / mL, or about In some embodiments, the cells, e.g., selected cells of a sample, are stimulated or subjected to stimulation in the presence of recombinant IL-2 at a concentration of 50 IU / mL, 60 IU / mL, 70 IU / mL, 80 IU / mL, 90 IU / mL, 100 IU / mL, 110 IU / mL, 120 IU / mL, 130 IU / mL, 140 IU / mL, 150 IU / mL, 160 IU / mL, 170 IU / mL, 180 IU / mL, 190 IU / mL, or 100 IU / mL. In some embodiments, the cells, e.g., selected cells of a sample, are stimulated or subjected to stimulation in the presence of 100 IU / mL or about 100 IU / mL of recombinant IL-2, e.g., human recombinant IL-2.
[0168] In some embodiments, cells, e.g., selected cells of a sample, are stimulated or subjected to stimulation in the presence of recombinant IL-7, e.g., human recombinant IL-7, at a concentration of 100 IU / mL to 2,000 IU / mL, 500 IU / mL to 1,000 IU / mL, 100 IU / mL to 500 IU / mL, 500 IU / mL to 750 IU / mL, 750 IU / mL to 1,000 IU / mL, or 550 IU / mL to 650 IU / mL. In particular embodiments, the cells, e.g., input cells, contain 50 IU / mL, 100 IU / mL, 150 IU / mL, 200 IU / mL, 250 IU / mL, 300 IU / mL, 350 IU / mL, 400 IU / mL, 450 IU / mL, 500 IU / mL, 550 IU / mL, 600 IU / mL, 650 IU / mL, 700 IU / mL, 750 IU / mL, 800 IU / mL, 750 IU / mL, 750 IU / mL, 750 IU / mL, or 1,000 IU / mL, or about The cells are stimulated or subjected to stimulation in the presence of IL-7 at a concentration of 50 IU / mL, 100 IU / mL, 150 IU / mL, 200 IU / mL, 250 IU / mL, 300 IU / mL, 350 IU / mL, 400 IU / mL, 450 IU / mL, 500 IU / mL, 550 IU / mL, 600 IU / mL, 650 IU / mL, 700 IU / mL, 750 IU / mL, 800 IU / mL, 750 IU / mL, 750 IU / mL, or 1,000 IU / mL. In a particular embodiment, the cells, e.g., selected cells of the sample, are stimulated or subjected to stimulation in the presence of 600 IU / mL or about 600 IU / mL of recombinant IL-7, e.g., human recombinant IL-7.
[0169] In some embodiments, cells, e.g., selected cells of a sample, are stimulated or subjected to stimulation in the presence of recombinant IL-15, e.g., human recombinant IL-15, at a concentration of 1 IU / mL to 500 IU / mL, 10 IU / mL to 250 IU / mL, 50 IU / mL to 200 IU / mL, 50 IU / mL to 150 IU / mL, 75 IU / mL to 125 IU / mL, 100 IU / mL to 200 IU / mL, or 10 IU / mL to 100 IU / mL. In particular embodiments, cells, e.g., cells of an input population, are administered 50 IU / mL, 60 IU / mL, 70 IU / mL, 80 IU / mL, 90 IU / mL, 100 IU / mL, 110 IU / mL, 120 IU / mL, 130 IU / mL, 140 IU / mL, 150 IU / mL, 160 IU / mL, 170 IU / mL, 180 IU / mL, 190 IU / mL, or 200 IU / mL, or about 5 In some embodiments, the cells, e.g., selected cells of a sample, are stimulated or subjected to stimulation in the presence of recombinant IL-15 at a concentration of 0 IU / mL, 60 IU / mL, 70 IU / mL, 80 IU / mL, 90 IU / mL, 100 IU / mL, 110 IU / mL, 120 IU / mL, 130 IU / mL, 140 IU / mL, 150 IU / mL, 160 IU / mL, 170 IU / mL, 180 IU / mL, 190 IU / mL, or 200 IU / mL. In some embodiments, the cells, e.g., selected cells of a sample, are stimulated or subjected to stimulation in the presence of 100 IU / mL or about 100 IU / mL of recombinant IL-15, e.g., human recombinant IL-15.
[0170] In particular embodiments, cells, e.g., selected cells of a sample, are stimulated or subjected to stimulation under stimulatory conditions in the presence of IL-2, IL-7, and / or IL-15. In some embodiments, the IL-2, IL-7, and / or IL-15 are recombinant IL-2, IL-7, and / or IL-15. In certain embodiments, the IL-2, IL-7, and / or IL-15 are human IL-2, IL-7, and / or IL-15. In particular embodiments, the one or more cytokines are or comprise human recombinant IL-2, IL-7, and / or IL-15. In certain embodiments, cells, e.g., selected cells of a sample, are stimulated or subjected to stimulation under stimulatory conditions in the presence of recombinant IL-2, IL-7, and IL-15. In certain embodiments, the cells are stimulated or subjected to stimulation under stimulatory conditions in the presence of 100 IU / mL or about 100 IU / mL of recombinant IL-2, 600 IU / mL or about 600 IU / mL of recombinant IL-7, and 100 IU / mL or about 100 IU / mL of recombinant IL-15. In some embodiments, the stimulatory conditions further comprise glutamine.
[0171] The conditions can include one or more of a particular medium, temperature, oxygen content, carbon dioxide content, time, agents such as nutrients, amino acids, antibiotics, ions and / or stimulatory factors such as cytokines, chemokines, antigens, binding partners, fusion proteins, recombinant soluble receptors, and any other agents designed to activate cells.
[0172] In some aspects, stimulation is performed according to techniques such as those described in U.S. Patent No. 6,040,177 to Riddell et al., Klebanoff et al. (2012) J Immunother., 35(9):651-660, Terakura et al. (2012) Blood. 1:72-82, and / or Wang et al. (2012) J Immunother. 35(9):689-701.
[0173] In some embodiments, stimulation is performed in serum-free medium. In some embodiments, the serum-free medium is a defined cell culture medium and / or a chemically defined cell culture medium. In certain embodiments, the serum-free medium is a defined culture medium that has been processed, for example, filtered to remove inhibitors and / or growth factors. In some embodiments, the serum-free medium contains proteins. In certain embodiments, the serum-free medium may contain serum albumin, hydrolysates, growth factors, hormones, carrier proteins, and / or attachment factors.
[0174] In some embodiments, stimulation is performed in serum-free medium as described in Section III herein or PCT / US2018 / 064627. In some embodiments, the serum-free medium comprises a basal medium (e.g., OpTmizer™ T Cell Expansion Basal Medium (ThermoFisher)) supplemented with one or more supplements. In some embodiments, the one or more supplements are serum-free. In some embodiments, the serum-free medium comprises a basal medium supplemented with one or more additional components for the maintenance, expansion, and / or activation of cells (e.g., T cells), such as those provided by additional supplements (e.g., OpTmizer™ T Cell Expansion Supplement (ThermoFisher)). In some embodiments, the serum-free medium comprises a serum replacement supplement, such as immune cell serum replacement, e.g., ThermoFisher, #A2596101, CTS™ immune cell serum replacement, or Smith et al. Clin Transl Immunology. 2015 Jan;4(1):e31. In some embodiments, the serum-free medium further comprises a free amino acid, such as L-glutamine. In some embodiments, the serum-free medium further comprises a dipeptide form of L-glutamine (e.g., L-alanyl-L-glutamine), such as the dipeptide in Glutamax™ (ThermoFisher). In some embodiments, the serum-free medium further comprises one or more recombinant cytokines, such as recombinant human IL-2, recombinant human IL-7, and / or recombinant human IL-15.
[0175] In some embodiments, stimulation, e.g., incubation under stimulating conditions, is carried out at room temperature (e.g., at or about 23°C). In some embodiments, stimulation, e.g., incubation under stimulating conditions, is carried out at or about 37°C.
[0176] The methods provided herein allow for the collection or elution of selected cells from a chromatography column without the addition of a competitor or free binder to elute the cells from the stationary phase. In some embodiments, the detachment of selected cells from the column is achieved by on-column stimulation. In some embodiments, for example, if the stimulant or stimulating reagent containing the stimulant is not bound, e.g., directly or indirectly, to the stationary phase of the chromatography column, the detached cells may remain bound to the stimulant or stimulating reagent containing the stimulant. Thus, in some embodiments, the detached cells may remain under stimulating conditions after detachment from the column and / or when collected and / or eluted. In some embodiments, the stimulating conditions are maintained for a period of time after removal (e.g., collection or elution) from the column. In some embodiments, at least a portion of the stimulation in the presence of the stimulant or stimulating reagent containing the stimulant is carried out in the internal cavity of a centrifuge chamber, e.g., under centrifugal rotation, as described in International Publication No. WO 2016 / 073602.
[0177] In some embodiments, stimulation performed after collection or elution of cells from a column is generally performed under mixing conditions, e.g., under rotational motion, generally at a relatively low force or speed, e.g., a speed less than that used to pellet cells, e.g., at a speed of 600 rpm to 1700 rpm, or about 600 rpm to 1700 rpm (e.g., 600 rpm, 1000 rpm, or 1500 rpm, or 1700 rpm, or about 600 rpm, 1000 rpm, or 1500 rpm, or 1700 rpm, or at least 600 rpm, 1000 rpm, or 1500 rpm, or 1700 rpm), e.g., a speed at which the RCF at the sample or wall of the chamber or other container is about 80 g to 100 g (e.g., 80 g, 85 g, 90 g, 95 g, or 100 g, or about 80 g, 85 g, 90 g, 95 g, or 100 g, or at least 80 g, 85 g, 90 g, 95 g, or 100 g). In some embodiments, rotation is performed using repeating intervals of such slow rotation followed by a rest period, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 seconds of rotation and / or rest, e.g., approximately 1 or 2 seconds of rotation followed by approximately 5, 6, 7, or 8 seconds of rest. In some embodiments, stimulation performed after collection or elution of cells from the column is performed under mixing conditions, e.g., rocking. In certain embodiments, stimulation is performed under static conditions, e.g., without centrifugation, shaking, rotation, rocking, or perfusion, e.g., continuous or semi-continuous perfusion of medium.
[0178] In some embodiments, the eluted and / or collected cells, e.g., cells still bound to the stimulator or stimulating reagent containing the stimulator, are transferred (e.g., transferred under sterile conditions) to a container such as a bag or vial and placed in an incubator. In particular embodiments, the incubator is set at 16°C, 24°C, or 35°C, or about 16°C, 24°C, or 35°C, or at least 16°C, 24°C, or 35°C. In some embodiments, the incubator is set at 37°C, about 37°C, or 37°C ± 2°C, ± 1°C, ± 0.5°C, or ± 0.1°C. In particular embodiments, stimulation under static conditions is performed in a cell culture bag placed in an incubator. In some embodiments, stimulation under rocking conditions is performed in a cell culture bag placed in an incubator. In some embodiments, the culture bag is composed of a single-web polyolefin gas-permeable film that allows monocytes, if present, to adhere to the bag surface.
[0179] 1. Use of stimulants and stimulating reagents for on-column stimulation In certain aspects, the stimulating conditions include incubating target cells (e.g., T cells) immobilized on a chromatography matrix (e.g., a stationary phase) with one or more stimulatory agents. In some embodiments, the stimulatory agent is included in a stimulating reagent. In some embodiments, the stimulatory agent is directly or indirectly bound to the chromatography matrix (e.g., the stationary phase) of the chromatography column. In some embodiments, the stimulatory agent is indirectly bound to the chromatography matrix (e.g., the stationary phase) of the chromatography column, e.g., via a selection reagent described herein, e.g., in Section II-A and / or Section IB, or a stimulating reagent described herein, e.g., in Section II-A and / or Section IC-lb. In some embodiments, the stimulatory agent is included in a stimulating reagent. In some embodiments, the stimulating reagent is bound to the chromatography matrix (e.g., the stationary phase) of the chromatography column. In some embodiments, the stimulating reagent is covalently bound to the chromatography matrix (e.g., the stationary phase). In some embodiments, the stimulatory agent is non-covalently bound to the chromatography matrix (e.g., the stationary phase).
[0180] In some embodiments, the stimulating reagent is not bound to or associated with a solid support, stationary phase, bead, microparticle, magnetic particle, and / or matrix (e.g., a chromatography matrix). In some embodiments, the stimulating reagent is flexible, does not contain a metallic or magnetic core, is composed entirely or primarily of organic multimers, and / or is not rigid. In some embodiments, the stimulating reagent is soluble. In some embodiments, the stimulating reagent is an oligomeric stimulating reagent (see, e.g., Section IC-1b). In some embodiments, the oligomeric stimulating reagent is soluble.
[0181] In certain embodiments, initiation of stimulation occurs when cells are incubated with or contacted with a stimulating agent. Thus, in some embodiments where the stimulating agent is bound directly or indirectly, e.g., via a selection or stimulating reagent, to the chromatography matrix (e.g., stationary phase) of the column, initiation of stimulation occurs when a sample containing target cells is added to the chromatography matrix (e.g., stationary phase) of the column. In some embodiments, if the stimulating agent is included in a stimulating reagent that is not associated (e.g., bound) with the chromatography matrix (e.g., stationary phase), initiation of stimulation occurs when the stimulating reagent (e.g., oligomeric stimulating reagent) is added to the stationary phase on which the target cells of the sample are immobilized. In some embodiments, if the stimulating agent is not directly or indirectly bound to the chromatography matrix (e.g., stationary phase) and is not included in the stimulating reagent (e.g., oligomeric stimulating reagent), initiation of stimulation occurs when the stimulating agent is added to the chromatography matrix (e.g., stationary phase).
[0182] In some embodiments, the stimulatory conditions or stimulatory reagents (e.g., oligomeric stimulatory reagents) comprise one or more stimulatory substances capable of activating the intracellular signaling domain of the TCR complex. In some embodiments, the one or more stimulatory substances are capable of activating the intracellular signaling domain of the TCR complex. In some embodiments, stimulatory substances contemplated herein include, but are not limited to, RNA, DNA, proteins (e.g., enzymes), antigens, polyclonal antibodies, monoclonal antibodies, antibody fragments, carbohydrates, lipids, lectins, or any other biomolecules with affinity for a desired target. In some embodiments, the desired target is a T cell receptor and / or a component of a T cell receptor. In certain embodiments, the desired target is CD3. In certain embodiments, the desired target is a T cell costimulatory molecule, e.g., CD28, CD137 (4-1-BB), OX40, or ICOS. In some embodiments, the stimulatory substance is an antibody or antigen-binding fragment thereof, e.g., a Fab.
[0183] In some embodiments, the stimulatory reagent (e.g., oligomeric stimulatory reagent) contains one or more stimulatory substances that bind to one or more of the following macromolecules on a cell (e.g., a T cell): CD2, CD3, CD4, CD5, CD8, CD25, CD27, CD28, CD29, CD31, CD44, CD45RA, CD45RO, CD54 (ICAM-1), CD127, MHC1, MHCII, CTLA-4, ICOS, PD-1, OX40, CD27L (CD70), 4-1BB (CD137), 4-1BBL, CD30L, LIGHT, IL-2R, IL-12R, IL-1R, IL-15R; IFN-gamma R, TNF-alpha R, IL-4R, IL-10R, CD18 / CD11a (LFA-1), CD62L (L-selectin), CD29 / CD49d (VLA-4), Notch ligands (e.g., Delta-like 1 / 4, Jagged 1 / 2, etc.), CCR1, CCR2, CCR3, CCR4, CCR5, CCR7, and CXCR3 or fragments thereof, and corresponding ligands for these macromolecules or fragments thereof. In some embodiments, the stimulator specifically binds to one or more of the following macromolecules on a cell (e.g., a T cell): CD28, CD62L, CCR7, CD27, CD127, CD3, CD4, CD8, CD45RA and / or CD45RO.
[0184] In some embodiments, the stimulatory agent is an antibody that binds to and / or recognizes one or more components of the T cell receptor. In particular embodiments, the stimulatory agent is an anti-CD3 antibody. In certain embodiments, the stimulatory agent is an antibody that binds to and / or recognizes a costimulatory molecule. In certain embodiments, the stimulatory agent is an anti-CD28 antibody. In some embodiments, the stimulatory reagent comprises an anti-CD28 antibody and an anti-CD3 antibody (e.g., a stimulator). In some embodiments, the stimulatory reagent comprises one or more stimulatory agents. In some embodiments, the stimulatory reagent comprises a first stimulatory agent and a second stimulatory agent. In some embodiments, the first stimulatory agent is an anti-CD3 antibody or antigen-binding fragment thereof, such as those described herein, and the second stimulatory agent is an anti-CD28 antibody or antigen-binding fragment thereof, such as those described herein. In some embodiments, the first stimulatory agent is an anti-CD3 Fab, such as those described herein, and the second stimulatory agent is an anti-CD28 Fab, such as those described herein.
[0185] In some embodiments, the stimulatory agent is an antibody, a bivalent antibody fragment, a F(ab)2, or a bivalent single-chain Fv fragment, e.g., when the stimulatory agent is not bound to a stimulating reagent (e.g., an oligomeric stimulating reagent) or a selection reagent. In some embodiments, PMA / ionomycin may be used to stimulate the cells.
[0186] In some embodiments, cells, e.g., selected cells of a sample, are stimulated or subjected to stimulation at a stimulator to cell ratio of at or about 3:1, 2.5:1, 2:1, 1.5:1, 1.25:1, 1.2:1, 1.1:1, 1:1, 0.9:1, 0.8:1, 0.75:1, 0.67:1, 0.5:1, 0.3:1, or 0.2:1. In certain embodiments, the ratio of stimulator to cells is 2.5:1 to 0.2:1, 2:1 to 0.5:1, 1.5:1 to 0.75:1, 1.25:1 to 0.8:1, or 1.1:1 to 0.9:1. In certain embodiments, the ratio of stimulator to cells is about 1:1 or 1:1. In certain embodiments, the ratio of stimulator to cells is about 0.3:1 or 0.3:1. In certain embodiments, the ratio of stimulator to cells is about 0.2:1 or 0.2:1.
[0187] In some embodiments, the cells are 6 0.01 μg, 0.02 μg, 0.03 μg, 0.04 μg, 0.05 μg, 0.1 μg, 0.2 μg, 0.3 μg, 0.4 μg, 0.5 μg, 0.75 μg, 1 μg, 1.2 μg, 1.4 μg, 1.6 μg, 1.8 μg, 2 μg, 3 μg, 4 μg, 5 μg, 6 μg, 7 μg, 8 μg, 9 μg or 10 μg per cell, In some embodiments, the cells are stimulated or subjected to stimulation in the presence of 1.4 μg, 1.6 μg, 1.8 μg, 2 μg, 3 μg, 4 μg, 5 μg, 6 μg, 7 μg, 8 μg, 9 μg, or 10 μg, or at least 0.01 μg, 0.02 μg, 0.03 μg, 0.04 μg, 0.05 μg, 0.1 μg, 0.2 μg, 0.3 μg, 0.4 μg, 0.5 μg, 0.75 μg, 1 μg, 1.2 μg, 1.4 μg, 1.6 μg, 1.8 μg, 2 μg, 3 μg, 4 μg, 5 μg, 6 μg, 7 μg, 8 μg, 9 μg, or 10 μg of a stimulating reagent.6 In a particular embodiment, the cells are stimulated or subjected to stimulation in the presence of 4 μg or about 4 μg per cell. 6 In a particular embodiment, the cells are stimulated or subjected to stimulation in the presence of 10 μg or about 3 μg per cell. 6 In a particular embodiment, the cells are stimulated or subjected to stimulation in the presence of 2.5 μg or about 2.5 μg per cell. 6 In a particular embodiment, the cells are stimulated or subjected to stimulation in the presence of 2 μg or about 2 μg per cell. 6 In a particular embodiment, the cells are stimulated or subjected to stimulation in the presence of 1.8 μg or about 1.8 μg per cell. 6 In a particular embodiment, the cells are stimulated or subjected to stimulation in the presence of 1.6 μg or about 1.6 μg per cell. 6 In a particular embodiment, the cells are stimulated or subjected to stimulation in the presence of 1.4 μg or about 1.4 μg per cell. 6 In a particular embodiment, the cells are stimulated or subjected to stimulation in the presence of 1.2 μg or about 1.2 μg per cell. 6 In certain embodiments, cells are stimulated or subjected to stimulation in the presence of 1 μg or about 1 μg per cell. 6 In various embodiments, the cells are stimulated or subjected to stimulation in the presence of 0.8 μg or about 0.8 μg per cell. 6 Stimulated or subjected to stimulation in the presence of 0.8 μg or about 0.8 μg per cell.
[0188] a. Irritating substances As noted above, in certain aspects, the methods provided herein employ a stimulatory agent. In some embodiments, the agent described in Section II-B is a stimulatory agent. In some embodiments, the stimulatory agent binds to a molecule on the surface of a cell, and binding of the stimulatory agent to the molecule can induce, deliver, or modulate a stimulatory signal in the cell. In some examples, the cell surface molecule (e.g., a receptor) is a signaling molecule. In some such examples, the stimulatory agent has the ability to specifically bind to a signaling molecule expressed by one or more target cells (e.g., T cells). In some examples, the stimulatory agent is any agent that has the ability to induce or deliver a stimulatory signal in a cell (e.g., T cell) upon binding to a cell surface molecule, such as a receptor. In some embodiments, the stimulatory signal can be immunostimulatory, in which case the stimulatory agent has the ability to induce, deliver, or modulate a signal involved in or that stimulates an immune response by the cell (e.g., T cell), e.g., increasing immune cell proliferation or expansion, immune cell activation, immune cell differentiation, cytokine secretion, cytotoxic activity, or one or more other functional activities of an immune cell. In some embodiments, the stimulatory signal can be inhibitory, in which case the stimulatory agent has the ability to induce, deliver, or modulate a stimulatory signal in a cell (e.g., a T cell) that is involved in or inhibits an immune response, e.g., inhibiting or reducing immune cell proliferation or expansion, immune cell activation, immune cell differentiation, cytokine secretion, cytotoxic activity, or one or more other functional activities of an immune cell.
[0189] In some embodiments, the stimulatory substance is a first stimulatory substance. In some embodiments, the first stimulatory substance binds to a receptor molecule on the surface of selected cells of the sample. Thus, optionally, the first stimulatory substance delivers, induces, or modulates a stimulatory signal. In some aspects, the delivery, induction, or modulation of a stimulatory signal by the first stimulatory substance results in stimulation of the cell. Thus, optionally, the first stimulatory substance delivers a stimulatory signal or provides a primary activation signal to the cell, thereby stimulating and / or activating the cell. In some embodiments, the first stimulatory substance further induces downregulation of a selection marker. As used herein, downregulation can include a reduction in expression, e.g., cell surface expression, of the selection marker compared to a previous time point.
[0190] In some embodiments, the target cell (e.g., T cell) comprises a TCR / CD3 complex and a costimulatory molecule such as CD28. In this case, the first stimulatory agent binds to the TCR / CD3 complex, thereby delivering a stimulatory signal (e.g., a primary signal, e.g., a primary activation signal) in the T cell, and the second stimulatory agent binds to the costimulatory CD28 molecule. In certain aspects, the first stimulatory agent and / or the second stimulatory agent further induce downregulation of a selection marker (e.g., a selection marker used to immobilize the target cell (e.g., T cell)).
[0191] In some embodiments, the first stimulatory agent delivers a TCR / CD3 complex-associated stimulatory signal (e.g., a primary signal) in a cell, e.g., a T cell. In some embodiments, the first stimulatory agent specifically binds to a molecule containing an immunoreceptor tyrosine-based activation motif, or ITAM. In some aspects, the first stimulatory agent specifically binds to CD3. Optionally, the first stimulatory agent that specifically binds to CD3 can be selected from the group consisting of an anti-CD3 antibody, a bivalent antibody fragment of an anti-CD3 antibody, a monovalent antibody fragment of an anti-CD3 antibody, and a proteinaceous CD3-binding molecule with antibody-like binding properties. The bivalent antibody fragment can be a F(ab')2-fragment or a bivalent single-chain Fv fragment, while the monovalent antibody fragment can be selected from the group consisting of a Fab fragment, an Fv fragment, and a single-chain Fv fragment (scFv). Optionally, the proteinaceous CD3 binding molecule with antibody-like binding properties may be an aptamer, a mutein based on a polypeptide of the lipocalin family, a glubody, a protein based on an ankyrin scaffold, a protein based on a crystal scaffold, an adnectin, or an avimer.
[0192] In some embodiments, the anti-CD3 Fab fragment can be derived from the CD3-binding monoclonal antibody produced by the hybridoma cell line OKT3 (ATCC® CRL-8001™; see also U.S. Pat. No. 4,361,549). The heavy chain variable domain and light chain variable domain of the anti-CD3 antibody OKT3 are described in Arakawa et al. J. Biochem. 120, 657-662 (1996) and comprise the amino acid sequences set forth in SEQ ID NOs: 31 and 32, respectively. In some embodiments, the anti-CD3 Fab comprises the CDRs of the variable heavy and light chains set forth in SEQ ID NOs: 31 and 32, respectively.
[0193] In some embodiments, the stimulatory substance is a second stimulatory substance. In some embodiments, the second stimulatory substance binds to a molecule on the cell surface, e.g., a cell surface molecule, e.g., a receptor molecule. In some embodiments, the second stimulatory substance has the ability to enhance, attenuate, or modify the stimulatory signal delivered via the molecule bound by the first stimulatory substance. In some embodiments, the second stimulatory substance delivers, induces, or modulates a stimulatory signal, e.g., a second or additional stimulatory signal. In some aspects, the second stimulatory substance enhances or strengthens the stimulatory signal induced by the first stimulatory substance. In some embodiments, the second stimulatory substance can bind to an accessory molecule and / or stimulate or induce a costimulatory signal or a secondary stimulatory signal. In some aspects, the second stimulatory substance binds to a costimulatory molecule and / or provides a costimulatory signal.
[0194] In some embodiments, the stimulatory agent, which can be a second stimulatory agent, binds, e.g., specifically binds, to a second molecule, which can be a costimulatory molecule, an accessory molecule, a cytokine receptor, a chemokine receptor, an immune checkpoint molecule, or a member of the TNF family or the TNF receptor family.
[0195] In some embodiments, the molecule on the cell, e.g., T cell, can be CD28, and the stimulator (e.g., it can be a second stimulator) specifically binds to CD28. In some aspects, the stimulator (e.g., it can be a second stimulator) that specifically binds to CD28 can be selected from the group consisting of an anti-CD28 antibody, a bivalent antibody fragment of an anti-CD28 antibody, a monovalent antibody fragment of an anti-CD28 antibody, and a proteinaceous CD28-binding molecule with antibody-like binding properties. The bivalent antibody fragment can be a F(ab')2-fragment or a bivalent single-chain Fv fragment, while the monovalent antibody fragment can be selected from the group consisting of a Fab fragment, an Fv fragment, and a single-chain Fv fragment (scFv). The proteinaceous CD28-binding molecule with antibody-like binding properties can be an aptamer, a mutein based on a polypeptide of the lipocalin family, a glubody, an ankyrin scaffold-based protein, a crystalline scaffold-based protein, an adnectin, or an avimer.
[0196] In some embodiments, the anti-CD28 Fab fragment can be derived from the antibody CD28.3 (deposited as a synthetic single-chain Fv construct in GenBank Accession No. AF451974.1; see also Vanhove et al, BLOOD, 15 July 2003, Vol. 102, No. 2, pages 564-570), whose variable heavy and variable light chains comprise SEQ ID NOs: 33 and 34, respectively. In some embodiments, the anti-CD28 Fab comprises the CDRs of the variable heavy and variable light chains shown in SEQ ID NOs: 33 and 34, respectively.
[0197] In some embodiments, the molecule on the cell, e.g., T cell, is CD90, and the stimulator (e.g., it can be a second stimulator) specifically binds to CD90. In some aspects, the stimulator (e.g., it can be a second stimulator) that specifically binds to CD90 can be selected from the group consisting of an anti-CD90 antibody, a bivalent antibody fragment of an anti-CD90 antibody, a monovalent antibody fragment of an anti-CD90 antibody, and a proteinaceous CD90-binding molecule with antibody-like binding properties. The antibody or antigen-binding fragment can be derived from any known in the art. See, e.g., anti-CD90 antibody G7 (Biolegend, catalog number 105201).
[0198] In some embodiments, the molecule on the cell, e.g., T cell, is CD95, and the stimulator (e.g., it can be a second stimulator) specifically binds to CD95. In some aspects, the stimulator (e.g., it can be a second stimulator) that specifically binds to CD95 can be selected from the group consisting of an anti-CD95 antibody, a bivalent antibody fragment of an anti-CD95 antibody, a monovalent antibody fragment of an anti-CD95 antibody, and a proteinaceous CD95-binding molecule with antibody-like binding properties. The antibody or antigen-binding fragment can be derived from any known in the art. For example, in some aspects, the anti-CD90 antibody can be monoclonal mouse anti-human CD95 CH11 (Upstate Biotechnology, Lake Placid, NY), anti-CD95 mAb 7C11, or anti-APO-1, such as those described in Paulsen et al. Cell Death & Differentiation 18.4(2011):619-631.
[0199] In some embodiments, the molecule on a cell, e.g., a T cell or a B cell, can be CD137, and the stimulator (e.g., it can be a second stimulator) specifically binds to CD137. In some aspects, the stimulator (e.g., it can be a second stimulator) that specifically binds to CD137 can be selected from the group consisting of an anti-CD137 antibody, a bivalent antibody fragment of an anti-CD137 antibody, a monovalent antibody fragment of an anti-CD137 antibody, and a proteinaceous CD137-binding molecule with antibody-like binding properties. The antibody or antigen-binding fragment can be derived from any known in the art. For example, the anti-CD137 antibody can be LOB12, IgG2a, or LOB12.3, IgG1, as described in Taraban et al. Eur J Immunol. 2002 Dec;32(12):3617-27. See also, e.g., US6569997, US6303121, Mittler et al. Immunol Res. 2004;29(1-3):197-208.
[0200] In some embodiments, the molecule on the cell, e.g., a B cell, can be CD40, and the stimulator, e.g., the stimulator (e.g., which can be a second stimulator, e.g., a second stimulator) specifically binds to CD40. In some aspects, the stimulator (which can be a second stimulator, e.g., a second stimulator) that specifically binds to CD40 can be selected from the group consisting of an anti-CD40 antibody, a bivalent antibody fragment of an anti-CD40 antibody, a monovalent antibody fragment of an anti-CD40 antibody, and a proteinaceous CD40 binding molecule with antibody-like binding properties.
[0201] In some embodiments, the molecule on a cell, e.g., a T cell, can be CD40L (CD154), and the stimulator (e.g., it can be a second stimulator) specifically binds to CD40L. In some aspects, the stimulator (e.g., it can be a second stimulator) that specifically binds to CD40L can be selected from the group consisting of an anti-CD40L antibody, a bivalent antibody fragment of an anti-CD40L antibody, a monovalent antibody fragment of an anti-CD40L antibody, and a proteinaceous CD40L-binding molecule with antibody-like binding properties. The antibody or antigen-binding fragment can be derived from any known in the art. For example, in some aspects, the anti-CD40L antibody can be Hu5C8, as described by Blair et al. in JEM vol. 191 no. 4 651-660. See also, e.g., WO1999061065, US20010026932, US7547438, and WO2001056603.
[0202] In some embodiments, the molecule on a cell, e.g., a T cell, can be an inducible T cell costimulatory molecule (ICOS), and the stimulator (e.g., it can be a second stimulator) specifically binds to ICOS. In some aspects, the stimulator (e.g., it can be a second stimulator) that specifically binds to ICOS can be selected from the group consisting of an anti-ICOS antibody, a bivalent antibody fragment of an anti-ICOS antibody, a monovalent antibody fragment of an anti-ICOS antibody, and a proteinaceous ICOS-binding molecule with antibody-like binding properties. The antibody or antigen-binding fragment can be derived from any known in the art. See, e.g., US20080279851 and Deng et al. Hybrid Hybridomics. 2004 Jun;23(3):176-82.
[0203] In some embodiments, the molecule on a cell, e.g., a T cell, can be a Linker for Activation of T cells (LAT), and the stimulator (e.g., it can be a second stimulator) specifically binds to LAT. In some aspects, the stimulator (e.g., it can be a second stimulator) that specifically binds to LAT can be selected from the group consisting of an anti-LAT antibody, a bivalent antibody fragment of an anti-LAT antibody, a monovalent antibody fragment of an anti-LAT antibody, and a proteinaceous LAT-binding molecule with antibody-like binding properties. The antibody or antigen-binding fragment can be derived from any known in the art.
[0204] In some embodiments, the molecule on a cell, e.g., a T cell, can be CD27, and the stimulator (e.g., it can be a second stimulator) specifically binds to CD27. In some aspects, the stimulator (e.g., it can be a second stimulator) that specifically binds to CD27 can be selected from the group consisting of an anti-CD27 antibody, a bivalent antibody fragment of an anti-CD27 antibody, a monovalent antibody fragment of an anti-CD27 antibody, and a proteinaceous CD27-binding molecule with antibody-like binding properties. The antibody or antigen-binding fragment can be derived from any known in the art. See, e.g., WO2008051424.
[0205] In some embodiments, the molecule on a cell, e.g., a T cell, can be OX40, and the stimulator (e.g., it can be a second stimulator) specifically binds to OX40. In some aspects, the stimulator (e.g., it can be a second stimulator) that specifically binds to OX40 can be selected from the group consisting of an anti-OX40 antibody, a bivalent antibody fragment of an anti-OX40 antibody, a monovalent antibody fragment of an anti-OX40 antibody, and a proteinaceous OX40 binding molecule with antibody-like binding properties. The antibody or antigen-binding fragment can be derived from any known in the art. See, e.g., WO2013038191, Melero et al. Clin Cancer Res. 2013 Mar 1;19(5):1044-53.
[0206] In some embodiments, the molecule on a cell, e.g., a T cell, can be HVEM, and the stimulator (e.g., it can be a second stimulator) specifically binds to HVEM. In some aspects, the stimulator (e.g., it can be a second stimulator) that specifically binds to HVEM can be selected from the group consisting of an anti-HVEM antibody, a bivalent antibody fragment of an anti-HVEM antibody, a monovalent antibody fragment of an anti-HVEM antibody, and a proteinaceous HVEM-binding molecule with antibody-like binding properties. The antibody or antigen-binding fragment can be derived from any known in the art. See, e.g., WO2006054961, WO2007001459, Park et al. Cancer Immunol Immunother. 2012 Feb;61(2):203-14.
[0207] In any of the above examples, the bivalent antibody fragment may be a (Fab)2' fragment or a bivalent single-chain Fv fragment, while the monovalent antibody fragment may be selected from the group consisting of a Fab fragment, an Fv fragment, and a single-chain Fv fragment (scFv). In any of the above examples, the proteinaceous binding molecule with antibody-like binding properties may be an aptamer, a mutein based on a polypeptide of the lipocalin family, a glubody, an ankyrin scaffold-based protein, a crystalline scaffold-based protein, an adnectin, and an avimer.
[0208] In some aspects, the stimulator specifically targets a molecule expressed on the surface of a target cell, where the molecule is a TCR, a chimeric antigen receptor, or a molecule containing an immunoreceptor tyrosine-based activation motif (ITAM). For example, the molecule expressed on the surface of the target cell is selected from a T cell or B cell antigen receptor complex, a CD3 chain, CD3 zeta, an antigen-binding portion of a T cell recepto...
Claims
1. A method for on-column stimulation of T cells, comprising the steps of: (a) adding an oligomeric stimulatory reagent capable of delivering a stimulatory signal in T cells to a stationary phase comprising a plurality of T cells immobilized on the stationary phase, thereby initiating incubation of the oligomeric stimulatory reagent with the plurality of T cells, the stationary phase is contained in a chromatography column and comprises a selection substance that specifically binds to a selection marker on the surface of the plurality of T cells or a subset thereof, and specific binding of the selection substance to the selection marker expressed by the one or more T cells immobilizes the one or more T cells on the stationary phase; the oligomeric stimulatory reagent comprises one or more stimulatory agents including (i) a first stimulatory agent that is an anti-CD3 antibody or antibody fragment, and (ii) a second stimulatory agent that is an anti-CD28 antibody or antibody fragment; process; and (b) harvesting one or more of the plurality of T cells from the stationary phase by gravity flow within 24 hours from the start of incubation, without the addition of a competitor or free binding agent to elute one or more of the plurality of T cells from the stationary phase, thereby producing a composition comprising stimulated T cells.
2. A method for on-column stimulation of T cells, comprising the steps of: (a) adding an oligomeric stimulation reagent to a stationary phase, the oligomeric stimulation reagent comprising one or more stimuli including (i) a first stimuli that is an anti-CD3 antibody or antibody fragment, and (ii) a second stimuli that is an anti-CD28 antibody or antibody fragment; (b) incubating the plurality of T cells immobilized on a stationary phase with one or more stimulatory agents to deliver a stimulatory signal in one or more T cells of the plurality of T cells, the stationary phase comprising a selection agent contained in a chromatography column and which specifically binds to a selection marker on the surface of the one or more T cells, and specific binding of the selection agent to the selection marker expressed by the one or more T cells immobilizes the one or more T cells on the stationary phase; and (c) harvesting the plurality of T cells from the stationary phase by gravity flow within 24 hours from the start of incubation, without the addition of a competitor or free binding agent to elute the one or more T cells from the stationary phase, thereby producing a composition comprising stimulated T cells.
3. A method for on-column stimulation of T cells, comprising the steps of: (a) applying a sample comprising a plurality of T cells to a stationary phase contained in a chromatography column, the stationary phase comprising a selection agent that binds to a selection marker on the surface of one or more T cells of the plurality of T cells, thereby immobilizing the one or more of the plurality of T cells on the stationary phase; (b) adding to the stationary phase an oligomeric stimulating reagent comprising one or more stimulating agents comprising (i) a first stimulating agent that is an anti-CD3 antibody or antibody fragment, and (ii) a second stimulating agent that is an anti-CD28 antibody or antibody fragment, thereby initiating incubation of the oligomeric stimulating reagent with one or more of the plurality of T cells; and (c) harvesting one or more of the plurality of T cells from the stationary phase by gravity flow within 24 hours from the start of incubation, without the addition of a competitor or free binding agent to elute one or more of the plurality of T cells from the stationary phase, thereby producing a composition comprising stimulated T cells.
4. 4. The method of claim 3, wherein the initiation of incubation with the stimulating reagent is performed within 10 minutes, within 20 minutes, within 30 minutes, within 45 minutes, within 60 minutes, within 90 minutes, or within 120 minutes after adding the sample containing the plurality of T cells to the stationary phase.
5. A method for on-column stimulation of T cells, comprising the steps of: (1) combining (a) a sample comprising a plurality of T cells and (b) a stationary phase comprising a selection substance capable of specifically binding to a selection marker expressed on the surface of one or more of the plurality of T cells, the stationary phase being comprised in a chromatography column, and wherein specific binding of the selection substance to the selection marker immobilizes the one or more of the plurality of T cells to the stationary phase; (2) adding to the stationary phase an oligomeric stimulating reagent comprising one or more stimulating agents, including (i) a first stimulating agent that is an anti-CD3 antibody or antibody fragment, and (ii) a second stimulating agent that is an anti-CD28 antibody or antibody fragment, thereby initiating incubation of the oligomeric stimulating reagent with the one or more T cells; and (3) harvesting one or more of the plurality of T cells from the stationary phase by gravity flow within 24 hours from the start of incubation, without the addition of a competitor or free binding agent to elute one or more of the plurality of T cells from the stationary phase, thereby producing a composition comprising stimulated T cells.
6. The method of any one of claims 1 to 5, wherein the oligomeric stimulation reagent comprises a plurality of streptavidin or streptavidin mutein molecules, and the size of the oligomeric stimulation reagent comprises at least 100 streptavidin tetramers or streptavidin mutein tetramers.
7. A method for on-column stimulation of T cells, comprising the steps of: (a) adding an oligomeric stimulating reagent to a stationary phase comprising a plurality of T cells immobilized on the stationary phase, thereby initiating incubation of the stimulating reagent with one or more T cells of the plurality of T cells, the stationary phase is contained in a chromatography column and comprises a selection agent that specifically binds to a selection marker on the surface of one or more T cells, and specific binding of the selection agent to the selection marker expressed by the one or more T cells immobilizes the one or more T cells to the stationary phase; The oligomeric stimulation reagent comprises one or more stimulatory agents including (i) a plurality of streptavidin or streptavidin mutein molecules, (ii) a first stimulatory agent that is an anti-CD3 antibody or antibody fragment, and (iii) a second stimulatory agent that is an anti-CD28 antibody or antibody fragment, and the size of the oligomeric stimulation reagent is (i) a radius of greater than 50 nm, (ii) at least 5×10 6 and / or (iii) comprises at least 100 streptavidin tetramers or streptavidin mutein tetramers, Process; (b) harvesting one or more of the plurality of T cells from the stationary phase by gravity flow within 24 hours from the start of incubation, without the addition of a competitor or free binding agent to elute one or more of the plurality of T cells from the stationary phase, thereby producing a composition comprising stimulated T cells.
8. 8. The method of claim 6 or 7, wherein the streptavidin or streptavidin mutein molecule reversibly binds to biotin, a biotin analogue or a streptavidin-binding peptide.
9. The streptavidin-binding peptide is Trp-Arg-His-Pro-Gln-Phe-Gly-Gly (SEQ ID NO: 7), Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 8), Ser-Ala-Trp-Ser-His-Pro-Gln-Phe-Glu-Lys-(GlyGlyGlySer) 3-Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO:15), SAWSHPQFEKGGGSGGGSGGSAWSHPQFEK (SEQ ID NO:16), Trp-Ser-His-Pro-Gln-Phe-Glu-Lys-(GlyGlyGlySer) 3 -Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 17), Trp-Ser-His-Pro-Gln-Phe-Glu-Lys-(GlyGlyGlySer) 2 -Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 18), and Trp-Ser-His-Pro-Gln-Phe-Glu-Lys-(GlyGlyGlySer) 2 Gly-Gly-Ser-Ala-Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 19), and The amino acid sequence Ile is added to a sequence position corresponding to positions 44 to 47 in streptavidin based on the amino acid sequence shown in SEQ ID NO:
1. 44 -Gly 45 -Ala 46 -Arg 47 or Val 44 -Thr 45 -Ala 46 -Arg 47 Streptavidin muteins comprising 9. The method of claim 8, wherein the compound is selected from the group consisting of:
10. 10. The method of claim 9, wherein the streptavidin mutein comprises an amino acid sequence set forth in any of SEQ ID NOs: 3-6, 27-28, and 104-105.
11. the selected agent comprises an agent selected from the group consisting of an antibody, an antibody fragment, a proteinaceous binding molecule with immunoglobulin-like function, an Ig domain-containing molecule, a cytokine, a chemokine, an aptamer, an MHC molecule, an MHC-peptide complex, a receptor ligand, and a binding fragment of any of the foregoing; The method according to any one of claims 2 to 10.
12. The method of any one of claims 1 to 11, wherein one or more stimulatory and / or selection agents independently comprise a monovalent antibody fragment.
13. The method of claim 12, wherein the monovalent antibody fragment is selected from the group consisting of a Fab fragment, an Fv fragment and a single-chain Fv fragment (scFv).
14. The method of any one of claims 1 to 13, wherein the first stimulatory agent is an anti-CD3 Fab and the second stimulatory agent is an anti-CD28 Fab.
15. Harvesting one or more of the T cells from the stationary phase may be performed within 2-24, 3-24, 4-24, 5-24, 6-24, 7-24, 8-24, 9-24, 10-24, 11-24, 12-24, 13-24, 14-24, 15-24, 16-24, 17-24, 18-24, 19-24, 20-24, 21-24, 22-24, 23-24, 24-24, 25-24, 26-24, 27-24, 28-24, 29-30, 31-32, 32-34, 33-36, 34-38, 35-38, 36-38, 37-38, 38-39, 39-40, 41-42, 42-44, 43-44, 44-46, 45-48, 46-48, 47-49, 48-50, 49-51, 52-53, 54-55, 56-57, 57-58, 58-59, 59-60, 60-61, 61-62, 62-63, 63-64, 64-65, 65-66, 66-67, 67-68, 68-69, 69-70, 70-71, 72-72, 73-74, 74-75, 75-76, 76-77, 77-78, 78-79, 79-80, 80 15. The method of any one of claims 1 to 14, wherein the method is performed within 4, 21 to 24, 22 to 24, 23 to 24, 2 to 23, 2 to 22, 2 to 21, 2 to 20, 2 to 19, 2 to 18, 2 to 17, 2 to 16, 2 to 15, 2 to 14, 2 to 13, 2 to 12, 2 to 11, 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, 2 to 4 or 2 to 3 hours.
16. 16. The method of any one of claims 1-15, wherein the T cells are derived from a whole blood sample, a buffy coat sample, a peripheral blood mononuclear cell (PBMC) sample, an unfractionated T cell sample, a lymphocyte sample, a leukocyte sample, an apheresis product, or a leukapheresis product.
17. 17. The method of claim 16, wherein the T cells are derived from a previously cryofrozen apheresis product or a leukapheresis product.
18. one or more stimulatory and / or selective agents are biotin analogues that reversibly bind to biotin, streptavidin or avidin; Trp-Arg-His-Pro-Gln-Phe-Gly-Gly (SEQ ID NO: 7), Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 8), Ser-Ala-Trp-Ser-His-Pro-Gln-Phe-Glu-Lys-(GlyGlyGlySer) 3 -Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 15), Trp-Ser-His-Pro-Gln-Phe-Glu-Lys-(GlyGlyGlySer) 3 -Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 17), SAWSHPQFEKGGGSGGGSGGSAWSHPQFEK (SEQ ID NO: 16), Trp-Ser-His-Pro-Gln-Phe-Glu-Lys-(GlyGlyGlySer) 2 -Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 18), and Trp-Ser-His-Pro-Gln-Phe-Glu-Lys-(GlyGlyGlySer) 2 Gly-Gly-Ser-Ala-Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 19) 18. The method of any one of claims 1 to 17, further comprising a streptavidin-binding peptide selected from the group consisting of: a calmodulin-binding peptide that reversibly binds to calmodulin; a FLAG peptide that reversibly binds to an antibody that binds to the FLAG peptide; or an oligohistidine tag that reversibly binds to an antibody that binds to the oligohistidine tag.
19. the selection marker is a T cell coreceptor; the selectable marker is a member of the T cell antigen receptor complex; The selection marker is the CD3 chain; The selection marker is CD3 zeta chain; The selection marker is CD8; The selection marker is CD4; The selection marker is CD45RA; The selection marker is CD27; the selection marker is CD28; and / or The selection marker is CCR7; 19. The method of any one of claims 1 to 18.
20. the selection marker is selected from the group consisting of CD3, CD4 and CD8; 20. The method of any one of claims 1 to 19.
21. The method according to any one of claims 1 to 20, wherein the specific binding between the selection agent and the selection marker does not induce a signal to the T cell or does not induce a stimulatory, activating and proliferative signal to the T cell.
22. The method of any one of claims 1 to 21, wherein the selection agent is an anti-CD3 Fab, an anti-CD8 Fab or an anti-CD4 Fab.
23. the oligomeric stimulating agent is soluble; the oligomeric stimulation reagent is not bound to a solid support, and / or the oligomeric stimuli reagent is flexible, does not contain a metallic or magnetic core, is composed entirely or primarily of organic polymers, and / or is not rigid; 23. The method of any one of claims 1 to 22.
24. The oligomer stimulating agent is A radius between 50 nm and 150 nm, between 75 nm and 125 nm, between 80 nm and 115 nm, or between 90 nm and 110 nm, inclusive; 5×10 7 g / mol to 5×10 8 g / mol, 1×10 8 g / mol to 5×10 8 g / mol, or 1×10 8 g / mol to 2×10 8 Molecular weight in g / mol, and / or 1,000 to 20,000 streptavidin tetramers or streptavidin mutein tetramers, 1,000 to 10,000 streptavidin tetramers or streptavidin mutein tetramers, or 2,000 to 5,000 streptavidin tetramers or streptavidin mutein tetramers The method of any one of claims 1 to 23, comprising:
25. 25. The method of any one of claims 1 to 24, wherein the oligomeric stimulation reagent is added to the stationary phase at a concentration of 1 μg / million cells to 2 μg / million cells.
26. 26. The method of any one of claims 1 to 25, wherein the selection substance is indirectly bound to the stationary phase via a selection reagent to which it reversibly binds.
27. 27. The method of claim 26, wherein the selection reagent comprises streptavidin; avidin; a mutein of streptavidin that reversibly binds to biotin or a biotin analog; an avidin or a mutein of streptavidin that reversibly binds to a streptavidin-binding peptide; a reagent comprising at least two chelating groups, the at least two chelating groups being capable of binding to a transition metal ion; a substance capable of binding to an oligohistidine affinity tag; a substance capable of binding to glutathione-S-transferase; calmodulin or an analog thereof; a substance capable of binding to calmodulin-binding peptide (CBP); a substance capable of binding to a FLAG peptide; a substance capable of binding to an HA tag; a substance capable of binding to maltose binding protein (MBP); a substance capable of binding to an HSV epitope; a substance capable of binding to a myc epitope; or a substance capable of binding to a biotinylated carrier protein.
28. Incubating with one or more stimuli causes one or more of the plurality of immobilized T cells to release from the stationary phase; and / or and / or wherein collecting by gravity flow comprises adding medium to the stationary phase that does not contain a competitor or free binder to elute the T cells from the stationary phase. the competitor or free binder comprises biotin or a biotin analog; 28. The method of any one of claims 1 to 27.
29. 29. The method of any one of claims 1 to 28, wherein the competitor or free binder comprises D-biotin.
30. 30. The method of any one of claims 1 to 29, further comprising the step of introducing into a T cell of said composition comprising stimulated T cells a recombinant nucleic acid molecule encoding a recombinant protein.
31. 31. The method of claim 30, wherein the recombinant protein is a chimeric antigen receptor, thereby generating a composition comprising engineered T cells.
32. 32. The method of claim 31 , wherein the composition comprises a transduced T cell.
33. The method of any one of claims 30 to 32, wherein the introduction of the recombinant nucleic acid is achieved by transduction with a viral particle.
34. 34. The method of claim 33, wherein the viral particle is a retroviral vector particle.
35. 35. The method of claim 34, wherein the viral particle is a lentiviral particle.
36. The method of any one of claims 30-34, further comprising culturing the composition comprising the engineered T cells under conditions for viral integration.
37. 37. The method of claim 36, further comprising culturing the composition comprising the engineered T cells at a temperature of 37°±2° C.
38. 38. The method of claim 36 or 37, wherein the step of culturing the composition comprising the engineered T cells is carried out for at least 18 hours and up to 96 hours, up to 72 hours, up to 48 hours, or up to 24 hours after introduction.
39. The method of any one of claims 30-38, further comprising culturing the composition comprising the engineered T cells under conditions for expanding the T cells.
40. 40. The method of claim 39, wherein the culturing step is carried out for a period of time not longer than 14 days, not longer than 12 days, not longer than 10 days, not longer than 8 days, not longer than 6 days, or not longer than 5 days.
41. The method of any one of claims 30-40, further comprising harvesting the engineered T cells, thereby generating an output population of engineered T cells.
42. 42. The method of claim 41, wherein the engineered T cells are harvested at a time point between 48 and 120 hours, inclusive, after initiation of exposure to the oligomeric stimulating reagent.
43. The method of claim 41 or 42, wherein the percentage of naive-like cells is greater than 60% of the total T cells in the population, the total CD4+ T cells in the population, the total CD8+ T cells in the population, or any of the preceding recombinant protein-expressing cells in the population at the time of harvest.
44. The method of claim 43, wherein the naive-like T cells comprise CD27+CCR7+ cells.
45. 45. The method of any one of claims 41-44, further comprising formulating the harvested cells for cryopreservation and / or administration to a subject.
46. 46. The method of any one of claims 41-45, further comprising formulating the harvested cells for cryopreservation and / or administration to a subject in the presence of a pharma- ceutically acceptable excipient or cryoprotectant.
47. The method of any one of claims 30 to 46, wherein the introducing, incubating and / or culturing steps are carried out in serum-free medium.
48. 48. The method of claim 47, wherein the serum-free medium does not contain recombinant human IL-2, recombinant human IL-15 or recombinant human IL-7.
49. The method of any one of claims 30 to 48, further comprising washing the T cells.
50. 50. The method of claim 49, wherein the washing step reduces or removes the oligomeric stimulating reagent and / or one or more stimulating substances in the composition.
51. the T cells comprise antigen-specific T cells or a population thereof, helper T cells or a population thereof, cytotoxic T cells or a population thereof, memory T cells or a population thereof, or regulatory T cells or a population thereof; and / or the T cells comprise CD3+ T cells or comprise CD4+ and / or CD8+ T cells; The method of any one of claims 1 to 50.
52. selecting a T cell subset from the stimulated T cells of said composition, followed by the introduction of any one of claims 30 to 51, to introduce the recombinant nucleic acid molecule into said selected T cell subset; selecting a T cell subset from a composition comprising engineered T cells, followed by the incubation of any one of claims 36 to 51, wherein said selected T cell subset is incubated under conditions for viral integration; selecting a T cell subset from a composition comprising engineered T cells, followed by a culturing step according to any one of claims 26 to 51, wherein the selected T cell subset is cultured under conditions for expanding the T cells; and / or selecting a T cell subset from a composition comprising the engineered T cells, followed by harvesting according to any one of claims 41 to 51, wherein the selected T cell subset is harvested to generate an output population of engineered T cells.
52. The method of any one of claims 1 to 51.
53. 53. The method of claim 52, wherein the selecting step is carried out by affinity column chromatography.
54. The method of claim 52 or 53, wherein the T cell subset is a naive-like T cell; is a T cell that is surface positive for a marker expressed on a naive-like T cell; is CCR7+CD45RA+, CD27+CCR7+, or CD62L-CCR7+; and / or expresses a recombinant protein.
55. The stationary phase comprises a chromatographic matrix; The stationary phase is a non-magnetic or non-magnetizable material; the stationary phase has a binding capacity of between 75 million and 125 million T cells per mL of stationary phase; and / or The stationary phase is 20 mL.
55. The method of any one of claims 1 to 54.
56. 56. The method of claim 55, wherein the stationary phase has a binding capacity of 2 billion ± 500 million cells.
57. 57. The method of claim 55 or 56, wherein the chromatography matrix is for column chromatography.
58. The method of any one of claims 1 to 57, wherein the method is performed automatically.
Citation Information
Patent Citations
Methods for culturing cells and kits and apparatus for same
WO2017068425A1
